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Abstract 
Pharmacoresistance in Epilepsy: An Integrative Genetic & Genomic Analysis 
Nasir Mirza 
Epilepsy effects up to 1% of the population, and up to 30% of people with epilepsy are 
pharmacoresistant—they continue to experience seizures despite treatment with maximal doses of 
multiple antiepileptic drugs. The causes of drug resistance in epilepsy remain poorly understood. In 
this work, I have used genetic and genomic analysis techniques to explore the causes of epilepsy 
pharmacoresistance. 
It has been reported that epilepsy pharmacoresistance results from impaired drug penetration into 
the epileptic focus secondary to a localized dysregulation of drug transporters. Solute carrier (SLC) 
transporters form the largest superfamily of multidrug transporters. I used novel in silico and 
stringent ex vivo strategies for identifying the SLCs that are dysregulated in the pharmacoresistant 
epileptic human hippocampus. I discovered that the SLCs dysregulated in the pharmacoresistant 
epileptic human hippocampus are either small metal ion exchangers or transporters of 
neurotransmitters, not antiepileptic drug transporters, and most likely contribute to 
pharmacoresistance by enhancing the intrinsic severity of epilepsy. This finding supports the newly-
proposed and intuitive ‘intrinsic severity hypothesis’ of epilepsy pharmacoresistance.  
According to the intrinsic severity hypothesis, pharmacoresistance in epilepsy results from the 
increased dysfunction of the biological pathways which underlie epilepsy. Hence, I proceeded to 
perform genome-wide genetic and genomic analyses in order to find the most important pathways 
underlying epilepsy and pharmacoresistance in epilepsy. I performed an integrative analysis of 
previously published large-scale gene expression profiling studies on brain tissue from epilepsy 
surgery; the largest and most robust microarray analysis of brain tissue from surgery for 
pharmacoresistant mesial temporal lobe epilepsy; and the first-ever genome-wide association study 
(GWAS) of pharmacoresistant focal epilepsy. By integrating the results of the genetic and genomic 
studies, I was able to show that pharmacoresistance is the result of accumulation of deleterious 
genetic variants of increasing severity and/or numbers within the genes that constitute the core 
pathways underlying epilepsy. I also found that the pathways disrupted in pharmacoresistant 
epilepsy, at both the genetic and genomic levels, belong to many different diverse and disparate 
functional domains, for example ‘axon guidance’, ‘transmembrane transport of small molecules’ and 
‘cell death signalling via NRAGE, NRIF and NADE’. However, using network analysis techniques, I 
showed that these seemingly unrelated pathways form a coherent highly interconnected network, 
and it can be expected that changes in one pathway in this network will have a cascading effect on 
the rest of the network. The most important pathways in these networks are the central ‘hub’ 
pathways, which I identified using betweenness centrality network analysis. 
I then performed the first-ever genetical genomics study in epilepsy using hippocampal samples 
from resective surgery for refractory mesial temporal lobe epilepsy. By integrating genome-wide 
genetic, genetical genomic and genomic studies, and then performing pathway, network and 
centrality analysis, I identified the most important putative central causal pathways underlying 
epilepsy pharmacoresistance: 'transmembrane transport of small molecules' and 'Deleted in 
colorectal cancer (DCC) mediated attractive signalling'. 
In conclusion, by performing genome-wide genetic, genetical genomic and genomic studies, 
followed by integrative analysis, pathway construction and network mapping, I have identified most 
important putative central causal pathways underlying epilepsy pharmacoresistance. 
6 
 
Publication 
 Mirza N., Vasieva O., Marson A.G. & Pirmohamed M. (2011) Exploring the genomic 
basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene 
expression profiling studies on brain tissue from epilepsy surgery. Hum Mol Genet 
20, 4381-94. 
Presentations 
 Mirza N., Vasieva O., Marson A.G., Pirmohamed M. (April 2012) Using Contrasting 
Bioinformatics Approaches to Prioritize Multidrug Transporters Underlying 
Pharmacoresistance in Epilepsy. Platform presentation at the ILAE Annual Meeting, 
London, UK. 
 Mirza N., Vasieva O., Marson A.G., Pirmohamed M. (November 2012) SLC 
Transporters in Pharmacoresistant Epilepsy: an integrative in silico and ex vivo 
analysis. Platform presentation at the American Epilepsy Society Meeting, San Diego, 
US. 
 Mirza N., Sills G., Jorgensen A., Marson A.G., Pirmohamed M. (May 2014) Which 
Genetic Pathways Underlie Pharmacoresistant Epilepsy? Platform presentation at 
the Association of British Neurologists Annual Meeting, Cardiff, UK. 
 Mirza N., Sills G., Jorgensen A., Johnson M., Pirmohamed M, Marson A.G. (June 
2014) Identifying the Causes of Pharmacoresistant Epilepsy through a Genome-Wide 
Association Study with Pathway and Network Analysis: From Complexity to 
Coherence to Centrality. Platform presentation at the Joint Congress of European 
Neurology, Istanbul, Turkey.  
 Mirza N., Sills G., Jorgensen A., Johnson M., Pirmohamed M, Marson A.G. (June 
2014) Identifying the Causes of Pharmacoresistant Epilepsy through a Genome-Wide 
Association Study with Pathway and Network Analysis: From Complexity to 
Coherence to Centrality. Platform presentation at the European Congress of 
Epileptology, Stockholm, Sweden.  
7 
 
Abbreviations 
ABC Adenosine triphosphate-binding cassette 
AD Alzheimer's disease 
AED Antiepileptic drug 
BCRP Breast cancer resistance protein  
CCK Cholecystokinin 
CCR1 Chemokine receptor 1 
CETA Concentration equilibrium transport assay 
CFG Convergent functional genomic 
CGP Computational gene prioritization 
CLB Clobazam 
CNS Central nervous system 
DAGs Disease-associated genes 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DCC Deleted in colorectal cancer receptor 
DEGs Differentially-expressed genes 
DICER Differential Correlation in Expression for meta-module Recovery 
DSCAM Down syndrome cell adhesion molecule 
EAE Experimental autoimmune encephalomyelitis 
EASE Expression analysis systematic explorer 
EDP Extreme discordant phenotype 
ENCODE Encyclopedia of DNA Elements 
eQTL Expression quantitative trait loci 
FDR False discovery rate 
FGF Fibroblast growth factor 
GABA -Aminobutyric acid 
GO Gene ontology 
GPCR G protein-coupled receptors 
GSCA Gene set co-expression analysis 
GWAS Genome-wide association study 
HS Hippocampal sclerosis 
IAC Inter-array correlation 
IBE International Bureau for Epilepsy 
ILAE International league against epilepsy 
ISVA Independent surrogate variable analysis 
JNK C-JUN N-terminal Kinase 
LOOA Leave-one-out analysis 
MAF Minor allele frequency 
MAQC Microarray Quality Control 
MAS5 Microarray suite 5.0 
MaTLE Mass-associated temporal lobe epilepsy 
MDT Multidrug transporter 
MIAME Minimum Information About a Microarray Experiment 
MTLE Mesial temporal lobe epilepsy 
NADE P75ntr-associated Cell Death Executor 
8 
 
NGF Nerve growth factor 
NPC Normal population controls 
NRAGE Neurotrophin receptor–interacting MAGE homolog 
NRIF Neurotrophin receptor-interacting factor  
OC Overlap coefficient 
OHSC Organotypic hippocampal slice culture  
p75NTR P75 neurotrophin receptor  
PC Principal component 
PET Positron emission tomography  
PIP Polymorphisms-in-probes  
PTLE Paradoxical temporal lobe epilepsy  
PwP Probes-with-polymorphisms  
QC Quality control 
QQ Quantile-quantile 
RIF Regulatory impact factor 
RIN RNA Integrity number 
SANAD Standard and New Antiepileptic Drugs 
SLC Solute carrier 
SNPs Single nucleotide polymorphism 
SVA Surrogate variable analysis 
TLE Temporal lobe epilepsy 
TW Tracy-Widom  
VGB Vigabatrin  
VGCC Voltage-gated calcium channels  
vGLUT1 Vesicular glutamate transporter isoform 1  
WGCNA Weighted Gene Co-expression Network Analysis  
WTCCC Wellcome trust case control consortium 
  
9 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
  
10 
 
Contents 
1.1 What is epilepsy? ........................................................................................................... 11 
1.2 Prevalence and burden of epilepsy ................................................................................ 12 
1.3 Pharmacological treatment of epilepsy ......................................................................... 13 
1.4 Pharmacoresistance in epilepsy ..................................................................................... 14 
1.5 Prognostic factors for pharmacoresistance in epilepsy ................................................. 15 
1.6 Aetiology of pharmacoresistance in epilepsy ................................................................ 16 
1.6.1 The MDT hypothesis ................................................................................................ 16 
1.6.1.1 Studies suggesting increased expression or function of P-gp in epilepsy ........ 17 
1.6.1.2 Does P-gp transport AEDs? ............................................................................... 20 
1.6.1.3 Is there an association between ABCB1 genotypes and response to AEDs? ... 22 
1.6.1.4 Transporters other than P-gp ........................................................................... 30 
1.6.2 The drug target hypothesis...................................................................................... 31 
1.6.3 The ‘intrinsic severity’ hypothesis ........................................................................... 32 
1.6.3.1 Seizure frequency as a marker of disease severity ........................................... 33 
1.6.3.2 Severity predicts treatment response .............................................................. 33 
1.6.3.3 Genetic contribution to intrinsic severity: ........................................................ 34 
1.6.3.4 Critiques of the intrinsic severity hypothesis: .................................................. 35 
1.7 Analytical strategies for studying complex genetic diseases ......................................... 36 
1.7.1 The genetic architecture of common epilepsies and response to AEDs ................. 36 
1.7.2 Studying structural genetic variation: ..................................................................... 38 
1.7.3 Studying genetic function: transcriptomic analysis................................................. 39 
1.7.4 Limitations of genetic and transcriptomic studies .................................................. 40 
1.7.5 Integrative approaches ............................................................................................ 41 
1.7.5.1 Network mapping ............................................................................................. 41 
1.7.5.2 Integration of intermediate phenotypes .......................................................... 49 
1.8 Aims of this work ............................................................................................................ 51 
1.9 References ...................................................................................................................... 52 
  
11 
 
Chapter 1: Introduction 
In this introductory chapter, I will define epilepsy; review its burden on the individual and 
society; explain its pharmacological treatment; describe the problem of resistance to this 
treatment; and list the features and prognostic indicators of, and explore possible causes 
underlying, this drug resistance. I will then define and describe the methodology of 
integrative genetics and genomic analysis and explain why this approach is needed in order 
to understand pharmacoresistance in epilepsy. 
1.1 What is epilepsy? 
In 2005, a Task Force of the International League Against Epilepsy (ILAE) formulated 
conceptual definitions of ‘seizure’ and ‘epilepsy’ (Fisher et al. 2005). An epileptic seizure was 
defined as ‘a transient occurrence of signs and/or symptoms due to abnormal excessive or 
synchronous neuronal activity in the brain’. Epilepsy was defined as ‘a disorder of the brain 
characterized by an enduring predisposition to generate epileptic seizures, and by the 
neurobiologic, cognitive, psychological, and social consequences of this condition’. The 
definition of epilepsy required the occurrence of at least one epileptic seizure. 
More recently, the ILAE commissioned a Task Force to formulate an operational definition 
of epilepsy for purposes of clinical diagnosis (Fisher et al. 2014). In December of 2013, the 
ILAE Executive Committee adopted the recommendations as a position of the ILAE. 
According to this definition, epilepsy is a disease of the brain defined by any of the following 
conditions 
1. At least two unprovoked seizures occurring >24 hours apart. 
2. One unprovoked seizure and a probability of further seizures similar to the general 
recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 
10 years. 
3. Diagnosis of an epilepsy syndrome. 
Seizure types are divided into two broad categories: (1) generalised or (2) focal (also termed 
partial or localization-related). Generalized seizures are conceptualized as those that 
originate at some point within, and rapidly engage bilaterally distributed networks (Berg et 
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al. 2010). Focal seizures originate in networks limited to one cerebral hemisphere (Berg et 
al. 2010). 
The behavioural manifestations of seizures are protean. This is especially true among focal 
seizures where the clinical features vary based on the cortical location of the seizure onset 
zone. For example, possible features of mesial temporal lobe epilepsy (TLE), which is 
commonly caused by hippocampal sclerosis (neuronal cell loss and gliosis in the 
hippocampus), include mnestic, gustatory and olfactory sensations. TLE is the most frequent 
type of refractory partial epilepsy and considered the prototype of surgically remediable 
epilepsies (Mayanagi et al. 1996). 
Table 1.1 Incidences of epileptic syndromes (per 100,000 person years) in three published 
studies 
Type Syndrome (Loiseau et al. 
1990) 
(Zarrelli et al. 
1999) 
(Olafsson et al. 
2005) 
Focal 
epilepsies 
Total 15.3 34.9 18.6 
Idiopathic 1.7 0.2 1.6 
Symptomatic 13.6 17.2 8.4 
Cryptogenic - 17.5 8.6 
Generalised 
epilepsies 
Total 7.2 7.7 3.9 
Idiopathic 6.1 3.7 3.1 
Cryptogenic 1.1 1.7 0.7 
Symptomatic - 2.3 0.1 
 
1.2 Prevalence and burden of epilepsy 
Epilepsy is the most common neurological disorder after stroke: 65 million people have 
epilepsy worldwide (Ngugi et al. 2010). The prevalence of epilepsy varies by population. In 
developed countries, the prevalence is around 700 per 100,000 (Hirtz et al. 2007). In low 
and middle income countries, the prevalence is generally higher. For example, in Ethiopia, a 
developing country, the prevalence of epilepsy is as high as 29.5 per 1000 (95% confidence 
interval 20.5 to 40.9 per 1000) (Ngugi et al. 2010; Thurman et al. 2011). There are 2.6 million 
people with epilepsy in Europe (Olesen et al. 2012), and 400,000 new cases each year 
(Forsgren et al. 2005). 
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The global disease burden from epilepsy, measured as disability-adjusted life years, is higher 
than that for Alzheimer’s disease and other dementias, multiple sclerosis, and Parkinson’s 
disease combined (Murray et al. 2012). The global disease burden from epilepsy is greater 
than that of breast cancer for women, and nearly four-times greater than that of prostate 
cancer for men (Murray et al. 2012). In Europe, the total cost of epilepsy per year is €13.8 
billion (Olesen et al. 2012). 
At the individual level, the consequences of epilepsy can be severe and include shortened 
lifespan, physical injury, neuropsychological and psychiatric sequelae, and social and 
financial disadvantage (Sperling 2004). 
 
1.3 Pharmacological treatment of epilepsy 
Currently available antiepileptic drugs (AEDs) aim to achieve symptom control, i.e., 
suppression of seizures, but have no known impact on the underlying pathophysiology of 
epilepsy. A seizure is the clinical manifestation of a hyperexcitable neuronal network, in 
which the electrical balance underlying normal activity is pathologically altered. Effective 
seizure treatment generally augments inhibitory processes or opposes excitatory processes.  
The serendipitous discovery of phenobarbital in 1912 marked the beginning of the modern 
pharmacotherapy of epilepsy (Yasiry & Shorvon 2012). In the 100 years since, many new 
AEDs have been discovered (Table 1.2). Their mechanisms of action (Table 1.2) fall into a 
number of general categories: the main groups include sodium channel blockers, calcium 
current inhibitors, -aminobutyric acid (GABA) enhancers, and glutamate blockers. 
However, the mode of action of some AEDs falls outside these broad categories. Also, many 
AEDs possess multiple mechanisms of action. Finally, the primary mode of action of some 
AEDs remains to be discovered (Guimaraes & Ribeiro 2010). 
A proportion of patients with epilepsy are pharmacoresistant (see section 1.4 below): they 
continue to experience seizures despite treatment with maximal doses of multiple AEDs 
with different molecular targets and mechanisms of actions. For such patients, surgical 
treatment options may be considered, including surgical resection of the epileptic focus (for 
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example the epileptic hippocampus in mesial temporal lobe epilepsy), vagal nerve 
stimulation (Englot et al. 2011), and deep brain stimulation (Lega et al. 2010). 
 
Table 1.2 AEDs: table listing year in which the AED was first approved or marketed in the US 
or Europe, and its mode of action. Data is from (Schmidt & Schachter 2014). 
AED Year Presumed mechanism of action 
Potassium bromide 1857 GABA potentiation? 
Phenobarbital 1912 GABA potentiation 
Phenytoin 1938 Na+ channel blocker 
Primidone 1954 GABA potentiation 
Ethosuximide 1958 T-type Ca2+ channel blocker 
Diazepam 1963 GABA potentiation 
Carbamazepine 1964 Na+ channel blockade 
Valproate 1967 Multiple, including: GABA potentiation, glutamate (NMDA) 
inhibition, sodium channel and T-type calcium channel blockade 
Clonazepam 1968 GABA potentiation 
Clobazam 1975 GABA potentiation 
Vigabatrin 1989 GABA potentiation 
Lamotrigine 1990 Na+ channel blocker 
Oxcarbazepine 1990 Na+ channel blocker 
Gabapentin 1993 Ca2+ channel blocker (α2d subunit) 
Topiramate 1995 Multiple, including: GABA potentiation, glutamate (AMPA) 
inhibition, sodium and calcium channel blockade 
Levetiracetam 2000 SV2A modulation 
Zonisamide 2000 Na+ channel blocker 
Stiripentol 2002 GABA potentiation, Na+ channel blocker 
Pregabalin 2004 Ca2+ blocker (α2d subunit) 
Rufinamide 2004 Na+ channel blocker 
Lacosamide 2008 Enhanced slow inactivation of voltage gated Na+ channels 
Eslicarbazepine 2009 Na+ channel blocker 
Perampanel 2012 Glutamate (AMPA) antagonist 
 
1.4 Pharmacoresistance in epilepsy 
The Task Force of the ILAE Commission on Therapeutic Strategies has defined the minimum 
criteria for drug resistant epilepsy as the ‘failure of adequate trials of two tolerated and 
appropriately chosen and used AED schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom’ (Kwan et al. 2010). To be regarded as 
an adequate trial, the AEDs must be “appropriate” for the patient’s epilepsy and seizure 
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type, and must be administered at therapeutic doses for sufficient lengths of time. Seizure 
freedom is defined as freedom from seizures for a minimum of three times the longest pre-
intervention inter-seizure interval (determined from seizures occurring within the past 12 
months) or 12 months, whichever is longer. This definition is based on observational cohort 
studies of newly diagnosed epilepsy in adults (Kwan & Brodie 2000; Mohanraj & Brodie 
2006) and children (Arts et al. 2004) which suggest that once two appropriately trialled AEDs 
have proven to be inefficacious, the probability of achieving seizure freedom with 
subsequent AED treatments is minimal. Some recent studies appear to suggest that a 
proportion of these patients may still become seizure-free with subsequent drug 
manipulation (Callaghan et al. 2007; Luciano & Shorvon 2007), but these studies were 
retrospective, and did not take into account the reasons for failure which may have included 
inappropriately chosen AEDs or suboptimal treatment schedules. A recent report from a 
prospective study in children documented that although many patients who had failed two 
adequate trials of AEDs had periods of seizure freedom with further drug trials, lasting 
remission remained elusive (Berg et al. 2006). 
30% of epilepsy patients are pharmacoresistant (Shorvon 1996; Tellez-Zenteno et al. 2014).  
1.5 Prognostic factors for pharmacoresistance in epilepsy 
A recent and comprehensive systematic review has summarized the evidence for 
independent prognostic factors for pharmacoresistant epilepsy derived from eleven 
published cohort studies (Wassenaar et al. 2013). Significant prognostic factors were 
symptomatic aetiology, focal seizures, younger age at onset, a high initial seizure frequency, 
epileptic EEG abnormalities, and several clinical items, such as a history of febrile seizures, 
status epilepticus, and a neurodevelopmental delay 
It is important to note that prognostic factors are not necessarily causally related to the 
outcome (Tripepi et al. 2008). Prognostic research is aimed at predicting the risk (that is the 
probability) of disease without any concern about causality. In contrast, aetiological 
research aims to investigate the causal relationship between putative determinants and a 
given disease. In the next section, we consider different theories which have been put 
forward in order to explain the development of pharmacoresistance in epilepsy. 
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1.6 Aetiology of pharmacoresistance in epilepsy 
Three distinct hypotheses have been put forward to explain the development of 
pharmacoresistance in epilepsy:  
1. The multidrug transporter (MDT) hypothesis. 
2. The drug target hypothesis. 
3. The intrinsic severity hypothesis. 
The merits and demerits of each hypothesis are discussed below. It is important to note, 
however, that these hypotheses are not mutually exclusive, and may act in an integrated 
manner to produce pharmacoresistance (Schmidt & Loscher 2009). 
1.6.1 The MDT hypothesis 
 
Figure 1.1 Examples of ABC and SLC transporters at the blood-brain barrier (Giardin 2006). 
ABC transporters require energy from ATP hydrolysis to actively remove compounds from 
the cell. In contrast, for many (though not all) SLCs the transport mechanism is based upon 
anion exchange. BCRP: breast cancer resistance protein; MDR1: multidrug resistance protein 
1, also known as P-gp; MRP: multidrug resistance protein; OATP: organic anion transporting 
protein; OCT: organic cation transporter. 
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Over the last two decades, the most popular and extensively studied hypothesis of epilepsy 
pharmacoresistance has been the MDT hypothesis (Chayasirisobhon 2009). According to 
this hypothesis, pharmacoresistance results from impaired drug penetration into the 
epileptic focus secondary to a localized dysregulation of drug transporters (Chayasirisobhon 
2009). MDTs have been implicated in pharmacoresistance in a number of diseases. The 
MDTs involved in drug resistance in humans are either adenosine triphosphate-binding 
cassette (ABC) proteins (Tiwari et al. 2011) or solute carrier (SLC) proteins (Figure 1.1) 
(Huang & Sadee 2006). There are over 450 known ABC and SLC proteins in total. However, 
research on the MDT hypothesis in epilepsy has been focused almost exclusively one ABC 
transporter: ABCB1 or P-glycoprotein (P-gp).  
1.6.1.1 Studies suggesting increased expression or function of P-gp in epilepsy 
P-gp was first suspected of playing a role in pharmacoresistance in 1979 when its expression 
was found to correlate with resistance to cancer chemotherapy in Chinese hamster ovary 
cells (Riordan & Ling 1979). In 1995, P-gp expression was shown to be increased (Tishler et 
al. 1995) in epileptic foci resected during brain surgery for intractable epilepsy. Since then, 
the overexpression of P-gp in epileptogenic lesions resected during brain surgery for 
refractory epilepsy was shown to be a common feature of different pathologies associated 
with drug-resistant epilepsy (Aronica et al. 2012), for example focal malformations of 
cortical development, hippocampal sclerosis, and tuberous sclerosis.  
Other data from studies on people with drug-resistant epilepsy have also been cited in 
support of a role for P-gp in epilepsy pharmacoresistance. Post-mortem analysis of tissue 
from pharmacoresistant temporal lobe epilepsy patients showed a significantly higher 
percentage area of P-gp-immunopositive labelling in the sclerotic epileptogenic 
hippocampus than in the contralateral hippocampus (Liu et al. 2012). A significant inverse 
linear correlation was found between the brain-to-plasma concentration ratio of an active 
metabolite of oxcarbazepine and the level of brain expression of the ABCB1 mRNA (Marchi 
et al. 2005). 
The results of a recent positron emission tomography (PET) imaging study (Feldmann et al. 
2013) are suggestive of higher P-gp activity in some brain regions for pharmacoresistant 
patients than for seizure-free temporal lobe epilepsy patients. PET revealed reduced uptake 
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of the radio-labelled form of verapamil, a P-gp substrate, in pharmacoresistant compared 
with seizure-free patients. Administration of P-gp inhibitor tariquidar led to an increase in 
the uptake of the radio-labelled substrate. However, it should be noted that the purported 
P-gp overactivity was also seen in areas outside the epileptic focus (for example the 
contralateral hippocampus), which is contrary to the MDT hypothesis, and the response to 
tariquidar was more pronounced in normal subjects than in the refractory epilepsy patients 
with purported P-gp overactivity. 
The results of some studies on animal models of epilepsy are also consistent with a possible 
role of P-gp in epilepsy pharmacoresistance. Kainic acid-induced limbic seizures transiently 
increase P-gp expression in the mouse hippocampus (Rizzi et al. 2002). Pharmacoresistant 
epileptic rats exhibit higher endothelial P-gp expression in limbic regions ipsilateral to the 
seizure focus than do pharmacosensitive rats (Volk & Loscher 2005). Brain/plasma ratio of 
phenytoin was significantly lower in brain regions that had P-gp overexpression (temporal 
hippocampus and parahippocampal cortex) in chronic epileptic rats than in the same brain 
regions in non-epileptic rats, and administration of P-gp inhibitor tariquidar to chronic 
epileptic rats significantly increased the phenytoin brain/plasma ratio in these brain regions 
(van Vliet et al. 2007). Also, studies utilising brain microdialysis in rats have shown that 
carbamazepine (Ma et al. 2013) and phenytoin (Potschka & Loscher 2001; Ma et al. 2013) 
levels in cerebral tissue extracellular fluid increase significantly after the administration of P-
gp inhibitors. Knock-out mice lacking P-gp protein show significant increase in phenytoin 
and carbamazepine concentrations in the hippocampus compared with wild-type mice (Rizzi 
et al. 2002). Co-administration of P-gp inhibitor tariquidar to phenobarbital-resistant rats 
restored the antiepileptic activity of phenobarbital without altering plasma 
pharmacokinetics of the antiepileptic drug (Brandt et al. 2006). Similarly, in the electrical 
post–status epilepticus rat model for temporal lobe epilepsy, co-administration of tariquidar 
improved the anticonvulsive action of phenytoin without altering plasma pharmacokinetics 
of the antiepileptic drug (van Vliet et al. 2006). 
Although the above findings are consistent with a possible role for P-gp in mediating 
pharmacoresistance in epilepsy, there is also a large body of compelling evidence (discussed 
below) which suggests that P-gp is unlikely to play a major role in the development of drug 
resistance in epilepsy. 
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1.6.1.2 Does P-gp transport AEDs? 
Table 1.3 AEDs shown not to be substrates for human P-gp 
AED References 
Carbamazepine (Owen et al. 2001; Mahar Doan et al. 2002; Weiss et al. 2003; 
Crowe & Teoh 2006; Baltes et al. 2007b; Feng et al. 2008; Luna-
Tortos et al. 2008; Zhang et al. 2011; Dickens et al. 2013) 
Diazepam (Cucullo et al. 2007; Feng et al. 2008) 
Ethosuximide (Crowe & Teoh 2006; Feng et al. 2008; Zhang et al. 2010) 
Gabapentin (Weiss et al. 2003; Crowe & Teoh 2006) 
Lacosamide (Zhang et al. 2013)  
Lamotrigine (Weiss et al. 2003; Crowe & Teoh 2006; Feng et al. 2008; Dickens et 
al. 2013) 
Levetiracetam (Baltes et al. 2007b) 
Midazolam (Feng et al. 2008) 
Phenobarbitone (Crowe & Teoh 2006) 
Phenytoin (Weiss et al. 2003; Crowe & Teoh 2006; Baltes et al. 2007b; Feng et 
al. 2008) 
Pregabalin (Chan et al. 2014) 
Rufinamide (Chan et al. 2014) 
Topiramate (Weiss et al. 2003; Crowe & Teoh 2006) 
Valproic acid (Weiss et al. 2003; Baltes et al. 2007a) 
Vigabatrin (Crowe & Teoh 2006) 
Zonisamide (Chan et al. 2014) 
 
If the overexpression of P-gp truly underlies pharmacoresistance in epilepsy, then many (if 
not all) AEDs must be substrates for this transporter. Although some studies have 
demonstrated the transport of a small number of AEDs by P-gp in animal models (Zhang et 
al. 2012), this transport was very weak. For vincristine, a classic P-gp substrate, inhibition of 
P-gp resulted in a 9-fold increase in brain uptake (Drion et al. 1996). In comparison, P-gp 
inhibition only increased the uptake of phenytoin, carbamazepine, phenobarbital, 
lamotrigine, and felbamate, 0.5- to 1.1-fold over baseline (Potschka et al. 2001; Potschka & 
Loscher 2001; Potschka et al. 2002). In the ABCB1 knockout mouse model, brain uptake of 
classic P-gp substrates vinblastine, cyclosporine, and digoxin increased 20- to 50-fold 
(Schinkel et al. 1994; Schinkel et al. 1995). In comparison, there was only a 2-fold increase 
for topiramate, and no increase in brain uptake for phenytoin, phenobarbital, 
carbamazepine, or lamotrigine (Sills et al. 2002). Therefore, the effect of P-gp on the brain 
uptake of AEDs in animal models is barely measurable (Anderson & Shen 2007). In addition, 
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there are inter-species differences in the substrate specificity of P-gp (Baltes et al. 2007b), 
and evidence for the lack of P-gp-mediated AED transport is even stronger in human studies. 
Numerous studies employing many different experimental models have repeatedly 
demonstrated that the most commonly prescribed AEDs are not substrates for human P-gp 
(Table 1.3).  
Is there any evidence that human P-gp is able to transport AEDs? Cucullo and colleagues 
(Cucullo et al. 2007) demonstrated weak transport of phenytoin by P-gp in an in vitro human 
epileptic blood-brain barrier model. However, other studies using the well-established 
hCMEC/D3 human blood-brain barrier model (Dickens et al. 2013); Caco-2 monolayers 
(Crowe & Teoh 2006); and transwell systems of polarized MDCKII dog kidney or LLC-PK1 pig 
kidney cells transfected with human ABCB1 (Weiss et al. 2003; Baltes et al. 2007b; Feng et 
al. 2008) have not found evidence to support transport of phenytoin by human P-gp.  
Given the lack of evidence for human P-gp-mediated transport of AEDs in studies using 
conventional widely accepted and well characterized in vitro assays, some researchers have 
recently employed a new in vitro system called concentration equilibrium transport assay 
(CETA) in an attempt to demonstrate transport of AEDs by human P-gp (Luna-Tortos et al. 
2008). The authors (Luna-Tortos et al. 2008) have argued that as AEDs have high 
permeability across cell barriers and low affinity for P-gp, diffusion across the cell layer may 
mask directional transport. In CETA, in order to remove the concentration gradient and thus 
diffusion, the drug is added at identical concentration to both sides of a polarized, P-gp-
overexpressing cell monolayer, instead of applying the drug to either the apical or 
basolateral side as in a conventional bi-directional assay. In the CETA system, P-gp-mediated 
transport has been demonstrated for phenytoin, phenobarbital, lamotrigine and 
levetiracetam (Luna-Tortos et al. 2008), topiramate (Luna-Tortos et al. 2009), oxcarbazepine 
and eslicarbazepine (Zhang et al. 2011), and lacosamide (Zhang et al. 2013). However, 
positive results in the CETA system cannot be taken as proof that P-gp-mediated transport 
of the AED is relevant in pharmacoresistant epilepsy, for the reasons stated below: 
1. The design of the CETA system is not an accurate representation of the conditions in 
vivo: the concentration of an actively transported drug is highly unlikely to be 
identical on both sides of a biological barrier in vivo (Dickens et al. 2013). 
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2. In the CETA system, the transport of even the most potently transported AED 
(topiramate) was approximately 75% less than for the classic P-gp substrate digoxin 
(Luna-Tortos et al. 2009), further demonstrating that AEDs are not strong substrates 
for P-gp. 
3. Given the high permeability of AEDs across cell barriers and their low affinity for P-
gp, the lack of AED transport in traditional bi-directional assays but weak transport in 
the CETA indicates that the passive diffusion component predominates over the 
active transport, resulting in the absence of significant efflux (Zhang et al. 2013). 
4. P-gp inhibitor tariquidar only partially inhibited transport of levetiracetam and 
phenobarbital (Luna-Tortos et al. 2008), demonstrating that P-gp was not solely 
responsible for the modest transport of these AEDs seen in the CETA system. 
5. The AED transport demonstrated by Luna-Tortos and colleagues (Luna-Tortos et al. 
2008) using the CETA system has not been recreated in an independent study, for at 
least one AED (Dickens et al. 2013). 
In summary, after many years of intense research efforts, there remains a lack of convincing 
evidence that AEDs are high-affinity substrates of human P-gp. 
1.6.1.3 Is there an association between ABCB1 genotypes and response to AEDs? 
In 2003, Siddiqui and colleagues reported a positive association between the ABCB1 
C.3435C>T genotype and poor response to AEDs (Siddiqui et al. 2003). Subsequent to this, at 
least 28 independent genetic association studies (Table 1.3) and at least three meta-
analyses (Leschziner et al. 2007; Bournissen et al. 2009; Haerian et al. 2010) have failed to 
find evidence for this association.  
Two other ABCB1 variants (C.2677C>T and C.1236C>T) have also been the subject of genetic 
association studies in pharmacoresistant epilepsy. For C.2677C>T, approximately 75% of the 
genetic association studies have been negative, while all the C.1236C>T genetic association 
studies have been negative (Table 1.4). Haplotypes of the three aforementioned variants 
have also been analysed and, again, have produced conflicting results (Table 1.4). 
Currently, there is no convincing evidence of a genetic association between ABCB1 variants 
and response to AEDs. It should be noted that the vast majority of the genetic association 
studies are underpowered. There is also a high degree of heterogeneity between the 
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studies, especially in the definition of drug resistance employed, the controls used, types of 
epilepsy included, and the range of AEDs utilised. There is a need for a well-designed and 
adequately powered study in order to resolve the controversial question of whether there is 
an association between ABCB1 genetic variants and epilepsy pharmacoresistance. 
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Table 1.4 Summary of published ABCB1 genotyping studies. 
First author Year Country n - T n - E Definition - T Definition - E Epilepsy 
type 
AEDs D A Gen 
 C.3435C>T                      
Siddiqui 2003 UK 200 115 4 seizures in year 1 year seizure free NS Various R Y CC 
Hajnsek 2004 Croatian 30 30 4 seizures in year 1 year seizure free Various Various R Y TT 
Tan 2004 USA 401 208 4 seizures in year 1 year seizure free Various Various R N - 
Hung 2005 Taiwan 108 223 10 seizures in year 2 year seizure free Various Various R Y CC 
Sills 2005 UK 230 170 1 seizure in a year 1 year seizure free Various NS R N - 
Kim 2006a Korea 99 100 4 seizures in year 1 year seizure free NS Various R N - 
Kim 2006b Korea 99 108 4 seizures in year 1 year seizure free NS Various R N - 
Seo 2006 Japan 126 84 1 seizure in a year 1 year seizure free Various Various R Y TT 
Chen 2007 China 50 164 UTD UTD UTD UTD R N - 
Ebid 2007 Egypt 63 37 1 seizure in 3 months 3 months seizure free Various PHT P Y CC 
Hung 2007 Taiwan 114 213 10 seizures in year 2 year seizure free Various Various R Y CC 
Kwan 2007 China 221 297 1 seizure per month  
over the previous year 
1 year seizure free Various Various R Y CC 
Leschziner 2007 UK 73 76 4 seizures in year or  
epilepsy surgery 
Any patient not 
fulfilling DRE criteria 
NS Various R N - 
Lu 2007 China 72 62 UTD UTD UTD UTD R Y CC 
Shahwan 2007 Ireland 124 242 <50% reduction in 
seizure frequency in 
year prior to recruitment 
50% reduction in 
seizure frequency in 
the year before 
recruitment 
Various Various R N - 
Dericioglu 2008 Turkey 89 100 Resective surgery for 
DRE 
Healthy volunteers Partial Various R N - 
Ozgon 2008 Turkey 44 53 4 seizures in year 1 year seizure free Various CBZ R N - 
Gao 2009 China 70 62 UTD UTD UTD UTD R N - 
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First author Year Country n - T n - E Definition - T Definition - E Epilepsy 
type 
AEDs D A Gen 
Kim 2009 Korea 198 193 4 seizures in year 1 year seizure free Partial Various R N - 
Kwan 2009 China 194 270 1 seizure per month  
over the previous year 
1 year seizure free Various Various R N - 
Lakhan 2009 India 94 231 4 seizures in year 1 year seizure free Various Various R N - 
Szoeke 2009 Australia,  
Scotland,  
Hong Kong 
208 334 1 seizure in 1 year of 
initial treatment 
 No seizures over the 
first year of treatment 
Various Various P N - 
Ufer 2009 Germany 118 103 NS NS Various Various R N - 
Vahab 2009 India 113 129 <6 months terminal 
remission with trials of 
2 AEDs 
1 year seizure free Various Various R N - 
Alpman 2010 Turkey 39 92 2 seizures while using 
2 AEDs within a 2-year 
period 
Healthy individuals  Various Various R N - 
Grover 2010 India 95 133 1 seizure in 10 months 10 months seizure 
free 
Various Various R N - 
Sanchez* 2010 Spain 111 178 4 seizures in year 1 year seizure free Various Various R N - 
Dong 2011 China 157 193 4 seizures in year 1 year seizure free Various Various R N - 
Haerian 2011a Malaysia 323 362 1 seizure in a year 1 year seizure free Various CBZ or 
VPA 
R N - 
Haerian 2011b Malaysia 249 256 1 seizure in a year 1 year seizure free Various VPA R N - 
Meng 2011 China 24 60 <50% reduction in 
seizure frequency in the 
year prior to last follow-
up 
50% reduction in 
seizure frequency in  
the year prior to last 
follow-up 
Various CBZ R N - 
Sayyah 2011 Iran 132 200 1 seizure per month  
over the previous year 
1 year seizure free Various Various R Y CC 
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First author Year Country n - T n - E Definition - T Definition - E Epilepsy 
type 
AEDs D A Gen 
Sporis 2011 Croatian 57 48 1 seizure per month  
over the previous year 
1 year seizure free Partial Various R N - 
Qu 2012 China 217 320 4 seizures in year 1 year seizure free Various Various R N - 
Sterjev 2012 Macedonia 68 94 4 seizures in year 1 year seizure free Various CBZ R N - 
Subenthiran  2013 Malaysia 162 152 NS 1 year seizure free Complex 
partial 
CBZ R Y TT 
Saygi 2014 Turkey 59 60 4 seizures in year 1 year seizure free Various Various R N - 
Seven 2014 Turkey 69 83 4 seizures over a period 
of 1 year with three 
AEDs 
NS Various Various R N - 
C.2677C>T                      - 
Hung 2005 Taiwan 108 223 10 seizures in year 2 year seizure free Various Various R N - 
Kim 2006 Korea 99 108 4 seizures in year 1 year seizure free NS Various R N - 
Seo 2006 Japan 126 84 1 seizure in a year 1 year seizure free Various Various R Y TT 
Kwan** 2009 China 194 270 1 seizure per month  
over the previous year 
1 year seizure free Various Various R Y TT 
Lakhan 2009 India 94 231 4 seizures in year 1 year seizure free Various Various R N - 
Vahab 2009 India 113 129 <6 months terminal 
remission with trials of 
2 AEDs 
1 year seizure free Various Various R N - 
Alpman 2010 Turkey 39 92 2 seizures while using 
2 AEDs within a 2-year 
period 
Healthy individuals  Various Various R N - 
Grover 2010 India 95 133 1 seizure in 10 months 10 months seizure 
free 
Various Various R N - 
Dong 2011 China 157 193 4 seizures in year 1 year seizure free Various Various R N - 
Haerian 2011 Malaysia 323 362 1 seizure in a year 1 year seizure free Various CBZ/VPA R N - 
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First author Year Country n - T n - E Definition - T Definition - E Epilepsy 
type 
AEDs D A Gen 
Haerian 2011 Malaysia 249 256 1 seizure in a year 1 year seizure free Various VPA R N - 
Meng 2011 China 24 60 <50% reduction in 
seizure frequency in the 
year prior to last follow-
up 
50% reduction in 
seizure frequency in  
the year prior to last 
follow-up 
Various CBZ R N - 
Sayyah 2011 Iran 132 200 1 seizure per month  
over the previous year 
1 year seizure free Various Various R Y - 
Subenthiran  2013 Malaysia 162 152 NS 1 year seizure free Complex 
partial 
CBZ R Y TT 
Seven 2014 Turkey 69 83 4 seizures over a period 
of 1 year with three 
AEDs 
NS Various Various R N - 
 C.1236C>T                     - 
Hung 2005 Taiwan 108 223 10 seizures in year 2 year seizure free Various Various R N - 
Kim 2006 Korea 99 108 4 seizures in year 1 year seizure free NS Various R N - 
Seo 2006 Japan 126 84 1 seizure in a year 1 year seizure free Various Various R N - 
Lakhan 2009 India 94 231 4 seizures in year 1 year seizure free Various Various R N - 
Vahab 2009 India 113 129 <6 months terminal 
remission with trials of 
2 AEDs 
1 year seizure free Various Various R N - 
Grover 2010 India 95 133 1 seizure in 10 months 10 months seizure 
free 
Various Various R N - 
Dong 2011 China 157 193 4 seizures in year 1 year seizure free Various Various R N - 
Haerian 2011 Malaysia 323 362 1 seizure in a year 1 year seizure free Various CBZ or 
VPA 
R N - 
Haerian 2011 Malaysia 249 256 1 seizure in a year 1 year seizure free Various VPA R N - 
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First author Year Country n - T n - E Definition - T Definition - E Epilepsy 
type 
AEDs D A Gen 
Meng 2011 China 24 60 <50% reduction in 
seizure frequency in the 
year prior to last follow-
up 
50% reduction in 
seizure frequency in  
the year prior to last 
follow-up 
Various CBZ R N - 
 Haplotype***                     - 
Zimprich 2004 Austria **** **** **** **** TLE Various R Y CGC 
Hung 2005 Taiwan 108 223 10 seizures in year 2 year seizure free Various Various R Y - 
Kim 2006 Korea 99 108 4 seizures in year 1 year seizure free NS Various R N - 
Seo 2006 Japan 126 84 1 seizure in a year 1 year seizure free Various Various R Y - 
Leschziner 2007 UK 73 76 4 seizures in year or  
epilepsy surgery 
 Any patient not 
fulfilling DRE criteria 
NS Various R N - 
Kwan 2009 China 194 270 1 seizure per month  
over the previous year 
1 year seizure free Various Various R Y - 
Lakhan 2009 India 94 231 4 seizures in year 1 year seizure free Various Various R N - 
Vahab 2009 India 113 129 <6 months terminal 
remission with trials of 
2 AEDs 
1 year seizure free Various Various R N - 
Alpman 2010 Turkey 39 92 2 seizures while using 
2 AEDs within 2-years 
Healthy individuals  Various Various R Y - 
Grover 2010 India 95 133 1 seizure in 10 months 10 months seizure 
free 
Various Various R N - 
Dong 2011 China 157 193 4 seizures in year 1 year seizure free Various Various R N - 
Haerian 2011 Malaysia 323 362 1 seizure in a year 1 year seizure free Various CBZ/VPA R N - 
Meng 2011 China 24 60 <50% reduction in 
seizure frequency in the 
year prior to last follow-
up 
50% reduction in 
seizure frequency in  
the year prior to last 
follow-up 
Various CBZ R N - 
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Symbol Description 
T Drug resistant epilepsy 
I Drug responsive epilepsy 
AED Antiepileptic drug 
A Association found? 
Gen Genotype 
D Design: Prospective or retrospective 
UTD Unable to determine as full article not available or not available in English 
TLE Temporal lobe epilepsy 
NS Not specified 
CBZ Carbamazepine 
PHT Phenytoin 
VPA Sodium valproate 
* In subgroup analysis, CC genotype was significantly associated with DRE in adults or those with symptomatic epilepsy 
** Association found in males and in patients with localization-related epilepsy 
*** Haplotypes were of C.1236C>T, C.2677C>T and C.3435C>T in all studies, except for Kwan et al. (2009): rs3789243 and 
G2677T/A, and Haerian et al. (2011): rs3789243, C.1236C>T, C.2677C>T, rs6949448, C.3435C>T. 
**** Cohort was divided into 3 groups according to seizures per month: A ≤2 seizures (n=44), B >2 and and <6 seizures (n=83), C ≥6 
seizures (n=66) 
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1.6.1.4 Transporters other than P-gp 
Other transporters studied in epilepsy pharmacoresistance include ABCG2 (breast cancer 
resistance protein or BCRP), and six ABCC proteins: ABCC1 to ABCC6 (multidrug resistance-
associated protein 1 to 6; MRP1 to MRP6).  
As is the case for P-gp, the expression of ABCC1-ABBC6 and ABCG2 is increased in epileptic 
foci resected during brain surgery for intractable epilepsy (Tishler et al. 1995; Dombrowski et 
al. 2001; Sisodiya et al. 2001; Sisodiya et al. 2002; Aronica et al. 2003; Aronica et al. 2004; Lazarowski 
et al. 2004; Vogelgesang et al. 2004; Aronica et al. 2005; Kubota et al. 2006; Lazarowski et al. 2006; 
Ak et al. 2007). 
Human ABCC1, ABCC2 and ABCC5 were unable to transport common AEDs (carbamazepine, 
valproate, levetiracetam, phenytoin, lamotrigine, phenobarbital and topiramate) even in the 
permissive CETA model (Luna-Tortos et al. 2009; Luna-Tortos et al. 2010). Similarly, 
primidone, phenobarbital, phenytoin, carbamazepine, lamotrigine, clonazepam, 
ethosuximide and valproic acid were not substrates for ABCG2 in transport experiments 
performed in human BCRP-expressing MDCKII cell lines (Cerveny et al. 2006). AED transport 
assays have not been performed for ABCC3, ABCC4 and ABCC6.  
A number of genetic association studies for ABCC2 variants and pharmacoresistant epilepsy 
have been published; a recent comprehensive meta-analysis of these studies found no 
significant associations (Grover & Kukreti 2013). Similarly, no association was found 
between polymorphisms in ABCC2 and response to carbamazepine (Radisch et al. 2014). No 
genetic association has been found between pharmacoresistant epilepsy and variations in 
ABCC5 or ABCG2 (Kim et al. 2009; Kwan et al. 2011).  
A conspicuous omission in the search for MDTs underlying epilepsy pharmacoresistance is 
the solute carrier (SLC) superfamily of transporters. The largest superfamily of MDTs is the 
SLC superfamily (Huang & Sadee 2006). There are more than 400 known SLC proteins. It 
would be useful to adopt a comprehensive and systematic approach to investigating the 
role SLC transporters might play in epilepsy drug resistance. 
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1.6.2 The drug target hypothesis 
The second major hypothesis of AED pharmacoresistance is the target hypothesis. According 
to the target hypothesis, epilepsy pharmacoresistance occurs when changes in drug targets 
make them less sensitive to AEDs (Schmidt & Loscher 2005; Remy & Beck 2006). Reduced 
sensitivity to carbamazepine, phenytoin and lamotrigine has been observed in hippocampal 
neurons from patients with intractable temporal lobe epilepsy (Vreugdenhil et al. 1998; 
Schaub et al. 2007). Two forms of the target hypothesis have been proposed: (1) acquired 
and (2) genetic. In the acquired form, the change in the target occurs in conjunction with 
epileptogenesis, as a result of seizures, or as a consequence of drug treatment. In 
the genetic form there is an inherited, inborn difference in the target that confers 
resistance.  
 
The following observations have been cited to support the acquired version of this 
hypothesis. Firstly, in kindled rats, sodium channels were found to exhibit reduced 
sensitivity to carbamazepine which returned to normal 5 weeks after kindling, indicating 
that the changes were related to kindling and not the epileptic state per se, which is 
persistent (Vreugdenhil et al. 1998; Vreugdenhil & Wadman 1999). Secondly, there is a loss 
in benzodiazepine sensitivity in a rat model of temporal lobe epilepsy resulting from 
alterations in the subunit composition of GABAAreceptors (Brooks-Kayal et al. 1998). Thirdly, 
resistance develops to benzodiazepines during prolonged status epilepticus as a result of 
internalization of synaptic GABAA receptors (Wasterlain & Chen 2008; Fritsch et al. 2010; 
Joshi & Kapur 2012).  
 
In support of the genetic version of the drug target hypothesis, the following study has been 
cited. Tate et al. (Tate et al. 2005) reported that a common functional polymorphism in 
the SCN1A gene, which encodes an isoform of voltage-activated sodium channels, was 
associated with the maximum doses of phenytoin and carbamazepine used clinically 
 
There are a number of major criticisms of the drug target hypothesis. Firstly, follow-on 
studies have failed to replicate the association between polymorphism in the SCN1A gene 
and maximum doses of AEDs prescribed (Tate et al. 2006; Zimprich et al. 2008). Secondly, a 
comprehensive genetic association study and meta-analysis has failed to identify any 
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association between SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to 
antiepileptic drugs (Haerian et al. 2013). Thirdly, in amygdala-kindled epileptic rats, there is 
no difference in the inhibitory effect of phenytoin on sodium channels in acutely isolated 
hippocampal neurons from phenytoin responders and non-responders (Jeub et al., 2002). 
Fourthly, the validity of the target hypothesis is challenged by the broad range of molecular 
targets of AEDs, which include subunits of voltage-gated sodium and calcium channels as 
well α2δ proteins that are associated with calcium channels, GABAAreceptors, the GAT-1 
GABA transporter, the GABA catabolic enzyme GABA transaminase, KV7/KCNQ/M potassium 
channels, the synaptic vesicle protein SV2A, and AMPA receptors (Meldrum & Rogawski 
2007). Patients with drug-resistant epilepsy are for the most part resistant to all AEDs. 
Hence, targets of all the AEDs would need to be simultaneously modified to produce true 
multidrug resistance. Given the diversity of molecular targets it seems improbable that all of 
the targets would be modified in such a way as to produce pharmacoresistance to all 
available AEDs. Many of the newer drugs act at novel molecular targets that are entirely 
distinct from the targets of the older agents. If target-specific mechanisms were a factor in 
pharmacoresistance, as new, mechanistically novel AEDs were introduced into clinical 
practice there should have been a substantial reduction in the incidence of 
pharmacoresistance, but this has not occurred (Rogawski 2013). 
In summary, it is unlikely that the drug target hypothesis provides a unifying basis for 
pharmacoresistance in epilepsy. 
1.6.3 The ‘intrinsic severity’ hypothesis 
In 2008, Rogawski and Johnson formulated the ‘intrinsic severity hypothesis’ of 
pharmacoresistance in epilepsy (Rogawski & Johnson 2008). They postulated that 
pharmacoresistance is related to disease severity (Rogawski & Johnson 2008), and severity 
simply reflects the magnitude of the underlying epileptic process. In addition, separate 
factors likely regulate severity. Severity factors could be acquired as stochastic events during 
development or by environmental insults, or they could be genetically determined 
(Rogawski 2013).  
Rogawski and Johnson (Rogawski & Johnson 2008) have argued that the current view of 
pharmacoresistance in epilepsy conceptualizes resistance as a problem separate from the 
 
 
33 
 
disease itself, and this notion has constrained research in the field. This notion has proven 
equally unfruitful in other human diseases. There has been an enormous effort to define a 
role for drug transporters including P-gp as a cause of multidrug resistance in cancer and to 
develop transporter-targeted pharmacological strategies to overcome drug resistance in 
cancer. However, this line of research has not impacted cancer therapeutics. In contrast, 
therapies that take advantage of a deep understanding of cancer biology have been 
remarkably successful (Simon 2006). Similarly in epilepsy, it has been argued (Loscher & Sills 
2007) that there is no evidence that pharmacoresistance develops through mechanisms 
separate from the disease state itself but considerable evidence that the epilepsy in an 
individual patient has an inherent severity that defines the response to medication. 
In order to examine the validity of the intrinsic severity hypothesis, a measure or marker of 
disease severity must be established. It has been suggested that seizure frequency is an 
appropriate marker of disease severity in epilepsy. 
1.6.3.1 Seizure frequency as a marker of disease severity 
The concept that factors related to the occurrence of frequent seizures are associated with 
refractoriness seems biologically plausible: if the epilepsy is of a nature that seizures are 
easy to trigger leading to frequent seizures, then the seizures may also be more difficult to 
suppress. It has been observed in many acute seizure models that suppression of seizures 
conferred by any given dose of AED can be overcome by increasing the intensity of the 
pharmacological or electrical seizure stimulus (Barton et al. 2001). This suggests that if 
susceptibility to seizures is sufficiently high, it may not be possible to prevent recurrence of 
seizures with any nontoxic dose of an AED. 
1.6.3.2 Severity predicts treatment response 
There have been a number of prospective studies of outcome in newly treated epilepsy 
(Cockerell et al. 1997; MacDonald et al. 2000; Sillanpaa & Schmidt 2006) (Musicco et al. 
1997; van Donselaar et al. 1997; Marson et al. 2005; Kim et al. 2006; Leschziner et al. 2006; 
Mohanraj & Brodie 2006). A consistent finding across these studies is that the single most 
important factor associated with prognosis is the frequency of seizures in the early phase of 
epilepsy. Both the number of seizures pre-treatment (Kim et al. 2006; Leschziner et al. 2006; 
Mohanraj & Brodie 2006) and in the immediate period after presentation (MacDonald et al. 
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2000) influence the chance of remission. Indeed, the frequency of seizures in the early 
phase of epilepsy is the dominant risk factor influencing the chance of remission of seizures, 
outweighing the contribution from other factors associated with prognosis. In the National 
General Practice Study of Epilepsy (MacDonald et al. 2000), having 4 seizures in the 6-month 
period after diagnosis of epilepsy, compared to having a single seizure, was associated with 
a halving of the chance of seizure remission. In a hospital-based prospective cohort, patients 
with 11 or more seizures pre-treatment were more than twice as likely to be uncontrolled 
than patients with two or less seizures pre-treatment, independent of the time from first 
seizure to starting treatment (Mohanraj & Brodie 2006). These epidemiological data suggest 
that there are differences in inherent epilepsy severity reflected in the frequency of seizures 
in the early phase of the disease that influence an individual patient's response to AEDs, 
much in the same way that any other disease can vary from mild to severe and show a 
variable response to treatment. The observation that the occurrence of frequent seizures is 
associated with poorer outcome suggests that common neurobiological factors may 
underlie both epilepsy severity and pharmacoresistance. 
1.6.3.3 Genetic contribution to intrinsic severity: 
It has been suggested that genetic factors contribute to intrinsic severity. A number of 
observations support this assertion. There are variations in AED sensitivity within outbred 
rats subjected to the same epileptogenic treatment (Loscher & Rundfeldt 1991; Loscher 
2011), even though there is no difference in the severity of the seizure triggering 
epileptogenesis. These epileptic animals exhibit dramatic individual variability in response to 
AEDs, strongly suggesting that genetic factors play a key role in determining whether 
pharmacoresistance does or does not develop. Moreover, several reports have identified 
specific genetic variants conferring altered epilepsy severity in transgenic mouse models. A 
subclinical mutation in Kcnq2 was found to significantly increase epilepsy severity in mice 
bearing an epilepsy-inducing mutation in Scn2a (Kearney et al. 2006), and, similarly, 
mutations in Scn2a and Kcnq2 were found to increase epilepsy severity in an Scn1a epilepsy 
mutant (Hawkins et al. 2011). Finally, the results of a twin study suggest that genetic 
determinants of epilepsy susceptibility contribute to response to treatment (Johnson et al. 
2003). This study observed high correlations for outcome among twins concordant for 
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epilepsy syndrome, suggesting that epilepsy susceptibility genes have a major influence on 
outcome. 
1.6.3.4 Critiques of the intrinsic severity hypothesis: 
The intrinsic severity hypothesis has been criticised for the following reasons: 
1. Some previously intractable patients do achieve seizure freedom with new AEDs 
(Callaghan et al. 2007; Luciano & Shorvon 2007; Brodie 2010). This does not affect 
the potential validity of the intrinsic severity hypothesis, since a new AED that acts 
by a novel mechanism may be effective in a subset of patients because it is especially 
suited to the neurobiological abnormality underlying their epilepsy.  
2. Some patients with infrequent seizures are drug refractory. It should be noted, 
however, that there is no absolute scale on which to consider seizures frequent or 
infrequent. Furthermore, seizure frequency is not the sole measure of severity. 
Hence, a patient with less frequent seizures may actually have more severe epilepsy 
in the context of the seizure type and epilepsy type. For example, a person 
experiencing generalised tonic-clonic seizures with lower frequency may have a 
more severe epilepsy than another experiencing simple partial seizures with a higher 
frequency. Finally, if epilepsy is caused by an evolving brain pathology, for example 
mesial temporal sclerosis worsening over time, epilepsy may become refractory after 
a period of remission (Berg et al. 2003). 
3. Where response to treatment is defined as achieving freedom from seizures for a 
given period of time, it has been suggested that there is a potential for infrequent 
seizures to be misinterpreted as seizure remission (French 2006). However, if 
infrequent seizures give an erroneous impression of drug responsiveness because of 
the long interval of time between seizures, the association of seizure frequency with 
chance of remission should depend on the duration of the remission period 
analysed. In fact, the association is the same whether remission of epilepsy is 
defined as absence of seizures for a period of 1 or 5 years duration (MacDonald et al. 
2000). In addition, if patients with infrequent seizures and those with frequent 
seizures were equally drug responsive, then the practice of empirical titration of AED 
dose according to seizure recurrence should result in patients with frequent seizures 
achieving more rapid titration and therefore achieving remission of seizures in a 
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shorter period of time than patients with more widely spaced seizures. In practice, 
the opposite is observed (Leschziner et al. 2006).  
4. An alternative interpretation of the epidemiological data is that recurrent seizures 
render the epilepsy more resistant to treatment later on, leading to an acquired 
state of drug resistance. However, there is little evidence that ‘seizures beget 
seizures’ (Berg & Shinnar 1997; Shorvon & Luciano 2007), and good evidence that 
the chances of long-term remission of seizures are not dependent on the duration of 
epilepsy or early drug therapy (Musicco et al. 1997; Marson et al. 2005; Mohanraj & 
Brodie 2006).  
In summary, the intrinsic severity hypothesis offers an intuitive and appealing explanation of 
pharmacoresistance in epilepsy, and is supported by a wide range of epidemiological data. 
At the core of this hypothesis is the idea that pharmacoresistance is caused by increased 
dysfunction of the neurobiological processes underlying epilepsy. This hypothesis remains 
untested in the laboratory. As the processes underlying epilepsy are at present poorly 
understood, it is important that a comprehensive unbiased genome-wide analytical 
approach is adopted in order to identify the central causal mechanisms behind this 
condition. 
1.7 Analytical strategies for studying complex genetic diseases 
1.7.1 The genetic architecture of common epilepsies and response to AEDs 
Common or sporadic epilepsies can be defined as epilepsies ‘without an elicitable strong 
family history, and which are not obviously part of a broader condition (e.g. without 
learning difficulties, somatic malformation or facial dysmorphism)’ (Sisodiya & Mefford 
2011). Twin and family studies provide persuasive evidence that common epilepsies and 
response to AEDs are complex genetic phenotypes: they show evidence of hereditability 
without exhibiting a Mendelian pattern of inheritance (Lennox 1951; Ottman et al. 1996; 
Johnson et al. 2003; Vadlamudi et al. 2004; Tsai et al. 2013).  
Complex genetic diseases are thought to be caused by an unknown number of multiple 
genes, usually interacting with various environmental factors (Davey Smith et al. 2005). 
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There is compelling evidence that common genetic variants contribute to the susceptibility 
to common disease (Lohmueller et al. 2003). Specifically in epilepsy, a number of common 
variants have been found to increase the risk of developing epilepsy (see section 1.7.2). It 
has been suggested that epilepsy is caused by a ‘heterogeneous but pathogenic subsets of 
susceptibility alleles drawn from a much larger pool of potential susceptibility genes, 
meaning variation at no individual susceptibility gene is necessary or sufficient for seizures’ 
(Dibbens et al. 2007). However, it should be noted that rare genitive variations have also 
been found in some cases of common epilepsies (Sisodiya & Mefford 2011). Studies 
performed to date have found rare genetic variants in only small percentages of people with 
common epilepsies (Chen et al. 2003; Helbig et al. 2009; Heinzen et al. 2010). For example, 
Heinzen and colleagues found that the 16p13.11 deletion affects approximately 0.6% of 
patients in a diverse sporadic epilepsy cohort (Heinzen et al. 2010). The role of rare variants 
in the common epilepsies is at present under exploration by deep-sequencing approaches. 
No genetic variants have so far been convincingly shown to influence drug response in 
epilepsy.  
Traditional ‘candidate gene’ approaches have proven unfruitful in uncovering the causes of 
complex diseases as the number of involved genes is large, the disease genes might differ in 
different individuals, and each gene has a small effect size (Cho et al. 2012). In order to 
meet the challenge of studying complex genetic diseases, tools have been developed for the 
simultaneous large-scale genome-wide analysis of genes and gene products. The most 
widely used of these tools are Genome-Wide Association Studies (GWAS) for the 
identification of disease-associated genetic variants, and microarray studies for the 
identification of disease-associated gene transcripts; these tools are described below 
(sections 1.7.2 and 1.7.3). 
The polygenicity underlying a complex disease poses an intriguing translational challenge: 
how can the many different genes be coherently connected together? A parsimonious 
hypothesis is that the polygenic basis of a complex disorder is manifested in the 
dysregulation of one or a number of specific pathways. Genetic variations at many different 
loci could introduce numerous slight alterations that result in a pathway(s) that is 
insufficiently robust in response to an environmental insult. Risk for a complex disorder 
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could be conferred by the dysfunction of the pathway(s) rather than any single gene. 
Network mapping techniques are needed to understand of the roles of pathways in complex 
biological traits; these techniques are also discussed below (section 1.7.5). 
1.7.2 Studying structural genetic variation: 
The structural genetic variants most commonly subjected to whole-genome high throughput 
analyses are single nucleotide polymorphisms (SNPs). SNPs—common DNA sequence 
variations in which a single nucleotide differs between individuals—are the most abundant 
form of human genetic variation (Marth et al. 1999). A Genome-Wide Association Study 
(GWAS) surveys the whole of the genome for disease-associated SNPs. Millions of SNPs are 
analysed in a typical GWAS. By comparing the allele frequencies of genotyped SNPs 
between individuals with and without disease, a GWAS can identify putative causal variants 
or variants that are in strong linkage disequilibrium with putative causal variants. GWAS is a 
powerful tool in the study of complex diseases. GWAS has an impressive track record of 
success in complex human diseases and has yielded a plethora of findings: there are now 
well over 2000 loci that are significantly and robustly associated with one or more complex 
traits (Visscher et al. 2012). GWAS have also led to a number of notable discoveries about 
response to therapeutics. For example, a SNP close to the IL28B gene is associated with 
response to treatment for hepatitis C (Ge et al. 2009): the good response genotype is 
associated with a greater than 80% chance of clearance in European- Americans, while the 
poor response genotype is associated with only about a 30% chance. 
Compared to emergent deep-sequencing techniques (see below), GWAS is a mature and 
inexpensive technology; quality control, imputation, and analysis are readily accomplished; 
and there are large amounts of data that can be used for comparisons (Klein et al. 2010). 
The SNP content of most commercially-available GWAS arrays is sufficient to capture the 
majority of common variation in European populations (Klein et al. 2010). 
To date, there has been only one published GWAS of AED response, which did not find any 
significant variants (Speed et al. 2014). There have been a number of GWAS studies of 
susceptibility to common epilepsies, and a recent meta-analysis that included 8696 cases 
and 26 157 controls (2014) identified statistically significant loci at 2q24.3, implicating 
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SCN1A, and at 4p15.1, harbouring PCDH7. The vast majority of effect sizes for individual 
variants identified in GWAS are generally small (odds ratio ≤ 1.5) (Stranger et al. 2011). It 
has been suggested by utilizing even larger sample sizes, further susceptibility variants for 
epilepsy can be identified. The strategy of using very large sample sizes has proven highly 
effective in other neurological diseases, for example multiple sclerosis (Beecham et al. 
2013). It should be noted that another technique for increasing the power to detect genetic 
associations in GWAS is to use network modelling; this method is discussed in further detail 
below (section 1.7.5). 
Next-generation DNA sequencing, which allows a near comprehensive analysis of genetic 
variants, has to date been applied to only a small cohort of sporadic (idiopathic generalized) 
epilepsy patients in one study (Heinzen et al. 2012) and was restricted to exome 
sequencing; this limited study did not produce positive results. Larger scale deep-
sequencing studies in epilepsy are underway, and are likely to play an important role in 
finding rare disease-associated genetic variations which cannot be detected through GWAS. 
The analytical techniques discussed in this section provide valuable information about 
genetic structural variations, but do not provide an insight into changes in genetic function 
associated with epilepsy. High throughput transcriptomic analysis is a useful tool for 
performing a genome-wide study of changes in genetic function. 
1.7.3 Studying genetic function: transcriptomic analysis  
Transcriptomic analysis techniques include microarray studies and RNA sequencing (RNA-
seq). RNA-seq offers a number of advantages over microarrays, including enhanced 
sensitivity, but is also more costly (Wang et al. 2009b). Currently, microarray analysis is the 
more commonly used technology. To date, there are no published RNA-seq analyses of 
epileptic brain tissue, whereas there are a number of such microarray studies, which will be 
discussed in detail in Chapter 2. The most common form of microarray technology is the 
cDNA microarray. In this, mRNA extracted from the sample is reverse transcribed, with the 
simultaneous incorporation of label, and the resulting cDNA provides a quantifiable signal 
when it binds to complementary DNA spotted, in a grid arrangement, on to a solid support 
such as a glass slide (Wildsmith & Elcock 2001). The primary output from such studies is a 
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list of ‘differentially expressed’ genes: genes with significantly altered levels of expression in 
disease tissue relative to controls. Traditionally, a few of the most significantly dysregulated 
genes are chosen for further validation and study.  
Microarray studies have been used extensively and successfully to investigate biomarkers 
and mechanisms of human diseases and drug response (Gupta et al. 2010; Mendrick 2011; 
Aguilar et al. 2014; Davies et al. 2014; Raddatz et al. 2014; Zhu et al. 2014). 
1.7.4 Limitations of genetic and transcriptomic studies 
Although GWAS and microarray studies are powerful investigative techniques, limitations in 
the way data from these studies are traditionally analysed has constrained their potential 
impact on the understanding of disease.  
Microarray studies, on their own, cannot determine whether identified gene expression 
changes cause the disease, or are caused by the disease, or are unrelated to the disease 
process. Furthermore, it has been suggested that many of detected changes in gene 
expression are specific to laboratory or experimental conditions, and provide limited 
information about the underlying disease aetiology (Wang et al. 2010). Finally, the 
traditional methodology of choosing a few of the most significantly dysregulated genes for 
further validation and study underuses the ‘depth’ inherent in the microarray data set. This 
piecemeal approach risks missing causally important genes and processes.  
GWAS, on their own, cannot determine if any identified associations are due to genetic 
variations that cause the disease or variations that are unrelated to the disease. Also, 
individual genetic variations tend to have a small effect size and tests for association may 
not reach a stringent genome-wide statistical significance threshold. Furthermore, the small 
effect sizes for these associations do not explain the observed heritability of most traits 
(Maher 2008). In addition, it is can be challenging to translate a genetic association into a 
functional connection with the trait: the diseased-associated variant might lie in a genomic 
region that is yet to be annotated, or it may fall within a gene with multiple potential roles 
depending on the biological context. Even if the gene is successfully annotated, it might be 
unsuitable for therapeutic targeting. 
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In order to overcome the above weakness, integrative data processing techniques have 
been developed, which are discussed below. 
1.7.5 Integrative approaches 
The integrative approaches being considered fall into two broad categories: (1) network 
mapping, and (2) integration of intermediate phenotypes. 
1.7.5.1 Network mapping 
If a disease is caused by the combined influence of many dysfunctional genes, the individual 
effect of each gene might be small and thus hard to detect. This difficulty is further 
aggravated by the fact that, for complex genetic disease, different cases of the same disease 
might be caused by varying combination of genetic perturbations (Cho et al. 2012). Of 
course, genes do not work in isolation; genes and gene products interact with each other to 
form complex interaction networks. Thus a perturbation in one gene can be propagated 
through the interactions, and affect the whole network. The fact that similar disease 
phenotypes result from the dysfunction of different genes suggests that these different 
genes are not unrelated but form part of the same molecular network (Schadt 2009). 
Therefore, in studies of complex diseases, researchers increasingly focus on groups of 
interconnected genes forming a network.  
The network-based analytical approach offers several advantages over single-marker or 
single-gene analysis. Taking GWAS pathway-based analysis as an example, this method has 
been shown to boost the power to identify genetic associations (Wang et al. 2007). Genetic 
heterogeneity may cause any one causal variant to exhibit only modest disease risk in the 
sample as a whole, since different individuals may possess different disease risk 
polymorphisms at different loci in the same gene, or in different genes. This will reduce 
power to detect any one variant by traditional association methods. However, if the genes 
in question are members of the same biological network, then considering the pathway as 
the unit of analysis may increase power to detect association between the genes and 
disease.  For similar reasons, association of disease with biological pathways may be easier 
to replicate across different studies than association with individual SNPs. This was clearly 
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shown in an analysis of Crohn's disease (Wang et al. 2009a), where the IL12/IL23 pathway 
showed evidence of enrichment in four independent GWAS, despite the genes and SNPs 
involved differing between the studies. In addition, by identifying additional susceptibility 
genes, pathway-based analysis can be used to fill-in part of the ‘missing heritability’ 
described above (Fridley & Biernacka 2011). Furthermore, compared with gene-based or 
SNP-based analysis, pathway-based analysis may yield more secure insights into disease 
biology since an associated pathway is likely to implicate function better than a hit in a 
single gene that may have many functional possibilities. Finally, as the most associated gene 
in a pathway might not be the best candidate for therapeutic intervention, targeting 
susceptibility pathways might also have clinical implications for finding additional drug 
targets.  
Numerous network construction techniques have been devised, which can be divided into 
three broad categories: (1) Physical interaction network construction which is dependent on 
prior knowledge of protein-protein interactions; (2) Functional interaction network 
construction which is dependent on prior knowledge of functional interactions; and (3) Co-
expression network construction which is independent of prior knowledge. These 
techniques are described below: 
Protein interaction networks (an example is shown in Figure 1.2) can be constructed on the 
basis of known protein-protein interactions which have been collated, from published 
literature, in a number of publicly accessible databases (Salwinski et al. 2004; Kerrien et al. 
2012; Chatr-Aryamontri et al. 2013). However, it should be noted that the human protein 
interactome is still far from being fully identified. Current protein-protein interaction data 
comprise interactions only among a relatively small subset of the proteins known to be 
present in humans (de Silva et al. 2006; Stumpf et al. 2008). It has been shown that network 
inference using incomplete protein-protein interaction data can lead to biased results (de 
Silva et al. 2006). 
 
 
43 
 
 
Figure 1.2 An example of a protein-protein interaction network (Russell & Aloy 2008). The 
disease network is built from known protein-protein interactions around genes associated 
with the onset of chronic (green) and acute (blue) forms of myeloid leukaemia. Some of the 
nodes in the disease network are either primary or secondary targets (yellow triangles) of 
imatinib (Gleevec), a drug used to treat people with chronic myeloid leukaemia. The use of 
imatinib has several associated adverse effects, the most frequent of which is 
myelosupression. Imatinib affects a number of proteins in the network directly related to 
the formation of bone marrow tissue (alert signs). The authors drew the figure with 
AxPathBuilder (http://www.anaxomics.com/). Nodes have been represented by different 
shapes depending on the number of interactions they make outside the depicted network, 
from the 6 interactions of IL5RA to the 347 of TRAF6. 
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While physical interaction networks connect proteins that physically interact with each 
other, functional interaction networks connect molecules that work together to effect the 
same function even if they do not necessarily physically interact. These functional units are 
generally referred to as pathways (see Figure 1.3 for an example). The genes in a pathway 
work in a tightly regulated and highly coordinated manner to bring about a specific function. 
A number of high-quality well-annotated manually-curated pathway databases are in 
existence (Tanabe & Kanehisa 2012; Caspi et al. 2014; Croft et al. 2014). Typically, each 
pathway in a database contains not only topological connectivity information but also the 
roles of molecules such as whether a given molecule is an activator or inhibitor of the 
activity of another molecule.  The pathway databases can be exploited for identifying 
enriched pathways within a set of results (Curtis et al. 2005). Pathway-based analysis has 
found wide-spread acceptance in microarray analysis, and is now beginning to be applied to 
GWAS (Yaspan & Veatch 2011). A considerable advantage of identifying significant pathways 
within the results of an analysis is immediate functional characterisation of the output, as 
each pathway serves a clearly defined purpose. A limitation of the pathway-enrichment 
analysis approach, as it has been most widely applied, is that each pathway is considered an 
isolated entity, and the interactions between them are not explored. However, biological 
pathways do not work in isolation, and different pathways may interact through either 
shared components or regulatory mechanisms (Ponzoni et al. 2014). With this in view, 
various methods have recently been devised in order to construct networks of enriched 
pathways from transcriptomic data. For example, the Enrichment Map tool (Merico et al. 
2010) displays connections between pathways by analysing the overlap between their 
annotated genes, whereas other methodologies construct pathway networks based on 
known physical interactions between proteins belonging to different pathways (Li et al. 
2008). 
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Figure 1.3 Figure of antigen presentation pathway taken from a study by Degenhardt and 
colleagues (Degenhardt et al. 2010). Metastatic and vertical growth phase melanoma cell 
lines were subjected to microarray-based gene expression analysis. Significantly 
differentially expressed genes between metastatic and vertical growth phase melanoma cell 
lines were loaded into and viewed with the Ingenuity pathway analysis software (Jimenez-
Marin et al. 2009). Red represents decreased expression of components of this pathway in 
metastatic cells compared to vertical growth phase cells. 
Co-expression network construction is based on the premise that functionally related genes 
are likely to show mutual dependence in their expression patterns (Cho et al. 2012). Hence, 
gene co-expression can be seen as an indication of a functional relationship between the 
genes. The construction of co-expression networks consists of two steps (Veiga et al. 2010). 
First, a pairwise comparison of all gene expression profiles is performed using a similarity 
metric. This results in a fully connected network among all genes, with the weight of each 
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link equal to the similarity metric. Second, the complete set of links is filtered by their 
weight, using hard or soft thresholding (Langfelder & Horvath 2008). Links that ‘survive’ 
thresholding constitute the co-expression network. Dense sub-networks (or modules) are 
often identified within the larger co-expression network (see Figure 1.4 for an example). 
Certain lines of evidence indicate that co-expression networks are biologically meaningful 
(Veiga et al. 2010). The resulting networks have special properties (for example scale-free 
topology or fat-tailed degree distribution) that are shared by many other biological 
networks, and are robust to the dataset used for network inference, but disappeared when 
networks were regenerated using randomised data. Moreover, hubs (genes with many links) 
in these co-expression networks were enriched in essential genes.  
A number of similarity measures can be employed for co-expression network construction, 
for example correlation or mutual information (MI). It should be noted that correlation is 
geared towards discovering linear relationships between gene expression profiles, which do 
not always reflect the biological situation (Lecca & Priami 2013). For example, multiple 
binding sites and saturation effects can make the relationship between a transcription 
factor and its target non-linear. Like correlation, MI is a measure that detects statistical 
dependence between two variables. But unlike correlation, it does not assume linearity, or 
other specific properties, of the dependence (Faith et al. 2007). As such, MI is able to detect 
regulatory interactions that might be missed by linear metrics such as the correlation 
coefficient. 
Possible biological causes of gene co-expression are direct or indirect regulation of one gene 
by the other, or co-regulation of both by a third gene. Therefore, gene co-expression can 
indicate a direct or indirect regulatory relationship. A special from of co-expression network 
is the gene regulatory network. Gene regulatory network reconstruction algorithms identify 
regulatory relationships based on the assumption that changes in the expression level of a 
transcription factor should be mirrored in the expression changes of the genes regulated by 
the transcription factor. Indirect links in an inferred gene regulatory network are deemed 
undesirable as they are assumed not to represent physical interactions (Veiga et al. 2010). 
Several filtering techniques have been developed to reduce inference of interactions via 
intermediaries. For correlation-based networks, vanishing partial correlation (the 
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correlation between two genes disappears when the effect of a third gene is taken into 
account) can be used to filter out indirect links (de la Fuente et al. 2004). For MI-based 
network inference methods, an example of an algorithm that filters out indirect links is 
ARACNe (Margolin et al. 2006). ARACNe employs MI to detect regulatory interactions and 
uses data processing inequality, an information-theoretical property, to test whether a link 
is indirect, and therefore should be removed from the network. Another example is the 
context likelihood of relatedness (CLR) algorithm (Faith et al. 2007). After computing the MI 
between regulators and their potential target genes, CLR calculates the statistical 
significance of each MI value: the algorithm compares the MI between a transcription 
factor-gene pair to the background distribution of MI scores for all possible transcription 
factor-gene pairs that include either the transcription factor or its target. The most probable 
interactions are those whose MI scores stand significantly above the background 
distribution of MI scores. 
The network inference methods described above are unsupervised and rely on gene 
expression data alone. Supervised and integrative methods of regulatory network inference 
have also been developed.  For example SIRENE (Supervised Inference of Regulatory 
Networks) (Mordelet & Vert 2008) predicts new gene regulatory relationships by taking as 
input gene expression data and a list of known regulatory relationships between 
transcription factors and target genes. In contrast to other methods for regulation inference 
based on the detection of similarity between expression profiles of transcription factors and 
their targets, SIRENE is based on the hypothesis that genes regulated by the same 
transcription factor exhibit similar expression variations. 
It has been reported that the overlap between the gene regulatory predictions from 
different network inference methods can be low (De Smet & Marchal 2010). However, in 
many biologically meaningful ways, for example enriched biological processes and 
pathways, the ranks of the degree centrality values and the major hub genes in the inferred 
networks, there is a high degree of consistency between different methods (de Matos Simoes 
et al. 2013). Furthermore, it has been observed that the results of different network 
inference methods show a similar degree of overlap with an external validation standard 
(De Smet & Marchal 2010). This suggests that the discrepancy in predicted interactions is 
not due to the failure of individual methods to infer biologically relevant interactions, but is 
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rather due to the complementarity of the different methods. Hence, it is likely that different 
methods highlight different interaction types, so aggregating the outcomes of 
complementary methods offers a means of improving the breadth and the accuracy of the 
predictions. Indeed, it has been shown that an ensemble of the predictions made by the 
best performing methods (‘wisdom of crowds’) more closely approximates the true gene 
regulatory network than the predictions made by each method separately (Marbach et al. 
2012). 
Genome-wide gene network analyses typically produce large networks that involve 
hundreds of gene interactions. Such networks might have interesting topological properties 
that are biologically meaningful, but are normally difficult to interpret in terms of cellular 
functionality. The prediction of the functional role of a network may be possible if the 
network contains a sufficient number of genes of known functions. If a subset of genes can 
be assigned a specific functional category, for example a particular biological pathway, then 
statistical tests can be used to determine if that subset is larger than expected by chance 
(see Figure 1.4 for an example). A variety of software tools have been developed to perform 
such an analysis (Tipney & Hunter 2010).  
  
 
 
49 
 
 
Figure 1.4 Human liver coexpression network (Friend 2010). Gene modules are identified 
within the network using a hierarchical clustering algorithm. The colours of the nodes 
represent their module assignments. Pathway enrichment terms are assigned to individual 
modules. 
 
1.7.5.2 Integration of intermediate phenotypes 
The analytical approach of integrating intermediate phenotypes—termed ‘systems 
genetics’—is useful for the identification of genes, pathways and networks that underlie 
common human diseases. The science of systems genetics has been developed in response 
to the need to understand how loci identified in GWAS contribute to disease susceptibility. 
Systems genetics approaches can be integrated with GWAS results to predict causal genes 
and their functions. 
Systems genetics utilizes intermediate molecular phenotypes to bridge DNA variations with 
the traits of interest. Most commonly, the intermediate molecular phenotype examined is 
expression of gene transcripts. Transcript levels can be considered intermediate phenotypes 
as DNA variation contributes to the clinical trait by perturbing gene expression. Studies 
using mice, rats, and human cells and tissues have revealed that the expression of a high 
 
 
50 
 
percentage of genes (≥30%) is substantially influenced by DNA variants (Romanoski et al. 
2010; van Nas et al. 2010; Orozco et al. 2012). Most significant SNPs for GWAS map outside 
protein-coding regions, and >75% of GWAS SNPs map to functional regulatory elements that 
have been identified in the Encyclopedia of DNA Elements (ENCODE) project (Schaub et al. 
2012). These results suggest that genetic variants that alter gene expression, rather than 
variants that alter protein sequences, form the primary basis of natural variation in complex 
traits.  
Genomic sequence variants that correlate with gene-expression levels are termed 
expression quantitative trait loci (eQTL). eQTL studies (also termed genetical genomics 
studies) are similar to traditional genetic-association studies, but instead of associating 
genetic variants with discrete traits such as disease status, eQTL studies correlate genetic 
variants with quantitative gene-expression levels.  It is important that the intermediate 
phenotype is analysed in the context that is the most relevant to the clinical trait. It has 
been shown that 69% to 80% of eQTLs operate in a cell-type specific manner (Dimas et al. 
2009), and 93% of eQTLs within the same tissue show significant evidence of gene-by-
environment interactions (Orozco et al. 2012). Hence, whole-genome transcriptome-
expression analysis should be performed in samples of pathological tissue from affected 
individuals and whole-genome genotyping must be performed in the same individuals. The 
transcript levels can then be tested for correlation with genomic sequence variants.  
eQTL studies can be used to link genomic sequence variations to transcriptomic changes to 
the clinical phenotype. An eQTL that maps to a disease locus can be considered a likely 
causal gene underlying the disease (Thessen Hedreul et al. 2013). In addition to identifying 
the likely causal variants, the eQTL data helps to provide an explanation of its mechanism of 
action. 
Systems genetics techniques with network modelling have been used successfully in a 
number of human studies. For example, in a recent study employing such techniques, KLF14 
was identified as a causal gene for multiple metabolic phenotypes and its mechanism of 
action was successfully determined (Small et al. 2011). In another study, systems genetics 
techniques revealed that a non-coding polymorphism at the 1p13 locus modulates a 
 
 
51 
 
regulatory pathway for lipoprotein metabolism and alters the risk for myocardial infarction 
in humans (Musunuru et al. 2010Musunuru et al. 2010). 
1.8 Aims of this work 
As detailed in the preceding sections, drug resistance in epilepsy is a significant clinical 
problem, the causes of which remain poorly understood. To date, the MDT hypothesis has 
been the most widely investigated putative explanation of epilepsy pharmacoresistance, 
with the vast majority of the research effort being focused on P-gp. However, a review of 
the evidence indicates that dysregulation of P-gp is unlikely to provide a unifying basis for 
pharmacoresistance in epilepsy. A glaring omission in the search for MDTs underlying 
epilepsy pharmacoresistance is the SLC superfamily of transporters—the largest superfamily 
of MDTs. There is a need to systematically search for evidence of dysregulation of SLCs in 
refractory epilepsy. The intrinsic severity hypothesis offers an intuitive and appealing 
explanation of pharmacoresistance in epilepsy, but remains untested in the laboratory. It is 
important that this possible explanation of drug resistance in epilepsy is objectively 
investigated. At the core of this hypothesis is the idea that pharmacoresistance is caused by 
increased dysfunction of the neurobiological pathways underlying epilepsy. Systems 
genetics techniques with network modelling provide the most suitable tools for trying to 
decipher the pathways underlying epilepsy and epilepsy pharmacoresistance. 
In order to fill the substantial gaps in knowledge described above, the following analyses are 
proposed in this work: 
1. I will Identify the SLC transporters significantly dysregulated in the 
pharmacoresistant epileptic focus. For this, I will use a robust in silico approach that 
exploits relevant published data and builds upon them using cutting-edge 
computational tools; I will then verify the output of the in silico analysis using a 
robust ex vivo approach. 
2. There have been a number of published genome-wide transcriptomic studies on 
brain tissue from epilepsy surgery, but they have failed to make an impact on our 
understanding of pharmacoresistance in epilepsy. I will discuss the causes behind 
this failure and tackle these causes by performing an integrative analysis of 
previously published large-scale gene expression profiling studies on brain tissue 
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from epilepsy surgery. Through this analysis, I will identify the genes, pathways and 
processes most consistently dysregulated in pharmacoresistant epileptic foci, and 
determine if these results support the MDT hypotheses, the drug target hypothesis 
or the intrinsic severity hypothesis of pharmacoresistance in epilepsy. 
3. In order to overcome some of the shortcomings of previously published 
transcriptomic studies on brain tissue from epilepsy surgery, I will perform the 
largest and most robust microarray analysis of resected pharmacoresistant epileptic 
hippocampal tissue from surgery for refractory mesial temporal lobe epilepsy. I will 
identify the differentially expressed genes, and differentially expressed and 
differentially connected pathways. I will then construct a network of differentially 
regulated pathways and identify the most central pathways in the network. 
4. I will perform a GWAS in order to identify genetic variants associated with the 
pharmacoresistant focal epilepsy phenotype and to identify biological pathways 
enriched with disease-associated variants. Again, I will construct a network of 
disease-associated pathways and identify the most central pathways in the network. 
5. I will perform a genetical genomics or eQTL study on resected pharmacoresistant 
epileptic hippocampal tissue from surgery for refractory mesial temporal lobe 
epilepsy, in order to identify genetic variants that regulate gene expression in the 
pharmacoresistant epileptic human hippocampus. eQTL analysis is an important tool 
for identifying causal disease loci. 
6. I will integrate the above genetic and genomic studies in order to determine if 
genetic evidence supports the intrinsic severity hypothesis. I will integrate the 
aforementioned genetic, genetical genomic and genomic studies in order to identify 
putative causal genes and pathways. Once again, I will construct a network of causal 
pathways and identify the most central causal pathways in the network. These are 
likely to be the most central causal pathways underlying pharmacoresistant epilepsy. 
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Chapter 2: An Integrative Analysis of Large-Scale Gene 
Expression Profiling Studies on Brain Tissue from 
Epilepsy Surgery 
2.1 Introduction 
As detailed in Chapter 1, epilepsies are among the most common neurological disorders, 
affecting up to 1% of the population (Sander 2003). Most patients with epilepsy become 
seizure-free with antiepileptic drug (AED) therapy. However, approximately 30% of epilepsy 
patients have a medically intractable condition even if treated with various AEDs at maximal 
dosages either alone or in combination (Shorvon 1996). A subset of patients with intractable 
epilepsy have the potential for a surgical cure, most commonly those with hippocampal 
sclerosis (Engel 2003). Surgical samples from patients with intractable epilepsy provide a 
unique opportunity to directly analyse the human epileptic focus in order to determine the 
causes of pharmacoresistance. Many different causes of pharmacoresistance have been 
postulated (see Chapter 1). The exact molecular mechanisms underlying 
pharmacoresistance, however, are still poorly understood. Alterations in the expression of a 
large number of genes are thought to be responsible, but most of the numerous genes that 
participate in the development of pharmacoresistance in epilepsy remain unidentified.  
To date, the vast majority of studies on samples from epilepsy surgery have focused 
primarily on a number of selected candidate genes. However, these techniques are not 
suitable for dissection of multiple interacting molecular pathways or screening potential 
molecular abnormalities when the list of candidate genes is extensive. In contrast, large-
scale microarray studies offer the advantage of assaying gene expression in a 
comprehensive, unbiased and genome-wide fashion. Analysing the expression profile of 
many genes simultaneously in large-scale expression studies, without making prior 
assumptions about candidate genes, allows the identification of new genes and molecular 
pathways associated with the condition. There have been at least 12 published large-scale 
gene expression studies on tissue from epilepsy surgery in the last ten years (see below). 
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However, they have failed to make a significant impact on our understanding of the causes 
of pharmacoresistance. In our view, this failure is due to several reasons.   
First, authors of most microarray studies have focused on selected genes or pathways in 
their published results. Large-scale gene profiling studies suffer from high numbers of false 
positive results. Before drawing conclusions about the differential expression of a specific 
gene, it is thought necessary to demonstrate independent experimental validation (King & 
Sinha 2001) using techniques such as reverse transcription-polymerase chain reaction. 
Therefore, it is commonplace to use the microarray as a screening tool, then to validate a 
few chosen genes for additional investigation. However, this methodology under-uses the 
‘depth’ inherent in the original microarray dataset and is prone to missing potentially 
important genes and networks. Hence, experts (Rhodes et al. 2002) have proposed using 
multiple microarray datasets that address similar hypotheses to simultaneously cross-
validate all of the positive results. This inter-study cross-validation approach has been 
adopted in the present work.  
Second, doubts have been raised about the reproducibility of microarray studies in epilepsy 
(Lukasiuk & Pitkanen 2004; van Gassen et al. 2008; Wang et al. 2010). It has been suggested 
that the majority of changes in gene expression are specific to laboratory or experimental 
conditions with very few genes demonstrating changes in more than two publications 
(Wang et al. 2010).  
Third, the results of different microarray studies have not been integrated to give a 
coherent picture of the genomic changes involved in epilepsy pharmacoresistance.  
We believe that the above problems can be overcome by testing the validity and 
reproducibility of the individual microarray studies and by performing an integrative analysis 
of all available microarray results. We are aware of only two previous published reviews 
which have included microarray studies on non-cancerous brain tissue from epilepsy surgery 
(Lukasiuk & Pitkanen 2004; Wang et al. 2010). However, neither of these reviews included 
all currently available microarray studies on brain tissue from epilepsy surgery; in fact, the 
study by Lukasiuk and Pitkänen, (2004) includes only one human microarray study, and the 
study by Wang et al., (2010) includes only three human large-scale gene expression studies. 
These reviews found a very small number of genes that showed similar expression profiles 
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and, hence, found it difficult to draw robust conclusions about the possible mechanism(s) of 
pharmacoresistance in epilepsy. In the present work, we have performed an integrative 
analysis of all available microarray studies on non-cancerous brain tissue from epilepsy 
surgery with the aim of identifying novel and important genes and networks that play a role 
in pharmacoresistance. 
2.2 Methods 
2.2.1 Inclusion Criteria 
We aimed to include all large-scale gene expression profiling studies fulfilling the following 
criteria: 
1. Recruited patients had clearly defined refractory epilepsy. 
2. The epileptic focus was ascertained on the basis of clinical features, 
electroencephalography, brain imaging, and post-operative tissue histology as 
necessary. 
3. ‘Pharmacoresistant’ tissue was compared with suitable control (non-epileptic or 
‘pharmacoresponsive’) tissue. 
4. Epileptic tissue analysed was not cancerous or neoplastic. 
5. At least 500 genes from across the genome were assayed. 
6. Minimum Information About a Microarray Experiment (MIAME)-compliant data was 
provided or, at the very least, a list of significantly regulated genes and the direction 
of change (up- or down-regulated) was provided. 
2.2.2 Search Strategy 
We searched records in Medline and Embase, without language restriction, between 
January 1987 and January 2011. Large-scale microarray technology was first described in 
1987 (Kulesh et al., 1987); hence 1987 formed the starting point for our search. We used the 
following search terms: (1) "gene-expression profiling", or (2) "microarray analysis", or (3) 
"transcription profiling", or (4) "cluster analysis", or (5) "Affymetrix", (6) or "GeneChip", or 
(7) “serial analysis of gene expression”, or (8) “SAGE”, and (1) “epilepsy”, or (2) “TLE”, or (3) 
“MTLE”. We also hand-searched the reference lists of every primary study, previously 
published systematic reviews and other review articles. 
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We also searched public repositories of microarray datasets: Array Express 
(www.ebi.ac.uk/arrayexpress), GEO (www.ncbi.nlm.nih.gov/geo), Stanford Microarray 
Database (smd.stanford.edu), University of Pennsylvania RAD 
(www.cbil.upenn.edu/RAD/php/index.php), UNC Microarray Database (genome.unc.edu), 
MUSC Microarray Database (proteogenomics.musc.edu/musc_madb.html), Genevestigator 
(www.genevestigator.com), Princeton University MicroArray database 
(puma.princeton.edu), University of Tennessee Microarray Database (genome.ws.utk.edu). 
2.2.3 Data Gathering: Raw Data 
We found 12 published genome-wide gene expression profiling studies on non-neoplastic 
tissue from epilepsy surgery. Raw data for the study by Ozbas-Gerceker et al., (2006) was 
available from the GEO database. Minimum Information About a Microarray Experiment 
(MIAME)-compliant data for the study by van Gassen et al., (2008) was available on the 
ArrayExpress database. MIAME-compliant data was not publically available for any other 
study.  The corresponding author from each of the remaining ten studies was contacted to 
request MIAME-compliant microarray results data, but MIAME-compliant data was not 
provided by any author. As raw data was only available for two studies performed on two 
entirely different platforms (Serial Analysis of Gene Expression and two-channel 
oligonucleotide microarray analysis), we judged that a useful integrative analysis of the raw 
data could not be performed, and raw data was not used in the present study. Instead, we 
obtained differentially regulated gene lists from individual studies, as detailed below. 
2.2.4 Data Gathering: Gene Lists 
Six studies published complete lists of all genes which were differentially regulated in 
epileptic tissue according to each study’s individually defined criteria (Becker et al. 2002; 
Becker et al. 2003; Arion et al. 2006; Jamali et al. 2006; Ozbas-Gerceker et al. 2006; Lee et 
al. 2007; van Gassen et al. 2008). Xi et al., (2009) published a partial list of gene regulated in 
their study. Xiao et al., (2008) directly provided a list of all genes which were differentially 
regulated in epileptic tissue according to their individually defined criteria. Three studies did 
not publish a list of regulated genes and their authors did not provide this on request (Lee et 
al. 2004; Li et al. 2006; Liu et al. 2007), and hence were excluded from further analysis in 
this systematic review. 
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2.2.5 Data Integration 
To allow inter-study comparison, gene identifiers from each study were converted to Entrez 
gene numbers, unless these were provided in the publication.  Affymetrix probe numbers 
were converted to Entrez gene numbers using NetAffx Analysis Center 
(www.affymetrix.com/analysis). All other gene identifiers were converted to Entrez gene 
numbers using MatchMiner (build 137, discover.nci.nih.gov/matchminer). 
For each gene list, changes in gene expression were changed to a binary score: any gene up-
regulated was given a score of +1, while any gene down-regulated was given a score of −1. 
The nine lists of regulated genes from the nine included studies were integrated in a MS 
Excel spreadsheet. 42 genes were excluded because of conflicting scores (that is, they were 
down-regulated in one study but up-regulated in another), leaving 1407 regulated genes in 
the integrated list incorporating all included studies. The total score was calculated for each 
gene.  
2.2.6 Data Validation 
The overlapping probabilities of differentially regulated gene lists were calculated using 
ConceptGen (conceptgen.ncibi.org/core/conceptGen), a gene set enrichment testing tool. 
ConceptGen uses the Expression Analysis Systematic Explorer (EASE) score (a modified 
Fisher's exact test widely employed in published literature) to test pairs of gene lists to 
determine if there exists a larger number of overlapping genes than is expected by chance  
(Hosack et al. 2003). P-values are then adjusted for multiple testing by calculating the False 
Discovery Rate (Benjamini & Hochberg 1995), values <0.05 being deemed significant. All of 
the gene lists from the included studies were tested in pairs in this manner. In addition, to 
test the validity of the list of genes differentially regulated in only one study, we compared 
this to a list of all genes from CarpeDB (www.carpedb.ua.edu), a dynamic continuously-
updated epilepsy genetics database. We extracted the human genes in the CarpeDB 
database. In addition, we extracted the rat and mouse genes and mapped them to human 
homologues using ConceptGen. 278 CarpeDB human, mouse and rat genes in total mapped 
to ConceptGen.  
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2.2.7 Gene Ontology Enrichment Analysis 
Gene ontology (GO) terms enrichment analysis was performed in the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 
(david.abcc.ncifcrf.gov). DAVID performs an enrichment test based on the EASE score, and a 
False Discovery Rate <0.05 is deemed significant. For biological process and cellular 
component terms, there were a large number of enriched broad GO terms, which made 
practical interpretation difficult. Hence, for biological process and cellular component 
domains, ‘Go Fat’ analysis was performed. Go Fat filters the broadest terms so that they do 
not overshadow the more specific terms. 
2.2.8 Pathway Analysis 
Ingenuity Systems (www.ingenuity.com) Core Analysis was used to determine significantly 
enriched canonical pathways and to build significantly enriched networks from the full list of 
differentially regulated genes. The significance of the association between our data set 
genes and the canonical pathways was measured in two ways: (1) a ratio of the number of 
genes from the data set that map to the pathway divided by the total number of genes that 
map to the canonical pathway is displayed, and (2) a Fischer’s exact test was used to 
calculate a p-value, determining the probability that the association between the genes in 
the data set and the canonical pathway was explained by chance alone. Networks were 
ranked by a score: the higher the score, the lower the probability of finding the observed 
data set genes in a given network by chance. The score takes into account the number of 
data set genes and the size of the network, and is the negative log of the p-value.  
2.2.9 Comparison with an Alzheimer’s Disease Brain Microarray Dataset 
To counter arguments that the genetic changes highlighted by this analysis are non-specific 
and could be found in any brain pathology, we compared our results with the results of a 
large-scale gene expression profiling study on brain samples from 34 individuals with 
Alzheimer’s disease (AD) (Liang et al. 2008). From this study, we extracted the list of genes 
exhibiting differential expression between AD-affected and normal hippocampi—an AD 
hippocampus dataset was used as most of the included epilepsy studies utilized 
hippocampal tissue. 3738 unique genes could be mapped to Entrez gene IDs. Ingenuity 
Systems Pathway Analysis was used to determine significantly enriched canonical pathways 
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from this gene list. The top ten canonical pathways from the epilepsy and AD datasets were 
then compared.  
2.3 Results 
2.3.1 Gene lists 
We found 12 published large-scale genome-wide gene expression profiling studies on non-
neoplastic tissue from epilepsy surgery (Becker et al. 2002; Becker et al. 2003; Arion et al. 
2006; Jamali et al. 2006; Ozbas-Gerceker et al. 2006; Lee et al. 2007; van Gassen et al. 2008; 
Xiao et al. 2008; Xi et al. 2009). Gene lists were available for nine genome-wide gene 
expression studies, and these were included in the present review. Seven studies published 
one differentially regulated gene list each. However, Lee et al., (2007) and van Gassen et al., 
(2008) used more than one type of control tissue and published more than one list of 
differentially regulated genes each. Lee et al., (2007) used two types of controls: (1) 
histologically normal CA1 from patients with ‘paradoxical temporal lobe epilepsy (PTLE)’, 
citing the evidence that the poor seizure free outcome (44%) in PTLE following 
hippocampectomy suggests that the hippocampus is unlikely to be epileptogenic in this 
group, and (2) histologically normal CA1 tissue from ‘mass-associated temporal lobe 
epilepsy (MaTLE)’ where the mass lesion was outside the hippocampus, citing the evidence 
that mesial temporal lobe epilepsy (MTLE) granule cells are hyperexcitable while those in 
MaTLE are not. The authors presented two lists of differentially regulated genes: (1) genes 
regulated by 1.5 fold or more for both MTLE vs. PTLE and MTLE vs. MaTLE, and (2) genes 
regulated 1.5 fold or more when MaTLE and PTLE were considered replicates of non-
sclerotic hippocampi. Regulated genes from both lists were integrated into the current 
systematic review, giving a list of 758 unique genes that could be mapped to Entrez gene 
numbers. Similarly, van Gassen et al., (2008), compared slices of sclerosed hippocampus 
with histologically normal hippocampal slices from patients with MTLE but no hippocampal 
sclerosis (HS). However, van Gassen et al., (2008) also compared normal hippocampal 
autopsy samples with histologically normal hippocampal slices from patients with MTLE but 
no HS. The non-HS MTLE and HS groups were found to share a large group of differentially 
expressed genes when compared to the autopsy group, and there was a significant overlap 
between functional gene classes affected in non-HS MTLE and HS groups when compared to 
autopsy samples. Hence, the autopsy vs non-HS MTLE gene list was also deemed 
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appropriate for inclusion in the current systematic review. In total, van Gassen et al., (2008) 
presented three differentially regulated gene lists: (1) autopsy vs HS, (2) autopsy vs non-HS, 
and (3) non-HS vs HS. Regulated genes from all three lists were integrated into the current 
systematic review. 24 genes had conflicting changes in expression (downregulated in one 
list but upregulated in another) and were excluded, leaving 521 unique genes. 
2.3.2 Study characteristics 
The nine included studies had sample sizes ranging from six to 60. All studies used test 
tissue from the temporal lobe, and all but three studies (Jamali et al. 2006; Xiao et al. 2008; 
Xi et al. 2009) used test tissue from the hippocampus. Gene expression profiling platforms 
used included one-channel microarrays, two-channel microarrays and Serial Analysis of 
Gene Expression (Table 2.1). The smallest microarray chip used was able to assay up to 588 
unique genes (Clontech’s Atlas Human Neurobiology array used by Becker et al. 2002), while 
the largest was able to assay up to 21,329 unique genes (Operon’s Human Array-Ready oligo 
set version 2.0 used by van Gassen et al. 2008).  
We assessed the methodological quality of the included studies. Each study had specific 
methodological strengths and weaknesses. For example, van Gassen et al. (2008) performed 
a like-for-like tissue comparison, detailed probe- and array-level quality control procedures, 
corrected p-values for multiple testing, and deposited MIAME-compliant data in a publically-
accessible repository, but used a modest sample size and applied no fold change criterion to 
differentially regulated gene lists. On the other hand, Xiao et al. (2008) used a large sample 
size and applied appropriate fold change criterion, but did not perform a like-for-like tissue 
comparison, or detail probe- and array-level quality control procedures, or perform 
correction for multiple testing, or deposit their data in a public database. Table 2.2 lists the 
criteria used to assess methodological quality, and the quality assessment outcomes for the 
individual studies. 
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Table 2.1 Included large-scale gene expression profiling studies on brain tissue from epilepsy surgery 
Name Test tissue Control tissue Chip Number of regulated 
genes 
Lee et al. 2007 Sclerosed CA1 from MTLE (n=8) Histologically normal CA1 from MaTLE 
(n=6) or PTLE (n=6) 
Affymetrix U133A 674 (MTLE vs PTLE and 
MTLE vs MaTLE)  
947 (MTLE vs others) 
van Gassen et al. 
2008 
Sclerosed hippocampus from MTLE 
patients (n=4) 
Hippocampus from MTLE patients 
without HS (n=4) and autopsy (n=4) 
Human Array-Ready 
oligo set version 2.0, 
Operon 
Biotechnologies 
Autopsy vs non-HS: 322  
Autopsy vs HS: 322 
non-HS vs HS: 206 
Xi et al. 2009 Anterior temporal neocortex 
epileptogenic zone (n=40) 
Anterior temporal neocortex removed 
for raised ICP (n=20) 
ns 143 
Ozbas-Gerceker 
et al. 2006 
Anterior hippocampus (n=6) Anterior hippocampus tissue from 
autopsy (n=1) 
SAGE 143 
Xiao et al. 2008 Temporal lobe (n=40): HS, FCD, etc Temporal neocortex, hippocampus, 
parietal cortex or frontal cortex from 
brain trauma patients (n=20) 
Biostar H-40s 142 
 
Arion et al. 2006 ‘Spiking areas’ from anterolateral 
temporal cortical samples (n=6) 
‘Non-spiking’ from anterolateral 
temporal cortical samples (n=6) 
Affymetrix U133A 76 
Becker et 
al.2003 
Sclerosed CA1 from MTLE (n=5) Dentate gyrus from same patients (n=5) Affymetrix U133A 25 
Becker et al. 
2002 
Sclerosed hippocampus (n=3) Normal hippocampus from tumor 
patients (n=2) or epilepsy patients (n=1) 
Atlas, Clontech 21 
 
Jamali et al. 
2006 
Entorhinal cortex (n=5) Lateral temporal neocortex (n=5) Micromax 16 
FCD=focal cortical dysplasia; HS=hippocampal sclerosis; ICP=intracranial pressure; IE=intractable epilepsy; MaTLE=mass-associated temporal 
lobe epilepsy; MTLE=mesial temporal lobe epilepsy; NIE=non-intractable epilepsy; ns=not specified; PTLE=paradoxical temporal lobe epilepsy; 
SAGE=serial analysis of gene expression. 
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Table 2.2 Critical appraisal of included studies. FDR: false discovery rate; FWER: Family-wise error correction. 
Study Sample size Like-for-like 
test & control 
tissues used 
Data QC 
procedures 
detailed 
Correction for 
multiple 
testing 
Effect size 
criterion applied 
Raw data 
provided 
Lee et al. 2007 20   FDR < 0.05 Fold change ≥ 1.5  
van Gassen et al. 2008 12   FWER < 0.05   
Arion et al. 2006 12   FDR=0.057 Fold change ≥ 1.2  
Jamali et al. 2006 10 §  na§ Fold change ≥ 2.56  
Xi et al. 2009 60    Fold change ≥ 2  
Ozbas-Gerceker et al. 2006 7 *     
Xiao et al. 2008 60    Fold change ≥ 2  
Becker et al. 2003 10    Fold change ≥ 1.5  
Becker et al. 2002 6      
§In the study by Jamali et al. 2006, tissue from the entorhinal cortex (test) was compared with tissue from the lateral temporal neocortex 
(control). However, genes were only considered regulated in the epileptic focus if quantitative RT–PCR confirmed no significant difference in 
expression between the entorhinal cortex and lateral temporal neocortex of non-epileptic autopsy brain samples. The statistical test employed 
was the ‘z-score’. 
Did not specify what, if any, statistical test used. 
*Autopsy control used. 
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2.3.3 Study heterogeneity 
There was heterogeneity within the studies and the number of genes found to be regulated 
in the individual studies varied widely (Table 2.1). The largest parts of this variation can be 
explained by: 
1. The number of genes that can be assayed by the different arrays (see above). 
2. The widely differing criteria used to define statistically significant change in gene 
expression (Table 2.2). 
Other sources of heterogeneity were: 
1. Differences in sample handling and RNA extraction techniques. 
2. Different gene expression profiling platforms used. 
3. Varying microarray data normalization procedures.  
4. Test tissue used: Sclerosed hippocampus was used by most studies, but other 
anatomical regions and other pathologies were also employed by some studies 
(Table 2.1). 
5. The use of at least four different types of control tissue:  (1) non-epileptic brain 
tissue removed from the same patients as part of the surgical procedure, (2) normal 
hippocampal tissue from autopsy, (3) normal brain tissue removed from other 
patients for various indications, (4) histologically normal hippocampal tissue from 
patients with MTLE.  
While acknowledging the heterogeneity within the studies, it is important to note that there 
is also an underlying commonality in the design of the studies: comparing gene expression 
between pharmacoresistant epileptic brain samples and non-epileptic or 
pharmacoresponsive brain samples. Although some of the differentially expressed genes 
identified in individual studies will be specific to the histological characteristics of the tissues 
being compared and to laboratory conditions, a significant subset of genes in each list 
represents the universal genetic changes linked with pharmacoresistance. As validation of 
this concept, we determined the size of the overlap between pairs of gene lists and 
calculated if this size was greater than would be expected by chance alone (see ‘Data 
validation’ section below). 
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2.3.4 Data validation 
The overlapping probabilities of differentially regulated gene lists were calculated—all of 
the gene lists from the included studies were tested in pairs. The size and statistical 
significance of the overlaps are shown in Appendix 1. Our results show that there was a 
statistically significant overlap between gene lists from studies done on different types of 
brain tissue using different array platforms (elaborated further below). 
To test the validity of the list of genes differentially regulated in only one study, we 
compared this to a list of all human genes and human homologues of mouse and rat genes 
from CarpeDB (www.carpedb.ua.edu), a dynamic continuously-updated epilepsy genetics 
database. Of the 278 genes thus extracted from CarpeDB, 54 overlapped with our list of 
genes differentially regulated in only one study. This overlap was statistically significant (FDR 
P=1.2x10−24).  
2.3.5 Overlapping gene lists 
Genes differentially expressed in three or four studies are listed in Table 2.3.  Prominently 
represented in these two lists are genes involved in neuroinflammation, in the control of 
synaptic transmission and in the restructuring of neuronal networks—specific examples are 
discussed below (see Discussion section). Genes differentially regulated in one study or two 
studies are shown in Appendix 2.  
2.3.6 Gene Ontology Enrichment Analysis 
The top 25 significantly enriched GO terms are listed in Table 2.4. The cellular component 
ontology term enrichment suggests that the most important processes in the development 
of pharmacoresistance are occurring in neuronal projections, in the growth cone, at the pre- 
and post-synaptic terminal, in the cytoskeleton and in membrane-bound vesicles. The most 
important molecular functions are calcium transport and signalling, cytoskeletal function, 
and transporter activity. The most significant biological processes are synaptic transmission 
and synaptic plasticity, regulation of the action potential, cellular cation homeostasis, axonal 
and dendritic morphogenesis, and cytoskeletal organization. 
2.3.7 Pathway Analysis 
The top 25 significantly enriched canonical pathways and networks are shown in Table 2.5. 
Details of all enriched pathways and networks are provided in Appendix 3. An explanation of 
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how some of the most significant pathways and networks might contribute to the 
development of pharmacoresistance is presented in the Discussion section. 
2.3.8 Comparison with an Alzheimer’s disease brain microarray dataset 
To counter arguments that the genetic changes highlighted by this analysis are non-specific 
and could be found in any brain pathology, we compared our results with the results of a 
microarray study on AD-affected hippocampi. From the AD study, we extracted 3738 unique 
genes which could be mapped to Entrez IDs. Ingenuity Systems Pathway Analysis was used 
to determine significantly enriched canonical pathways from this gene list. In Table 2.6, we 
compare the top ten canonical pathways from the AD and the epilepsy datasets which 
convincingly demonstrated that there was no overlap between the identified top canonical 
pathways for the two datasets. In addition, the processes performed by the canonical 
pathways were also very different. For example, the top five canonical pathways in the 
pharmacoresistant epilepsy dataset are related to restructuring of neuronal networks 
(cholecystokinin signalling), modulation of synaptic transmission (synaptic long term 
potentiation, neuropathic pain signalling), and neuroinflammation (semaphorin signalling, 
chemokine signalling), while the top five pathways in the AD dataset are related to protein 
degradation (protein ubiquitination pathway), energy metabolism (mitochondrial 
dysfunction, oxidative phosphorylation), and translational regulation (regulation of eIF4 and 
p70S6K signalling, eIF2 signalling). 
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Table 2.3 Genes differentially expressed in three or four studies 
Symbol Description Molecular function Up or down 
regulated 
Number of 
studies 
GABRA5 GABA-A receptor, alpha 5 GABA-A receptor activity Down 4 
NRGN Neurogranin calmodulin binding Down 4 
CCL2 Chemokine (C-C motif) ligand 2 CCR2 chemokine receptor binding Up  4 
GFAP Glial fibrillary acidic protein protein binding Up 4 
CPLX2 Complexin 2 syntaxin binding Down 3 
ENC1 Ectodermal-neural cortex  actin binding Down 3 
HPCAL4 Hippocalcin like 4 calcium channel regulator activity Down 3 
INHBA Inhibin, beta A cytokine activity Down 3 
PLCB1 Phospholipase C, beta 1 calcium ion binding Down 3 
PSD Pleckstrin and Sec7 domain containing ARF guanyl-nucleotide exchange factor activity Down 3 
SNAP25 Synaptosomal-associated protein, 25kDa SNARE binding Down 3 
STMN2 Stathmin-like 2 protein binding Down 3 
CAPN3 Calpain 3, (p94) calcium ion binding Up 3 
CD99 CD99 molecule protein binding Up 3 
CDK2AP1 CDK2-associated protein 1 DNA binding Up 3 
DYNLT1 Dynein, light chain, Tctex-type 1 motor activity Up 3 
OGG1 8-oxoguanine DNA glycosylase damaged DNA binding Up 3 
PABPC4 Poly(A) binding protein, cytoplasmic 4 RNA binding Up 3 
RDX Radixin actin binding Up 3 
SPARC Secreted protein, acidic, cysteine-rich calcium ion binding Up 3 
TF Transferrin ferric iron binding Up 3 
ZFP36L1 Zinc finger protein 36, C3H type-like 1 AU-rich element binding Up 3 
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Table 2.4 Gene ontology term enrichment 
Molecular Function Biological Process Cellular Component 
protein binding transmission of nerve impulse neuron projection 
Binding synaptic transmission Synapse 
calmodulin binding cell projection organization Vesicle 
cytoskeletal protein binding neuron development cytoplasmic vesicle 
kinase activity cell-cell signalling cell fraction 
protein kinase activity Behaviour Cytosol 
actin binding neuron differentiation cell projection 
nucleotide binding neuron projection development vesicle membrane 
protein serine/threonine kinase activity learning or memory membrane-bounded vesicle 
ribonucleotide binding cell projection morphogenesis plasma membrane part 
purine ribonucleotide binding response to organic substance Axon 
transferase activity, transferring phosphorus-
containing groups 
cell morphogenesis cytoplasmic membrane-bounded vesicle 
phosphotransferase activity, alcohol group as 
acceptor 
cellular component morphogenesis synapse part 
purine nucleotide binding cell part morphogenesis cell soma 
structural molecule activity cell motion insoluble fraction 
transporter activity neuron projection morphogenesis cytoplasmic vesicle part 
lipid binding regulation of synaptic plasticity cytoplasmic vesicle membrane 
adenyl ribonucleotide binding regulation of neuron projection development membrane fraction 
cation-transporting ATPase activity response to endogenous stimulus coated vesicle 
protein complex binding regulation of cell projection organization clathrin-coated vesicle 
ATP binding intracellular signalling cascade plasma membrane 
protein tyrosine kinase activity glial cell development site of polarized growth 
di-, tri-valent inorganic cation transmembrane 
transporter activity 
cellular ion homeostasis synaptic vesicle 
#24 not significant regulation of cell death clathrin coated vesicle membrane 
#25 not significant regulation of axonogenesis growth cone 
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Table 2.5 Top 25 canonical pathways 
Canonical Pathways 
Cholecystokinin/Gastrin-mediated Signaling 
Synaptic Long Term Potentiation 
Semaphorin Signaling in Neurons 
Neuropathic Pain Signaling In Dorsal Horn Neurons 
Chemokine Signaling 
GNRH Signaling 
RhoA Signaling 
Renin-Angiotensin Signaling 
Role of NFAT in Cardiac Hypertrophy 
Glutamate Receptor Signaling 
Axonal Guidance Signaling 
CDK5 Signaling 
Integrin Signaling 
CXCR4 Signaling 
Ephrin Receptor Signaling 
Molecular Mechanisms of Cancer 
Melatonin Signaling 
Thrombin Signaling 
CREB Signaling in Neurons 
Protein Kinase A Signaling 
IGF-1 Signaling 
Regulation of Actin-based Motility by Rho 
Calcium Signaling 
ERK/MAPK Signaling 
Corticotropin Releasing Hormone Signaling 
 
 
Table 2.6 Top 10 canonical pathways 
Pharmacoresistant epilepsy Alzheimer’s disease 
Cholecystokinin/Gastrin-mediated Signalling Protein Ubiquitination Pathway 
Synaptic Long Term Potentiation Mitochondrial Dysfunction 
Semaphorin Signalling in Neurons Regulation of eIF4 and p70S6K Signalling 
Neuropathic Pain Signalling In Dorsal Horn Neurons eIF2 Signalling 
Chemokine Signalling Oxidative Phosphorylation 
GNRH Signalling Purine Metabolism 
RhoA Signalling Breast Cancer Regulation by Stathmin1 
Renin-Angiotensin Signalling NRF2-mediated Oxidative Stress Response 
Role of NFAT in Cardiac Hypertrophy Huntington's Disease Signalling 
Glutamate Receptor Signalling Estrogen Receptor Signalling 
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2.4 Discussion 
2.4.1 Study heterogeneity and validation 
While there is heterogeneity within the studies included in this review, there also is an 
underlying commonality in their design: comparing the gene expression between 
pharmacoresistant epileptic brain samples and non-epileptic or pharmacoresponsive brain 
samples. Although some of the differentially expressed genes identified in individual studies 
will be specific to the histological characteristics of the tissues being compared and to 
laboratory conditions, a significant subset of genes in each list represents the universal 
genetic changes linked with pharmacoresistance. As validation of this concept, our pairwise 
comparisons showed that there was a statistically significant overlap between gene lists 
from studies done on different types of brain tissue using different types of array 
technologies. For example, a study comparing various epileptic focus pathologies (focal 
cortical dysplasia, temporal lobe malacia, hippocampus sclerosis, neuron loss, neuron 
degeneration, gliosis, astrocytosis) with normal tissue from various brain regions of brain 
trauma patients using a Biostar H-40s microarray (Xiao et al., 2008) had a statistically 
significant overlap (FDR=1.2x10−2) with a study comparing sclerosed CA1 with histologically 
normal CA1 from MTLE patients using an Affymetrix U133A microarray (Lee et al., 2007).  
In addition, a significant number of the 1174 genes which were differentially expressed in 
only one study (a ‘non-corroborated gene set’) are also likely to be relevant to 
epileptogenesis and pharmacoresistance. To demonstrate this we compared the non-
corroborated gene set with CarpeDB, a dynamic continuously-updated epilepsy genetics 
database. Of the 278 genes extracted from CarpeDB, 54 genes overlap with our non-
corroborated gene set. This overlap is highly significant (FDR=1.2x10−24). This suggests that 
the non-corroborated gene list is also an important data source which should be 
appropriately studied and interpreted (see below). 
It is of course possible that some of the gene expression changes identified in this analysis 
are the consequence, rather than the cause, of refractory seizures; this limitation is inherent 
in large-scale gene expression profiling studies and, hence, also in this analysis. The 
causative role of candidate genes identified as potentially playing a part in the development 
of pharmacoresistance will need to be established with further investigation, such as 
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electrophysiological studies in hippocampal neuronal cultures or studies in rodent epilepsy 
models where the expression of the relevant gene has been appropriately altered. Another 
limitation which applies to all transcriptomic studies, and also to this analysis, is that mRNA 
concentration may not be a predictor of protein abundance or activity because of the many 
processes downstream of mRNA synthesis (for example, alternative mRNA splicing and 
microRNA regulation) that may affect the total amount and activity of protein in tissue.   
2.4.2 Data integration 
Microarray technology has become an important tool for biological research, but it can 
suffer from both low sensitivty and high false positive rates (Rhodes et al. 2002). One way of 
overcoming these limitations is to use meta-analysis methods that integrate the results of 
separate microarray studies. Meta-analysis is a classical statistical methodology for 
combining results from different studies addressing the same scientific questions, and has 
recently been applied to the analysis of microarray data, increasing both the sensitivity and 
reliability of measurements of gene expression changes (Rhodes et al. 2002). Two basic 
meta-analysis methods have been applied to microarray studies: (1) combining p-values for 
each gene from the individual studies to estimate an overall p-value for each gene across all 
studies (Rhodes et al. 2002), and (2) integrating effect size estimates to obtain an overall 
estimate of the average effect size (Choi et al. 2003). However, the majority of studies 
included in this review did not provide the basic information that would allow either meta-
analysis method to be applied. This being the case, we integrated the gene lists provided by 
each study to generate lists of genes consistently regulated in two, three or four studies. 
This integrative technique successfully improved the reliability of the regulated gene lists, 
without enhancement of the sensitivity. Hence, the 233 genes shown in this review to 
overlap between two or more studies are a ‘corroborated gene set’ unlikely to be specific to 
the histological characteristics of the tissues being compared or to laboratory conditions, 
and most likely to represent universal genetic changes linked with epileptogenesis and 
pharmacoresistance. For GO term enrichment analysis, canonical pathway analysis and 
network analysis, we included both the corroborated and non-corroborated gene sets. This 
is because a significant number of the non-corroborated genes are also likely to be relevant 
to pharmacoresistance, as demonstrated by the significant overlap with the CarpeDB 
database. Further, in terms of genes found to be regulated in single studies, we took the 
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view that different genes validate each other if they are significantly enriched together in a 
GO term category, canonical pathway or an interaction network. 
2.4.3 What does this analysis tell us about the mechanism of pharmacoresistance? 
Current theories on pharmacoresistance in epilepsy include the multidrug transporter 
(MDT) hypothesis, the drug target hypothesis, and the inherent severity hypothesis 
(Schmidt & Loscher 2009). It has recently been suggested that these processes are likely to 
act not in a mutually exclusive manner, but rather an integrated manner, to cause 
pharmacoresistance (Schmidt & Loscher 2009). The current analysis supports this view, 
suggesting that all three hypotheses may be important. However, much of the integrated 
evidence generated by this analysis is weighted towards the intrinsic severity hypothesis. 
2.4.3.1 MDT hypothesis 
According to the MDT hypothesis, pharmacoresistance results from impaired drug 
penetration into the epileptic focus secondary to dysregulation of drug transporters 
(Chayasirisobhon 2009). Studies on the role of MDTs in pharmacoresistant epilepsy have, 
hence far, been limited to a small number of selected adenosine triphosphate-binding 
cassette (ABC) transporters, with a predominant focus on ABCB1 (Lazarowski et al. 2007). It 
is interesting to note that ABCB1, which has been the focus of the majority of research on 
the role of MDTs in epilepsy pharmacoresistance (Hughes 2008), was not shown to be 
dysregulated in any of the included studies, even though a probe for ABCB1 was present on 
the arrays of at least four of the nine studies. The role that solute carrier (SLC) transporters 
may play in epilepsy pharmacoresistance is much neglected. SLC transporters have been 
shown to play a role in cancer pharmacoresistance (Gupta et al. 2011), but their potential 
role in epilepsy pharmacoresistance has not been studied. Twenty-seven different SLC 
transporters were shown to be dysregulated in the studies included in this analysis. These 
findings suggest that the search for drug transporters relevant to epilepsy 
pharmacoresistance needs to be expanded to include SLC transporters. 
2.4.3.2 Drug target hypothesis 
According to the drug target hypothesis, pharmacoresistance is caused by the modification 
of one or more drug target molecules.  
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An important AED drug target is the voltage-gated sodium channel. These channels consist 
of α and β subunits. To date, nine -subunits and four -subunits have been identified. It 
has been suggested that in pharmacoresistant epilepsy subunit composition of these 
channels is altered, such that the expression of AED-insensitive subunit combinations is 
promoted. The SCN1A subunit gene has been the focus of most research so far (Loscher et 
al. 2009). This analysis showed that the expression of SCN2A, SCN3A, SCN3B and SCN8A was 
also altered in pharmacoresistant epilepsy. SCN2A was downregulated in two different 
microarray studies included in this analysis. In support of this finding, SCN2A was also 
downregulated in epileptic foci in a radioactive in situ hybridisation study (Whitaker et al. 
2001). In addition, two different SCN2A polymorphisms have been reported to be 
associated with epilepsy pharmacoresistance (Kwan et al. 2008; Lakhan et al. 2009). The 
role of SCN2A, and the other subunits identified in this analysis, should be confirmed in 
future studies. 
Another important AED target is the GABAA receptor (Rogawski & Loscher 2004). The 
pharmacological properties of GABAA receptors depend on the combination of subunits of 
which there are more than 20 to choose from (Brooks-Kayal et al. 1998). Three GABAA 
receptor subunit genes were shown to be downregulated in the studies included in this 
analysis: GABRA5, GABRB3 and GABRG2. Mutations in the GABRG2 gene are associated with 
a number of familial epilepsy syndromes: generalized epilepsy with febrile seizures plus, 
type 3 (Baulac et al. 2001; Harkin et al. 2002; Carvill et al. 2013), childhood absence epilepsy 
(Wallace et al. 2001; Kananura et al. 2002), familial febrile seizures (Audenaert et al. 2006), 
and familial idiopathic generalized epilepsy (Lachance-Touchette et al. 2011). 
GABRA5 was downregulated in four of the included studies. Using immunohistochemical 
labelling, Bethmann et al., (2008) showed that GABRA5 subunit protein expression in the 
hippocampi of antiepileptic drug resistant rats was significantly lower than in responsive 
rats (Bethmann et al. 2008). Bonin et al., (2007) have shown that the depolarizing current 
required to generate an action potential was two-fold greater in neurons from wildtype 
than from GABRA5 knockout mice (Bonin et al. 2007). Phenytoin (Mariotti et al. 2010) and 
carbamazepine (Almgren et al. 2008) have been shown to up-regulate GABRA5, and this has 
been suggested to be involved in their antiepileptic mechanism. GABRA5-selective inverse 
agonists have been shown to have convulsant or proconvulsant effect in mice in a dose-
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dependent manner and proportional to the extent of GABRA5 efficacy (Atack et al. 2006). 
The current analysis reveals strong evidence of downregulation of GABRA5 in human 
epileptic tissue. Further studies are needed to look for associations between polymorphisms 
in the GABRA5 gene and pharmacoresistance, and for ways to reverse the downregulation 
of GABRA5.  
2.4.3.3 Intrinsic severity hypothesis 
The observation that a high frequency of seizures prior to onset of treatment is a prognostic 
signal of increased severity and future drug failure suggests that common neurobiological 
factors may underlie both disease severity and pharmacoresistance (Schmidt & Loscher 
2009). A number of processes are thought to contribute to the development of 
pharmacoresistant epilepsy through promoting severity: neuroinflammation, enduring 
increases in excitatory synaptic transmission, changes in GABAergic inhibition, neuronal cell 
death, and the development of aberrant innervation patterns in part arising from reactive 
axonal growth (Gall & Lynch 2004). Although this review lends supports to all these 
processes playing a part, three basic themes were most prominently overrepresented in the 
gene list assembled: 
1. Neuroinflammation 
2. Modulation of synaptic transmission 
3. Restructuring of neuronal networks 
It is worth noting that although the important processes highlighted by this analysis may 
appear somewhat non-specific, the pattern of genetic changes demonstrated is distinctly 
different from those seen in other common brain pathologies, as shown by our comparison 
with an AD dataset.  
What follows is a brief summary of the aforementioned three themes, as represented by 
our analysis. From the themes, we highlight novel and important genes and pathways. This 
is not a comprehensive précis, and we invite interested researchers to peruse the gene lists 
and enriched GO terms, pathways and networks to find other genes, pathways and 
networks of interest.  
Neuroinflammation 
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It is being increasingly recognised that inflammation plays an important role in the 
pathogenesis of epilepsy (Vezzani & Granata 2005). The role of chemokine- and 
semaphorin-induced inflammation in the development of refractory epilepsy is little studied 
(Fabene et al. 2010). Our analysis suggests that chemokine and semaphorin signalling plays 
a significant role in epilepsy pharmacoresistance. We have also identified particular 
chemokines and semephorins that are potentially important therapeutic targets.  
Chemokines 
The chemokine signalling canonical pathway was shown to be dysregulated in our analysis, 
and the chemokine CCL2 and chemokine target Inhibin β-A were prominent in our gene list. 
Chemokines can induce neuronal hypersynchronization and neuronal epileptiform activity 
(Seiffert et al. 2004; Ivens et al. 2007; Marchi et al. 2007), leading to seizure generation in 
animal models of epilepsy (Fabene et al. 2008). CCL2 upregulation has been linked to 
increased susceptibility to seizures in a 'two-hit' seizure model in rats (Somera-Molina et al. 
2009), and valproic acid has been shown to downregulate CCL2 mRNA in rat brain (Sinn et 
al. 2007).  Inhibin β-A is a member of the transforming growth factor-β superfamily 
(Unsicker & Krieglstein 2002) and may mediate neuroprotective actions of basic fibroblast 
growth factor (Alzheimer & Werner 2002). Zhang et al., (2009) have identified inhibin -A as 
one of a set of neuroprotective genes, termed Activity-regulated Inhibitor of Death (AID) 
genes, which promote survival of hippocampal neurons after growth factor withdrawal or 
staurosporine treatment in vitro and after kainic acid-induced status epilepticus in vivo 
(Zhang et al. 2009). 
In addition, the canonical pathway of chemokine receptor CXCR4 was dysregulated. 
Increased expression of CXCR4 allows for increased CXCL12 binding. CXCL12 induces a slow 
inward current followed by a spontaneous synaptic activity via ionotropic glutamatergic 
receptors (Ragozzino et al. 2002), and induces microglia to release TNFα, which potentiates 
prostaglandin-dependent Ca++ activation and glutamate release (Lee et al. 2007). Other 
dysregulated chemokines in our analysis were CCL3, CCL4, CCL28, CCL3L1, CX3CL1 and 
CXCL14. 
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Figure 2.1 Up-regulated genes in the semaphorin pathway. The intensity of the colour 
indicates the number of studies in which the gene is up-regulated. 
 
Semaphorin Signaling in Neurons 
The current review reveals the upregulation of the semaphorin pathway (Figure 2.1), most 
importantly Sema4D and Plexin B1. Semaphorins are a large family of secreted and 
transmembrane molecules that function as repulsive axon guidance factors (Kolodkin et al. 
1993) and modulate dendritic and axonal arborizations of developing neurons. In addition, 
semaphorins play a significant role in microglia activation and in neuroinflammation. A 
recent study by (Okuno et al. 2010) has shown that Sema4D promoted inducible nitric oxide 
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synthase expression by primary mouse microglia. This expression was Plexin B1-dependent 
as it was abolished in Plexin B1-deficient cells. Moreover, during the development of Myelin 
Oligodendrocyte Glycoprotein-peptide-induced experimental autoimmune 
encephalomyelitis (EAE), the expression of Sema4D and Plexin B1 was induced in infiltrating 
mononuclear cells and microglia, respectively (Okuno et al. 2010). Wild-type Myelin 
Oligodendrocyte Glycoprotein-specific T cells adoptively transferred into Plexin B1-deficient 
mice were not able to induce the disease. Similarly, bone marrow chimeric mice with Plexin 
B1-deficient central nervous system resident cells were not able to develop EAE. 
Furthermore, blocking antibodies against Sema4D significantly inhibited neuroinflammation 
during EAE development. Mutations in members of the semaphorin gene family have been 
associated with a number of  human diseases: SEMA4A variants with retinitis pigmentosa, 
cone-rod dystrophy and congenital blindness (Abid et al. 2006), and SEMA3E variants with 
CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, 
genital hypoplasia, ear anomalies/deafness) syndrome (Lalani et al. 2004). The role 
semaphorins play in the inflammatory processes associated with epilepsy is not yet known, 
but deserves further study. 
Modulation of synaptic transmission 
The cellular component ontology term enrichment shows that some of the most important 
processes in the development of pharmacoresistance are occurring in membrane-bound 
vesicles and at the pre- and post-synaptic terminal. The most significant biological processes 
are cellular cation homeostasis, synaptic transmission and synaptic plasticity. The enriched 
gene ontology terms suggest that the most important molecular functions in the 
development of pharmacoresistance are calcium transport and signalling, and transporter 
activity. Therefore, changes in calcium signalling and in synaptic structure and function were 
shown to be important in our analysis. 
Calcium signalling 
Network 3 shows that changes in calcium-mediated cell signalling leading to alterations in 
neuronal excitability are likely to be important in the development of pharmacoresistance in 
epilepsy. The network reveals dysregulation of proteins regulating calcium channels 
(calcium-binding protein 1 and calpastatin), of proteins involved in calcium homeostasis 
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(inositol 1,4,5-triphosphate receptor, type 1, ATPase Ca++ transporting cardiac muscle slow 
twitch 2, ATPase Ca++ transporting plasma membrane 1, solute carrier family 8 
sodium/calcium exchanger member 1, calcium channel voltage-dependent alpha 2/delta 
subunit 1, calcium channel voltage-dependent gamma subunit 3, calcium channel voltage-
dependent alpha 2/delta subunit 1, adenosylhomocysteinase-like 1), and of calcium-
dependent signalling proteins (calpain 3, and calcium-binding protein 1). Calcium signalling 
is amongst the top 25 enriched canonical pathways in our gene list. Calcium signalling, 
therefore, is likely to play a significant part in pharmacoresistance and its manipulation may 
be an important therapeutic strategy—two potential target genes which overlap in three or 
more studies are neurogranin and SNAP-25.  
Neurogranin has been implicated in the modulation of postsynaptic signal transduction 
pathways, in synaptic plasticity (Kubota et al. 2008), and in the enhancement of long-term 
potentiation by promoting calcium-mediated signalling (Huang et al. 2004), and it is 
hypothesized that it participates in the action of valproate (Wu et al. 2011). SNAP-25 
modulates neurotransmitter exocytosis (Schiavo et al. 1997; Augustine 2001; Chapman 
2002; Zhang et al. 2002) and negatively regulates voltage-gated calcium channels (VGCC) in 
glutamatergic neurons (Condliffe et al. 2010). Silencing of endogenous SNAP-25 in 
glutamatergic neurons leads to an augmentation of VGCC activity, which would increase 
network excitability. Reductions in SNAP-25 expression have been correlated with 
neurological conditions characterized by increased network excitability. For example, VGCC 
currents are up-regulated resulting in absence-like epilepsy and hyperactivity (Risinger & 
Bennett 1999) in the Coloboma mouse mutant characterized by the heterozygous deletion 
of the SNAP-25 gene. Also, alterations in SNAP-25 expression have been described in human 
patients with attention deficit hyperactivity disorder and schizophrenia (Zhang et al. 2002).  
Alterations in synaptic structure and function 
As stated above, GO term enrichment analysis suggests that some of the most important 
processes in the development of pharmacoresistance are occurring in membrane-bound 
vesicles and at the pre- and post-synaptic terminal and some of the most significant 
biological processes are synaptic transmission and synaptic plasticity.  
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Network 1 reveals that there is dysregulation of proteins involved in maintaining synaptic 
structure and function. There is dysregulation of pre-synaptic cytomatrix proteins (bassoon, 
ELKS/RAB6-interacting/CAST family member 2, and piccolo), an active zone protein (PTPRF 
interacting protein, binding protein 1), a protein which controls presynaptic residual Ca++ 
concentrations (ATPase Ca++ transporting plasma membrane 2), proteins in postsynaptic 
sites which form a multimeric scaffold for the clustering of receptors, ion channels, and 
associated signaling proteins (calcium/calmodulin-dependent serine protein kinase and 
DLG2), and proteins which may play a role in clustering of NMDA receptors at excitatory 
synapses (DLG3). Complexin, a part of the SNARE complex (Neher 2010) which is the core of 
the synaptic release machinery (Sudhof & Rothman 2009), was downregulated in three 
studies and is particularly deserving of further study. Perturbations of the complexin 
proteins causes an increase in spontaneous and asynchronous release of neurotransmitter 
in some types of synapses, indicating an inhibitory role of the proteins (Neher 2010). Hence, 
the reduction in complexin 2 expression in the epileptic focus, as demonstrated in this 
review, could lead to increases in excitatory synaptic transmission, and deserves further 
study. 
Restructuring of neuronal networks 
The gene ontology enrichment analysis suggests that some of the most important processes 
in the development of pharmacoresistance are occurring in the cytoskeleton, the dendrite, 
the axon, and the growth cone. Some of the most significant biological processes are 
apoptosis, cytoskeletal organization, neuronal development and differentiation, axonal and 
dendritic morphogenesis, and one of the most important molecular functions in the 
development of pharmacoresistance is cytoskeletal function. In support of this, Network 2 
reveals dysregulation of proteins involved in apoptotic mechanisms (translocase of inner 
mitochondrial membrane 23, histone cluster 1 H1c, peptidylprolyl isomerase F, dedicator of 
cytokinesis 1, and jumonji domain containing 6), in cell growth (protein tyrosine kinase 2, 
protein tyrosine phosphatase non-receptor type 12, and neural precursor cell expressed 
developmentally down-regulated 9), and in cell shape maintenance (tensin 1). Network 3 
reveals dysregulation of proteins involved in neurogenesis, neurite outgrowth and axon 
guidance (neurogenic differentiation 2, neurofascin, and dihydropyrimidinase-like 3). 
Network 1 reveals that there is also dysregulation of proteins involved in axon guidance 
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(protein tyrosine phosphatase receptor type f and protein tyrosine phosphatase receptor 
type D). Similarly, the enriched canonical pathways include axonal guidance signalling, RhoA 
signalling (which plays a significant role in actin stress fibers formation), CDK5 signalling 
(which regulates neurite outgrowth), and ephrin receptor signalling (which is involved in 
nervous system development). The cholecystokinin (CCK) signalling pathway was the most 
significantly enriched canonical pathway in our analysis (Figure 2.2) and has an important, 
yet understudied, role in the development of aberrant neuronal networks. 
Cholecystokinin Signaling 
CCK controls the perisomatically targeting inhibitory interneurons of the hippocampus (Lee 
& Soltesz 2011). In kindling rodent models of epilepsy, there is a reduction of GABA-evoked 
inhibitory post-synaptic currents in the hippocampus, and this loss corresponds with a 
reduction in CCK-labelled interneurons (Sayin et al. 2003). In humans, the CCK content of 
cortical tissue from which active epileptic spiking was recorded at the time of surgery was 
significantly decreased in comparison to tissue samples from patients in whom the lateral 
temporal cortex was electrographically free of epileptiform spikes (Iadarola & Sherwin 
1991). CCK may have anticonvulsant and neuroprotective properties. Pretreatment of 
hippocampal slices with sulfated CCK blocked the effect of kainic acid on synaptic 
transmission (Aitken et al. 1991). Seizures in a breed of rat with congenital audiogenic 
seizure were suppressed by cholecystokinin octapeptide injected intraperitoneally (Zhang et 
al. 1993) and by intracerebral injection of a CCK gene vector (Zhang et al. 1992). Seizures 
induced by picrotoxin and electroshock are inhibited by intracerebroventricular 
administration of cholecystokinin in rats (Kadar et al. 1984). There is also a positive 
influence of CCK on the anticonvulsant efficacy of vigabatrin (Ferraro & Sardo 2009). CCK 
genetic variants have not been studied specifically in epilepsy, but variants in the gene are 
known to be associated with another common brain disorder: Parkinson’s disease (Fujii et 
al. 1999). CCK, therefore, is another potential therapeutic agent that should be further 
studied. 
2.5 Conclusions 
Large-scale gene expression profiling studies on brain tissue from epilepsy surgery have 
been performed largely with the aim of generating hypotheses about the causes of 
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epileptogenesis and pharmacoresistance. Although there have been at least 12 such studies 
in the last ten years, they have failed to make a significant impact on our understanding of 
pharmacoresistance in epilepsy for the reasons which have been outlined in this chapter.  
Our analysis shows that there is a statistically significant overlap between the gene lists of 
studies performed on different kind of epileptic foci using different types of microarrays. We 
have used an inter-study cross-validation technique to simultaneously verify the expression 
changes of large numbers of genes. We have performed an integrative analysis of the gene 
lists from different studies to identify the cellular components, biological processes, 
molecular functions, pathways, networks and individual genes which are likely to be 
important in the development of refractory epilepsy.  
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Figure 2.2 Down-regulated genes in the CCK pathway. The intensity of the colour indicates 
the number of studies in which the gene is down-regulated. 
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Chapter 3: SLC Transporters in Pharmacoresistant 
Epilepsy: An Integrative In Silico & Ex Vivo Analysis  
3.1 Introduction 
Epilepsies are among the most common neurological disorders, affecting up to 1% of the 
population (Sander 2003). Most patients with epilepsy become seizure-free with 
antiepileptic drug (AED) therapy. However, approximately 30% of epilepsy patients are 
pharmacoresistant: they continue to experience seizures even if treated with various AEDs 
at maximal dosages (Shorvon 1996). A number of hypotheses have been put forward to 
explain pharmacoresistance (Chayasirisobhon 2009); one of these is the multidrug 
transporter (MDT) hypothesis. According to this hypothesis, pharmacoresistance results 
from decreased drug concentrations at the epileptic focus secondary to a localized 
dysregulation of drug transporters (Chayasirisobhon 2009), which could either increase drug 
efflux from, or reduce influx into, the epileptic focus.  
The largest superfamily of MDTs is the solute carrier (SLC) superfamily which are mainly 
influx transporters (Huang & Sadee 2006). Downregulation within the epileptic focus of SLC 
transporters which are normally expressed at significant levels could thus potentially 
contribute to the development of pharmacoresistance. There are approximately 400 known 
SLC proteins in total, but very few of these have been studied in epilepsy. 
Mesial temporal lobe epilepsy (MTLE), in which seizures originate from the hippocampus, is 
the most common cause of refractory epilepsy and the most common indication for 
epilepsy surgery (Engel 2003). In this study, therefore, we focus on SLCs most relevant to 
this phenotype.  
In order to identify the SLCs which are downregulated in the pharmacoresistant epileptic 
hippocampus, we devised a robust in silico approach that exploits relevant published data 
and builds upon them using cutting-edge computational tools; we then verified the output 
using a robust ex vivo approach. We anticipate that our in silico strategy will be adaptable to 
other pathologies and protein families. 
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Figure 3.1 Our in silico strategy; see text for details. SLC=solute carrier transporter 
3.2 Methods: 
3.2.1 In silico analysis 
Our in silico strategy was to:  
1. rank SLCs based on the strength of the published evidence of their downregulation in 
pharmacoresistant epileptic foci, if such data is available;  
2. for SLCs with no such published data, rank genes based on the computationally-
determined likelihood of their downregulation in pharmacoresistant epileptic foci; 
this step was limited to the SLCs most abundantly expressed in the normal human 
hippocampus, as these SLCs are most likely to be functionally important in the 
pharmacoresistant epileptic hippocampus;  and 
3. based on 1 and 2 above, create a prioritized list of SLCs most likely to be 
downregulated in pharmacoresistant epileptic foci. 
The individual steps and processes are illustrated schematically in Figure 3.1. 
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Integrative analysis of microarray studies: We started by performing an integrative analysis 
of large-scale gene expression profiling studies on brain tissue from epilepsy surgery—
details of this analysis can be found in Chapter 1. Data relating to SLCs from this analysis was 
carried forward into the convergent functional genomics step.  
Convergent functional genomics (CFG): CFG is an approach for prioritizing candidate genes 
for complex disorders by integrating and tabulating multiple lines of evidence, such as 
human and animal-model gene and protein expression data (Le-Niculescu et al. 2007). In 
order to implement the CFG approach, each SLC transporter was scored on the strength of 
the evidence of down-regulation of the gene or protein in epileptic foci of humans or of 
animal models of pharmacoresistant epilepsy. The search strategy and search terms used in 
order to find this data is detailed in Appendix 4. Details of the scoring system are given in 
Table 3.1. 
Table 3.1 Convergent Functional Genomics scoring scheme for SLC transporters 
Evidence Score Reason 
Gene/protein expression data   
Downregulated in ≥2 studies on 
pharmacoresistant MTLE epileptic 
foci 
1 Maximum weight given to confirmed 
downregulation in MTLE, which is our 
phenotype of interest 
Downregulated in only 1 study on 
pharmacoresistant MTLE epileptic 
foci 
0.50 Lower score given to non-replicated evidence 
Downregulated in ≥1 study on 
pharmacoresistant non-MTLE 
epileptic foci 
0.50 Lower score given to evidence in other 
phenotypes 
Evidence of downregulation in brain 
tissue from animal models of 
pharmacoresistant epilepsy 
0.25 Lowest score for animal models 
 
Six SLC transporters (SLC1A2, SLC1A3, SLC2A3, SLC12A5, SLC17A7 and SLC24A3) were 
deemed to have strong evidence in support of a role in epilepsy pharmacoresistance (see 
Discussion below). These six transporters were used as ‘training genes’ for computational 
gene prioritization.  
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Computational gene prioritization (CGP): To perform CGP, we used a bioinformatics 
software application called Endeavour (Tranchevent et al. 2008), whose key feature is that it 
uses multiple genomic data sources (e.g. sequence, expression, literature and annotation) to 
estimate how promising a candidate gene is by measuring its similarity with a set of training 
genes. The training genes are those which are already known to play a role in the biological 
process under study. The underlying assumption is that the most promising candidate genes 
are the ones that exhibit most similarities with the training genes. CGP was performed using 
all available data sources in Endeavour. 
Our training gene set comprised the top scoring SLCs from the CFG step: SLC1A2, SLC1A3, 
SLC2A3, SLC12A5, SLC17A7 and SLC24A3. Our candidate gene set comprised SLCs which are 
highly likely to be expressed—and abundantly so—in the normal human hippocampus. This 
candidate gene set was created as described below. 
Determining the presence and abundance of SLC transcripts in the normal human 
hippocampus: In order to determine the presence and abundance of SLC transcripts in the 
normal human hippocampus, we extracted data from publically-available large-scale 
microarray studies on the human hippocampus. We searched the ArayExpress (Parkinson et 
al. 2007) and GEO (Edgar et al. 2002) databases for studies fulfilling the following criteria: 
1. Studies done using the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array. 
This chip was chosen as: (i) it is a single-channel array, (ii) it is one the most 
comprehensive whole human genome expression arrays available, and (iii) it is 
widely used.  
2. Studies which included samples from normal post-mortem human hippocampus in 
the analysis. 
3. Studies for which MIAME-compliant data was publically available. 
For the included studies, CEL files relating to normal hippocampal tissue were downloaded 
for processing. Using this strategy, we obtained 73 CEL files relating to 73 different normal 
hippocampal tissue samples from four different studies (GEO accession numbers: GSE3526, 
GSE5281, GSE7307 and GSE11882). 
 
 
112 
 
Quality control (QC) analysis and normalization was performed on the downloaded CEL files 
using the affyAnalysisQC pipeline through the arrayanalysis.org webportal (Eijssen et al. 
2013). We used the following options: (1) Absent (A), Marginal (M) and Present (P) calls 
were computed based on the MAS5 function; (2) re-annotation of the probes was 
performed using a custom Chip Definition File environment from the BrainArray database.   
For each gene, the number of P, M and A calls was summed using a value of 1 for P and 0.50 
for M, and 0 for A. Genes with a cumulative score of 37 or above were chosen as there was 
greater evidence of their presence than of their absence. These chosen genes were than 
ranked by transcript abundance as described below. 
We used ‘rank product’—a non-parametric statistic that detects items that are consistently 
highly ranked in a number of lists—to create one combined hierarchical list of transcript 
abundance. Analysis was performed in R using the RankProd Bioconductor package (Hong et 
al. 2006). The function ‘RPadvance’, which performs the rank product analysis for multiple-
origin data, was used. From this analysis, the 50 most abundant SLCs were chosen as the 
candidate gene set—all these genes had a false discovery rate (FDR) of less than 5% for 
being ranked amongst the 50 most abundant SLC genes. 
Computational verification of CGP results: To validate our CGP approach and prioritized 
lists, the following steps were undertaken: 
1. The validity of the CGP result is vitally dependent on the quality of the training set. 
Therefore, to ensure the quality of the training set, we: 
a. performed a comprehensive literature review of our training genes to show 
that they are highly likely to be involved in epilepsy pharmacoresistance (see 
details in Discussion section), and 
b. performed leave-one-out analysis (LOOA). LOOA was performed in order to 
assess the quality (homogeneity) of the training set. LOOA was performed 
using a specifically designed utility provided by the authors of Endeavour. 
This analysis comprises multiple automated validation runs. In each 
validation run, one gene, termed the 'defector' gene, was deleted from a set 
of training genes and added to 99 randomly selected test genes. The 
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software then determined the ranking of this defector gene. This procedure 
makes it possible to assess the quality (homogeneity) of the training set 
2. We set up an in silico experiment. For this experiment, we created (i) a ‘positive 
control’ training set comprising the most consistently down-regulated genes from 
our previously mentioned integrative analysis of gene-expression profiling studies on 
brain tissue from epilepsy surgery (Mirza et al. 2011), and (ii) a ‘negative control’ 
training set consisting of randomly chosen genes from our integrative analysis. Both 
the control training sets were used to perform CGP of the same 50 SLC genes.  The 
list of genes comprising the control training sets can be found in the Appendix 5. We 
hypothesized that the ‘positive control ranking’ would be significantly similar to the 
original ranking, whereas the ‘negative control ranking’ would be dissimilar to the 
original ranking. We compared the original CGP ranking to the positive control and 
negative control CGP rankings in turn, using the following two methods: 
a. We calculated the size of the overlap between the top 20 genes in the two 
lists, and calculated the probability of this overlap occurring by chance 
according to the hypergeometric equation using the function phyper in R 
(Fury, Batliwalla et al. 2006). 
b. We compared the two gene lists using the Bioconductor package OrderedList 
(Lottaz, Yang et al. 2006). This package determines if there exist significant 
order similarities between pairs of gene lists. The package quantifies the 
similarity between ordered gene lists; the significance of the similarity is 
estimated from random scores computed on perturbed data.   
Creation of the final in silico gene list: To create the final in silico list of 20 genes, we 
amalgamated the CFG and CGP results. Giving precedence to genes with direct published 
evidence of downregulation, CFG genes were placed at the top of the list in rank order, 
followed by the CGP genes, with a cut-off being applied at a total of 20 genes. As our chosen 
cut-off of 20 total genes could be deemed arbitrary, we created for testing two further lists 
of 10 and 30 total genes. 
3.2.2 Ex vivo analysis 
Sample collection: Samples used in the study originated from three UK sites: the Walton 
Centre for Neurology and Neurosurgery in Liverpool, the Salford Royal Hospital in Salford 
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and the Southern General Hospital in Glasgow. We aimed to recruit patients of age 5 years 
and older with pharmacoresistant mesial temporal lobe epilepsy of at least 3 months 
duration for which a therapeutic temporal lobectomy was being undertaken. As recently 
proposed by the ILAE, pharmacoresistance was defined as the failure of adequate trials of 
two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as 
monotherapies or in combination) to achieve sustained seizure freedom (Kwan et al. 2010). 
The diagnosis of MTLE was made by the treating clinician based on seizure semiology, MRI 
brain and EEG characteristics being consistent with a seizure focus in the mesial temporal 
lobe. Patients suspected of having a neoplastic or malignant temporal lobe lesion were 
excluded. After surgery, the hippocampus was divided into two portions: (1) one portion 
was preserved for RNA isolation, (2) the other portion underwent histological analysis by an 
experienced neuropathologist. Any subjects found to have a neoplastic or malignant lesion 
on histological analysis were excluded. The portion preserved for RNA isolation was either 
stored in RNAlater (Liverpool and Glasgow) or frozen directly at -80 oC (Salford). It should be 
noted that the quality of the RNA generated from the directly frozen brain samples was not 
significantly different from RNAlater-preserved samples: mean RIN values were 7.82 and 
7.25 respectively, and two-sample t-test p-value for difference between group RINs was 
0.07. 
Frozen post-mortem histologically-normal hippocampal samples from donors with no 
known brain diseases were obtained from the MRC Edinburgh Brain Bank (Edinburgh, UK) 
and the Queen Square Brain Bank (London, UK).  
RNA isolation: Brain samples were disrupted and homogenized in an appropriate volume of 
QIAzol lysis reagent (Qiagen, Crawley, United Kingdom) by using a TissueRuptor handheld 
rotor-stator homogenizer (Qiagen, Crawley, United Kingdom). Total RNA was extracted from 
the homogenates using the RNeasy Lipid Tissue Mini Kit (Qiagen, Crawley, United Kingdom), 
according to the manufacturer’s instructions. RNA quality was examined by capillary 
electrophoresis on an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA) and Agilent 2100 
Expert software was used to calculate the RNA Integrity number (RIN) of each sample. Purity 
of the RNA sample was assessed using a NanoDrop1000 Spectrophotometer. Capillary 
electrophoresis traces were also examined. Samples with RNA integrity number  scores 
(RIN) below 6, obvious RNA degradation, significant 18S or 28S ribosomal  RNA degradation, 
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ratio of absorbance at 260nm and 280nm <1.95, or with  noticeable DNA or  background  
contaminants  did  not pass  QC,  and  were  withheld from microarray analysis.  It should be 
noted that RNA samples with RIN scores of 6 and lower have been successfully used for 3’ 
microarrays (Hawrylycz et al. 2012) and exon microarrays (Trabzuni et al. 2011). 
Microarrays: The microarrays were processed at the Centre for Genomics Research in the 
University of Liverpool (http://www.liv.ac.uk/genomic-research/). 50ng of total RNA was 
amplified and labelled using the Agilent Low Input Quick Amp One-Colour Labeling Kit and 
labelled RNA was hybridized to Agilent SurePrint G3 Custom Exon 8x60K Microarrays 
designed to contain probes for each exon of 936 selected genes, including all known SLC 
genes. Standard Agilent protocols were followed. The quality of the synthesized cRNA was 
assessed using an Agilent Bioanalyzer 2100—the resulting electropherograms were found to 
be satisfactory.  Each scanned image was viewed for visible artefacts, and if multiple 
artefacts were present, the array was rejected. Detailed QC reports were generated for each 
array using the Feature Extraction 11.0.1.1 Software (Agilent, Palo Alto, CA). Based on these 
reports, we excluded arrays in which more than 1% of features were non-uniform outliers, 
or the average of the net signals in negative controls was >40, or the average of the 
background-subtracted signals in negative controls was <-10 or >5, or the standard 
deviation of the background-subtracted signals in negative controls was >10, or the residual 
noise after spatial detrending was >15, or the median coefficient of variation for spike-in 
probes or non-control probes was >12%, or the dose-response curve of the spike-ins had a 
slope of <0.9 or >1.20, or the spike-in detection limit was <0.01 or >2. One array failed on 
five of these metrices and, hence, was excluded. Intensity data was extracted from the 
remaining arrays using the Feature Extraction Software. In line with the manufacturer’s 
recommendations, spatial and multiplicative detrending was applied but background 
subtraction was not. 
Data exported from Feature Extraction Software was imported into GeneSpring GX Software 
(Agilent, Palo Alto, CA). Features which were population outliers, saturated or non-uniform 
were flagged as ‘Compromised’ and filtered out. 75th percentile normalization, the default 
method recommended by Agilent for their exon arrays, was performed. Gene level values 
were obtained by summarizing the signal intensity values of probes mapping to various 
exons in the gene. As GeneSpring does not include functions that allow adjusting for 
 
 
116 
 
confounders and covariates, gene-level intensities were exported and further analysed using 
the limma package in R. This package has been used successfully for exon microarray 
analysis—see, for example, (Okoniewski et al. 2007; Zhang et al. 2007; Hall et al. 2011; Liu et 
al. 2011; Alagaratnam et al. 2013). Covariates included in the model were RIN, age, sex and 
batch—eight arrays (four cases and four controls) were processed together on each slide, 
hence, each batch comprised the eight samples processed together on each slide. 
From the microarray analysis, we created a list of SLCs significantly downregulated in the 
pharmacoresistant epileptic hippocampus. To be deemed significantly downregulated, SLC 
genes had to fulfil the following criteria: (1) strong evidence of expression in normal 
hippocampal tissue: the gene was flagged ‘detected’ in more than half of control samples; 
(2) FDR < 0.05; (3) fold-change ≥ 1.5. 
Quantitative Real-Time PCR: For each sample included in the microarray analysis, 1.8 µg of 
total RNA was reverse transcribed, according to the manufacturer's instructions, using the 
QuantiTect reverse transcription kit (Qiagen Inc., Valencia, CA) with integrated removal of 
genomic DNA contamination. 
Quantitative real-time PCR (qRT-PCR) was performed for three of the most significantly 
downregulated SLC genes. qRT-PCR was performed using the QuantiFast Multiplex PCR Kit 
(Qiagen Inc., Valencia, CA). Proprietary primer and FAM-labelled probe sets for target genes 
SLC24A3 (QF00004536), SLC47A1 (QF0052735) and SLC25A23 (QF00499555) were 
purchased from Qiagen (Qiagen Inc., Valencia, CA). Proprietary primer and MAX-labelled 
probe set for endogenous control GAPDH (QF00531132) was bought from Qiagen (Qiagen 
Inc., Valencia, CA), and for endogenous control CALR (Hs.PT.51.19228618) from IDT 
(Glasgow, UK). These two genes were chosen as endogenous controls as they are amongst a 
small group of validated ‘high quality’ housekeeping genes which have previously been 
shown to exhibit high expression and low variance (She et al. 2009), and they were also 
found to be invariant between the cohorts in our study after adjusting for covariates (data 
not shown). Each sample was assayed in triplicate using a duplex format in which a target 
gene and a control gene are assayed in the same well. The duplex format gives more reliable 
results as there is no well-to-well variability due to co-amplification of the internal control. 
To enable detection of contamination, ‘no template controls’ (containing all the 
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components of the reaction except for the template), and ‘no reverse transcriptase controls’ 
(containing all the components except for the reverse transcriptase) were included in 
triplicate for each target gene-control gene combination. The qRT-PCR reactions were 
conducted on the ABI 7900HT Fast Real-Time PCR System (Applied Biosystems, CA, USA), 
using conditions recommended for the QuantiFast Multiplex PCR Kit by its manufacturer. 
qRT–PCR data were analyzed using the RQ manager version 2.2 (Applied Biosystems, CA, 
USA). In line with the manufacturer’s recommendations, all baseline and threshold values 
were reviewed and adjusted manually where necessary. Further analysis was performed in 
DataAssist (Applied Biosystems, CA, USA). Expression levels of each target gene were 
normalized to the geometric mean of the two endogenous controls. Fold change (relative to 
the epilepsy group) was calculated, and a p-value was generated based on a two-sample, 
two-tailed Student’s t-test comparing the two groups and then adjusted using the 
Benjamini-Hochberg False Discovery Rate. 
3.2.3 Overlap between computational and microarray results 
The statistical significance of the overlap between the computationally-generated gene list 
and the list of SLCs significantly downregulated in our microarray was calculated using the R 
function phyper.  
  
 
 
118 
 
3.3 Results 
3.3.1 In silico analysis 
CFG: The results of the CFG analysis are summarized in Table 3.2; references for the data 
used can be found in Appendix 6. As Table 3.2 shows, there was data in published literature 
relating only to 17 SLC transporters. We also wished to obtain a prioritized list of SLC 
transporters that have hence far been overlooked in epilepsy research. To do this, we used 
the software ‘Endeavour’ to perform CGP.  
Table 3.2 Results of the CFG analysis for SLC transporters. Please see the methods section 
for a description of the scoring system employed. 
Transporter Total score 
SLC1A2 1.5 
SLC1A3 1.5 
SLC17A7 1.5 
SLC24A3 1 
SLC2A3 1 
SLC12A5 1 
SLC30A3 0.5 
SLC8A2 0.5 
SLC47A1 0.5 
SLC4A8 0.5 
SLC15A2 0.5 
SLC8A1 0.5 
SLC17A1 0.5 
SLC6A20 0.5 
SLC16A1 0.5 
SLC1A6 0.5 
SLC1A1 0.5 
 
CGP: To create a training gene set, we utilized the six SLC transporters with the highest CFG 
scores and with replicated evidence in support of a role in epilepsy pharmacoresistance. To 
assess the quality of our chosen training set, we performed leave-one-out cross-validation. 
The results of this analysis show that four defector genes were ranked first, while two were 
ranked second (see Appendix 7). This demonstrates that the training set is homogenous. We 
also performed a comprehensive literature review of our training genes to show that they 
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are highly likely to be involved in epilepsy pharmacoresistance (see Discussion section 
blow). 
To compile a candidate gene set for CGP, we created a hierarchical list of the most abundant 
SLC transporters in the normal human hippocampus. To do this, we performed a ‘meta-
analysis’ of 73 publically-available Affymetrix GeneChip Human Genome U133 Plus 2.0 
Arrays on the normal human hippocampus, as described in the Methods section. The results 
of this meta-analysis can be found in the Appendix 8. The 50 most abundant SLC genes were 
taken forward as the candidate gene set for CGP. All these genes had an FDR of less than 5% 
for being ranked amongst the 50 most abundant SLC genes.  
To verify the results of the above CGP, we performed a second CGP of the same candidate 
SLC genes using a different and independently selected ‘positive control’ training set: the 10 
genes most consistently downregulated in the integrative analysis of large-scale microarray 
studies on brain tissue from epilepsy surgery presented in Chapter 1. We compared the 
results of the two CGPs (original and positive control): of the top 20 genes in each list, 13 
were common to both lists. The probability of this overlap occurring by chance alone is 
0.004, according to the hypergeometric equation. We also compared the two prioritized 
gene lists using the Bioconductor package OrderedList (Lottaz et al. 2006). The order of 
genes in the two lists was significantly similar (p-value=0.01). In contrast, when the original 
CGP ranking was compared with the ‘negative control’ CGP ranking, generated using a 
‘negative control’ training set of randomly chosen genes from our integrative analysis, there 
was no significant overlap in the top 20 genes of the two lists (p=0.614) and no significant 
similarity between the order of genes in the two lists (p=0.10). 
Creation of the final in silico gene list: To create the final in silico gene list, we amalgamated 
the CFG and CGP results. Giving precedence to genes with direct published evidence of 
downregulation, CFG genes were placed at the top of the list in rank order, followed by the 
CGP genes. In order to test the accuracy of in silico gene lists of varying sizes, we created 
lists of 10, 20 and 30 genes (Table 3.3). 
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3.3.2 Ex vivo analysis 
For ex vixo validation, we collected 24 hippocampal samples from surgery for 
pharmacoresistant mesial temporal lobe epilepsy and obtained 24 histologically-normal 
post-mortem hippocampal samples from donors with no known brain disease. Important 
patient and donor individual and sample characteristics are summarized in Table 3.4.  
There was no statistically significant difference in the sex distribution of the two groups (the 
number of males in cases was 12, and in controls was 18, 2= 2.2222, df = 1, p-value = 
0.136). There was a statistically significant difference in the mean RIN values for the two 
groups (7.487500 in cases and 6.383333 in controls, 2-sample t-test p-value < 0.05). RIN was 
included as a covariate in the linear model used to analyse the microarray data.  There was 
also a statistically significant difference in the mean age of the two groups (36.33333 years 
in cases and 53.95833 years in controls, 2-sample t-test p-value <0.05). Again, age was 
included as a covariate in the linear model used to analyse the microarray data. 
One of the control samples failed microarray QC evaluation (see Methods section) and, 
hence, was excluded, leaving 24 disease samples and 23 normal control samples for 
subsequent analysis. We filtered out SLC genes lacking strong evidence of expression in the 
control samples (see Methods section) and utilized linear models implemented in the R 
Bioconductor package limma for data analysis, including as covariates batch, RIN, age and 
sex. 18 SLC genes (Table 3.5) were significantly downregulated (FDR < 0.05, fold change ≥ 
1.5).  qRT-PCR results for the three tested SLC genes were highly concordant with the 
microarray results (Table 3.5) 
3.3.3 Overlap between computational and microarray results 
We calculated the size of the overlap between the 18 SLC genes shown to be down-
regulated by our microarray and our in silico gene lists of 10, 20 and 30 SLC genes 
respectively. All three overlaps were highly significant, with p-values of 8.4 x 10-7, 7.9 x 10-6 
and 9.9 x 10-7 respectively. 
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Table 3.3 In silico gene list of 30 genes. 
In silico list of 30 
genes 
SLC1A2 
SLC1A3 
SLC17A7 
SLC24A3 
SLC2A3 
SLC12A5 
SLC30A3 
SLC8A2 
SLC47A1 
SLC4A8 
SLC15A2 
SLC8A1 
SLC17A1 
SLC6A20 
SLC16A1 
SLC1A6 
SLC1A1 
SLC1A4 
SLC6A1 
SLC24A2 
SLC12A7 
SLC25A22 
SLC6A8 
SLCO1C1 
SLC7A5 
SLCO3A1 
SLC7A11 
SLC25A11 
SLC4A3 
SLC20A1 
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Table 3.4 Sample characteristics. RIN=RNA Integrity Number 
Sample Phenotype Age Sex RIN  Sample Phenotype Age Sex RIN 
D1 Case 41 F 7.4 N1 control 81 M 6.5 
D2 Case 23 F 6.8 N2 control 78 F 6.2 
D3 Case 51 M 6 N3 control 84 F 6.6 
D4 Case 49 F 6.9 N4 control 91 F 6.7 
D5 Case 50 F 7.8 N5 control 88 M 6.3 
D6 Case 45 F 6.6 N6 control 38 M 6.1 
D7 Case 12 M 7 N7 control 50 M 6.2 
D8 Case 29 F 7.8 N8 control 45 M 6.3 
D9 Case 33 M 6.8 N9 control 39 M 6.1 
D10 Case 25 F 7.1 N10 control 40 M 6 
D11 Case 34 M 7 N11 control 61 M 6.2 
D12 Case 33 M 8.8 N12 control 63 F 6.2 
D13 Case 33 M 8.6 N13 control 66 M 6.2 
D14 Case 22 F 7.3 N14 control 22 F 6.3 
D15 Case 48 M 7.6 N15 control 27 M 6.3 
D16 Case 39 F 7.4 N16 control 45 M 6.9 
D17 Case 29 F 7.1 N17 control 44 F 6.7 
D18 Case 44 M 7.9 N18 control 50 M 6.5 
D19 Case 40 F 6.6 N19 control 43 M 6.6 
D20 Case 48 M 8.5 N20 control 46 M 6.8 
D21 Case 23 M 8.4 N21 control 51 M 6.2 
D22 Case 63 M 7.9 N22 control 48 M 6 
D23 Case 31 M 8.2 N23 control 43 M 6.6 
D24 Case 27 F 8.2      
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Table 3.5 Microarray and qRT-PCR results. FDR=false discovery rate 
Gene 
Symbol 
Microarray results qRT-PCR results 
FDR Fold-change FDR Fold-change 
SLC24A3 1.65 x10-4 3.7 0 3.7 
SLC47A1 1.49 x10-3 2.6 1.60 x10-3 2.8 
SLC25A23 3.38 x10-4 2.3 1.00 x10-4 1.9 
SLC8A2 1.64 x10-5 2.0  
SLC17A7 3.89 x10-3 1.8 
SLC25A41 1.20 x10-5 1.6 
SLC26A10 5.28 x10-5 1.6 
SLC4A3 8.02 x10-5 1.6 
SLC4A7 2.26 x10-2 1.6 
SLC12A5 1.24 x10-2 1.6 
SLC7A1 6.81 x10-5 1.6 
SLC16A2 3.38 x10-4 1.6 
SLC25A22 1.88 x10-4 1.6 
SLC29A4 1.22 x10-3 1.5 
SLC8A1 1.24 x10-2 1.5 
SLC35E2 6.80 x10-4 1.5 
SLC4A8 1.83 x10-4 1.5 
SLC18A2 2.89 x10-2 1.5 
 
3.4 Discussion: 
Our contributions, in the present work, are twofold. The first contribution is 
methodological—we have developed a novel in silico strategy that can aid epilepsy research 
by prioritizing specific genes for study from within large gene sets. The second contribution 
is biological—we have identified the most significantly downregulated SLCs in the 
pharmacoresistant epileptic human hippocampus. 
3.4.1 In silico strategy 
There are more than 400 known SLC proteins. From amongst these, we were able to make a 
prioritized list of 20 SLCs, using our in silico approach, which was highly predictive of our 
robust exon microarray results. We wish to highlight the following novel and noteworthy 
elements of our in silico strategy that are particularly responsible for its success: 
1. We validated the output from each step of our strategy, before carrying that output 
forward into the next step: 
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a. The ‘training gene-set’ created through CFG was validated using LOOA and a 
detailed literature review. 
b. The prioritized gene list from the CGP step was validated using a completely 
novel approach, by performing an in silico experiment. We prioritized the 
candidate genes using a robust independent ‘positive control’ training set 
(containing the most consistently downregulated genes from nine 
microarray studies) and showed that there was significant overlap and rank 
order similarity between the two prioritized lists. To compare, we prioritized 
the same genes using a ‘negative control’ training set consisting of a random 
selection of differentially regulated genes from the aforementioned nine 
microarray studies; the latter prioritized gene list had neither a significant 
overlap nor significant rank order similarity with our first list. 
2. When creating the candidate gene list for CGP, we adopted a robust filtering 
approach, which is discussed in detail below. 
Filtering the candidate genes for CGP: SLC proteins are, in the main, influx transporters. We 
were interested, therefore, in SLC transporters that are most highly expressed in the normal 
human hippocampus, but downregulated in the pharmacoresistant epileptic focus. To 
create a hierarchical list of the most abundant SLC transporters in the normal hippocampus, 
we extracted data from four different single-channel large-scale microarray studies. In this 
way, we were able to combine the gene expression data for 73 different donor samples and, 
hence, obtain a robust estimate of the relative abundance of genes in the human 
hippocampus. 
Before creating the hierarchical list of transcript abundance, we filtered out non-expressed 
genes—not all genes are expressed at levels that are biologically significant in any particular 
tissue—based on ‘fraction present’ according to Affymetrix Microarray Suite 5.0 (MAS5) 
detection call. The MAS5 data processing algorithm provides a qualitative detection call 
(Absent, Present or Marginal) for each probe set on each array (Shi et al. 2006); this 
detection call is based on a non-parametric statistical test (Wilcoxon signed rank test) (Shi et 
al. 2006) of whether significantly more perfect matches show hybridization signal than their 
corresponding mismatches. We retained genes that were called Present in more than 50% 
of the samples, i.e. there was greater evidence of their presence than of their absence. 
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Filtering on detection call has been demonstrated to reduce the number of false positive 
findings (McClintick et al. 2003; McClintick & Edenberg 2006; Pepper et al. 2007; Hackstadt 
& Hess 2009). Cross-platform correlation also increases as the percent present call filter is 
increased (Shippy et al. 2004). 
To create one hierarchical list of transcript abundance for the retained genes, we used ‘rank 
product’—a non-parametric statistic that detects items that are consistently highly ranked 
in a number of lists to create one combined list (Hong et al. 2006). The premise of the rank 
product approach is that highly expressed genes should be highly ranked in each 
independent biological replicate set. The rank product method entails ranking genes by 
expression level within each replicate, then computing the product of the ranks across the 
replicates; the rank product value for each gene increases if the gene is consistently present 
at the top of the lists. The rank product can be translated into a measure of statistical 
significance by comparing the observed rank product statistic to a rank product statistic 
obtained from a large number of simulated data sets. On this basis, a ‘percent false positive’ 
value is calculated for each gene as an estimate of the FDR. Converting expression values 
into ranks increases robustness against noise and heterogeneity across studies. The rank 
product method has high sensitivity and specificity and desirable operating characteristics, 
as demonstrated in extensive numerical studies (Breitling & Herzyk 2005; Hong et al. 2006; 
Jeffery et al. 2006; Hong & Breitling 2008). Although developed originally for microarrays, 
the rank product method has found widespread acceptance in diverse settings, for example 
RNAi analysis (Birmingham et al. 2009), proteomics (Wiederhold et al. 2009) and machine 
learning model selection (Hoefsloot et al. 2008). The 50 most abundant SLC genes were 
taken forward for CGP. All these genes had an FDR of less than 5% for being ranked amongst 
the 50 most abundant genes.  
Our robust approach to candidate gene set selection improved the results of the CGP—by 
filtering out SLCs from the candidate set that were less likely to be relevant, more relevant 
SLCs were ranked more favourably. If no filters were applied to the candidate gene set, the 
overlap between the top CGP and microarray results was not statistically significant 
(p=0.3861). But by filtering into the candidate set genes which were present in more than 
50% of meta-analysis samples and were amongst the 50 most abundant SLCs, the overlap of 
the top CGP and microarray results became statistically significant (p=0.0087).  
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Limitations of our in silico approach: One possible criticism of our CFG-cum-CP approach is 
that as we have prioritized genes based on a training set derived from data mining, any 
functionally important SLC proteins that have been neglected in epilepsy research to date 
will also be overlooked in this study. However, we feel that our data collection and collation 
methodology minimizes the effect of this limitation as we have gathered data not only from 
studies focusing on one or more selected genes but also from genome-wide microarray 
studies. Furthermore, our CFG-cum-CP gene list compares favourably with the prioritized 
gene list created using an independent training set derived from nine microarray studies; 
the latter training set does not contain any SLC genes. 
It should be noted that for collating published MDT gene and protein expression data, we 
included studies not only on microvascular endothelial (blood-brain barrier) cells isolated 
from epileptic foci, but also studies on brain parenchymal tissue obtained from epilepsy 
surgery. This is because in epileptic foci, MDTs have been shown to be dysregulated not only 
in the capillary endothelial cells (Tishler et al. 1995; Dombrowski et al. 2001; Calatozzolo et 
al. 2005; van Vliet et al. 2005; Volk & Loscher 2005; Sisodiya et al. 2006), but also in the 
perivascular glia (Tishler et al. 1995; Aronica et al. 2003b; Lu et al. 2004; Calatozzolo et al. 
2005), and even in the neurons (Seegers et al. 2002; Aronica et al. 2003a; Aronica et al. 
2004; Lazarowski et al. 2004a; Lazarowski et al. 2004b; Lazarowski et al. 2004c; Marchi et al. 
2004; Marchi et al. 2005; Hoffmann et al. 2006). MDTs expressed in the lesional perivascular 
glia may facilitate the transport of AEDs between the extraneuronal space and the blood. 
Furthermore, altered expression of MDTs in neurons also contributes to AED resistance as 
demonstrated in a recent study on the Drosophila epilepsy model (Bao et al. 2011). 
Effectiveness of our in silico approach: Our in silico predictive gene lists of various sizes—
10, 20 or 30 genes—were very significantly enriched for truly downregulated SLCs, with p-
values as significant as 8.4 x 10-7. This demonstrates that our in silico strategy shows much 
promise for the task of prioritizing specific genes for study from within very large datasets. 
Its performance with different phenotypes and gene groups will vary depending on the 
quality and quantity of base data available. However, the approach is intuitive, pragmatic 
and practical, and includes suggested methods for computational verification of outputs 
making it more attractive to future researchers.  
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3.4.2 Ex vivo strategy 
To ensure that our ex vivo analysis was robust, we chose to make use of an exon array. The 
whole-transcript amplification protocol of exon arrays allows more accurate measurement 
of gene expression than standard microarrays (Kapur et al. 2007; Xing et al. 2007; Lockstone 
2011). Stringent QC filters were applied to arrays and individual features, and a ‘percent 
present’ filter was applied to the genes to reduce false positives. Finally, important technical 
(batch and RIN) and clinical (age and sex) covariates were included in the linear model; this 
reduced the false positive rate significantly. For example, without adjusting for these 
important covariates, 540 out of 936 genes (56%) covered by the exon array would be 
differentially expressed at an FDR of 0.05 (detailed data not shown); such a high rate of 
differential expression clearly indicates the presence of false positive results. After adjusting 
for these covariates, only 56 out of 936 genes (6%) are differentially expressed at an FDR of 
0.05.  
It is interesting to note that three training genes (SLC1A2, SLC1A3 and SLC2A3), created 
from CFG and used for CGP, were not significantly dysregulated in our exon array. SLC1A2 
and SLC1A3 were not significantly downregulated in any previous epilepsy microarray study, 
although they were downregulated in previous PCR studies; this may be a result of the 
wider dynamic range of PCR assays. SLC2A3 was significantly downregulated in two previous 
microarray studies and was also borderline significant in our study, but failed to fulfil our 
stringent cut-off criteria—p-value was 0.02, and fold-change was 1.3 in our analysis. 
3.4.3 SLC proteins downregulated in the pharmacoresistant epileptic human hippocampus 
Table 3.6 summarizes the functions of the 18 SLC proteins downregulated in our exon array. 
As examples, three of the proteins are discussed in greater detail below, in order to 
illustrate their potential role in epilepsy pharmacoresistance. 
SLC12A5 is a neuron-specific potassium-chloride symporter which is expressed throughout 
the central nervous system (Payne et al. 1996; Lu et al. 1999; Williams et al. 1999). As 
demonstrated by our analysis, it is one of the most abundant SLC transporter transcripts in 
the hippocampus and its downregulation in pharmacoresistant epilepsy has been confirmed 
in independent studies (Palma et al. 2006; Lee et al. 2007). Studies in animal models reveal 
that a reduction in SLC12A5 expression results in an increased susceptibility to the 
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development of seizures: complete deletion of SLC12A5 is incompatible with life (Hubner et 
al. 2001), a 95% reduction in SLC12A5 expression results in handling-induced seizure 
behaviour (Woo et al. 2002), and heterozygous animals have a lower threshold for epileptic 
seizures—electrophysiological measurements in the hippocampus show hyperexcitability 
and animals demonstrate a twofold increase in pentylenetetrazole-induced seizures (Woo et 
al. 2002).  
SLC17A7 encodes vesicular glutamate transporter isoform 1 (vGLUT1).  There are two other 
known isoforms of vGLUT: vGLUT2 and and vGLUT3. vGLUTs mediate the uptake of 
glutamate into synaptic vesicles. The three vesicular glutamate transporters are expressed 
in distinct populations of neurons, and SLC17A7 is the predominant vGLUT in the 
hippocampus (Rasmussen et al. 2007). SLC17A7 was downregulated in pharmacoresistant 
MTLE in a large-scale microarray study (Lee et al. 2007). In agreement with this, both 
SLC17A7 transcript and protein levels were downregulated in another study that used 
immunohistochemistry, immunofluorescence, in situ hybridization, Western blotting, and 
quantitative polymerase chain reaction to quantitate SLC17A7 in pharmacoresistant MTLE 
(van der Hel et al. 2009). Reduced vGLUT1  immunoreactivity was also found in epileptic 
peritumoural neocortex (Alonso-Nanclares & De Felipe 2005). In a recent study, SLC17A7-
heterozygous mice displayed increased anxiety (Tordera et al. 2007), but the authors did not 
determine if there was neuronal hyperexcitability or if there was a reduced seizure 
threshold in these animals. Interestingly, mice heterozygous for SLC17A6 (which encodes 
vGLUT2) show increased susceptibility to clonic seizures induced by pentylenetetrazol 
(Schallier et al. 2009), while mice lacking SLC17A8 (which encodes vGLUT3) exhibit primary 
generalized epilepsy (Seal et al. 2008). Further studies are needed to determine if 
downregulation of SLC17A7 predisposes to epilepsy. 
SLC24A3 encodes the plasma membrane sodium/calcium exchanger NCKX3 (Blaustein & 
Lederer 1999). SLC24A3 transcripts are most abundant in the brain, with highest levels 
found in hippocampal CA1 neurons (Kraev et al. 2001). SLC24A3 was downregulated in two 
independent microarray studies on the pharmacoresistant epileptic hippocampus (Lee et al. 
2007; van Gassen et al. 2008). Although SLC24A3 has not been studied specifically in 
epilepsy research, supportive evidence for its possible role in epilepsy comes from the 
observation that the downregulation of the functionally-similar sodium/calcium exchanger 
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NCX3 leads to the hyperexcitability of hippocampal neurones in gerbils—NCX3 
immunoreactivity in the hippocampus of seizure-sensitive gerbils is lower than that of 
seizure-resistant gerbils (Park et al. 2011). 
As can be seen from Table 3.6, the vast majority of the identified SLC proteins are either 
small metal ion exchangers or transporters of neurotransmitters, particularly glutamate. 
Given the key roles played by ionic transport and gluatmatergic transmission in neuronal 
function, it stands to reason that these should be the most important SLC proteins in the 
epileptic hippocampus. However, for SLC transporters of metal ions, there is as yet no 
evidence of non-endogenous substrate transport—their small endogenous ionic substrates 
are markedly dissimilar to most xenobiotics, so it might be expected that they are not 
readily involved in xenobiotic transport (Dobson & Kell 2008). Similarly, there is no evidence 
as yet that the transporters of glutamate or of other neurotransmitters are able to transport 
therapeutic drugs. Therefore, while these SLCs potentially mediate pharmacoresistance in 
epilepsy, it is unlikely that they do this through altered transport of AEDs, but rather by 
enhancing the intrinsic severity of epilepsy (Schmidt & Loscher 2009).   
3.5 Conclusions 
We have developed a novel in silico strategy that can aid epilepsy research by prioritizing 
specific genes for study from within large gene sets. We have identified the most 
significantly downregulated SLCs in the pharmacoresistant epileptic human hippocampus. 
The role of these SLCs in the epileptic hippocampus will need to be defined through future 
functional studies. 
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Table 3.6 Functions of the 18 SLC proteins downregulated in the exon microarray. Data from 
Gene (http://www.ncbi.nlm.nih.gov/gene) and UniPort 
(http://www.uniprot.org/help/uniprotkb). 
Gene 
Symbol 
Function 
SLC24A3 Calcium, potassium:sodium antiporter activity 
SLC47A1 Monovalent cation:hydrogen antiporter activity 
SLC25A23 Calcium-dependent mitochondrial solute carrier activity 
SLC8A2 Sodium:calcium exchange activity 
SLC17A7 L-glutamate transmembrane transporter activity 
SLC25A41 Mitochondrial ATP-magnesium:phosphate carrier activity 
SLC26A10 Anion exchange activity 
SLC4A3 Anion exchange activity 
SLC4A7 Sodium bicarbonate cotransporter activity 
SLC12A5 Potassium:chloride transporter activity 
SLC7A1 Transport of the cationic amino acids (arginine, lysine and ornithine) 
SLC16A2 Thyroid hormone transporter 
SLC25A22 Transport of glutamate across the inner mitochondrial membrane 
SLC29A4 Reuptake of monoamines into presynaptic neurons 
SLC8A1 Sodium:calcium exchanger activity 
SLC35E2 Transport of nucleotide sugars into endoplasmic reticulum and Golgi bodies 
SLC4A8 Sodium- and carbonate-dependent chloride:bicarbonate exchange activity 
SLC18A2 Vesicular transport of biogenic amine neurotransmitters 
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Chapter 4: A New Microarray Analysis of Brain Tissue 
from Epilepsy Surgery 
4.1 Introduction 
Genome-wide transcriptomic studies continue to be a cornerstone in the investigation of 
mechanisms underlying complex diseases. Because of their whole genome approach, 
microarray studies enable researchers to identify not only differentially expressed genes, 
but also dysregulated pathways and networks. Such a holistic approach is essential for 
uncovering the many interlinked biological processes that are likely to be underlying a 
multifactorial condition like pharmacoresistant epilepsy. 
There are a number of published microarray studies on brain tissue from surgery for 
pharmacoresistant epilepsy; these studies have been extensively examined in Chapter 2. 
Although the previously published microarray studies have provided important insights into 
this condition, they suffer from a number of important methodological weaknesses, of 
which the following are particularly noteworthy:  
1. The sample sizes have been small: the largest published study on hippocampal tissue 
from pharmacoresistant mesial temporal lobe epilepsy to date included 8 disease 
samples only. 
2. In recent years, it has become widely recognized that adjusting for batch effect, 
hidden sources of heterogeneity and polymorphisms-in-probes is essential in 
microarray analysis; previously published microarray studies on human epilepsy have 
not accounted for these confounders. 
3. The previous microarray studies have not attempted to objectively demonstrate the 
therapeutic and causal relevance of the identified differentially expressed genes. 
4. The previous microarray studies have been limited to an analysis of differential 
expression; differential connectivity has not been studied and, hence, much of the 
information contained in the gene expression datasets has been ignored. 
5. A few previous microarray studies have included pathway-based analyses. However, 
as individual pathways do not function in isolation, it is useful to construct a network 
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of pathways and to identify the most central pathways in this network; this has not 
been attempted before. 
In order to resolve these deficiencies, we have performed the largest and most robust 
microarray analysis of brain tissue from surgery for pharmacoresistant mesial temporal lobe 
epilepsy. 
4.2 Aims 
1. To perform a robust microarray analysis of hippocampal tissue from surgery for 
pharmacoresistant mesial temporal lobe epilepsy. 
2. To objectively demonstrate the therapeutic and causal relevance of the differentially 
expressed genes from the microarray study. 
3. To identify differentially expressed pathways. 
4. To identify differentially connected pathways. 
5. To construct a network of differentially expressed and differentially connected 
pathways. 
6. To identify the ‘hub’ pathways. 
4.3 Methods 
4.3.1 Sample collection 
Samples used in the study originated from three UK sites: the Walton Centre for Neurology 
and Neurosurgery in Liverpool, the Salford Royal Hospital in Salford and the Southern 
General Hospital in Glasgow. We aimed to recruit patients of age 5 years and older with 
pharmacoresistant mesial temporal lobe epilepsy of at least 3 months durations for which a 
therapeutic temporal lobectomy was being undertaken. As recently proposed by the ILAE, 
pharmacoresistance was defined as the failure of adequate trials of two tolerated, 
appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or 
in combination) to achieve sustained seizure freedom. The diagnosis of MTLE was made by 
the treating clinician based on seizure semiology, MRI brain and EEG characteristics being 
consistent with a seizure focus in the mesial temporal lobe. Patients suspected of having a 
neoplastic or malignant temporal lobe lesion were excluded. After surgery, the 
hippocampus was divided into two portions: (1) one portion was preserved for RNA 
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isolation, (2) the other portion underwent histological analysis by an experienced 
neuropathologist. Any subjects found to have a neoplastic or malignant lesion on 
histological analysis were excluded. The portion preserved for RNA isolation was either 
stored in RNAlater (Liverpool and Glasgow) or frozen directly at -80 oC (Salford). It should be 
noted that the quality of the RNA generated from the directly frozen brain samples was not 
significantly different from RNAlater-preserved samples: mean RIN values were 7.82 and 
7.25 respectively, and two-sample t-test p-value for difference between group RINs was 
0.06554. 
Frozen post-mortem histologically-normal hippocampal samples from donors with no 
known brain diseases were obtained from the MRC Edinburgh Brain Bank (Edinburgh, UK) 
and the Queen Square Brain Bank (London, UK).  
4.3.2 RNA isolation 
Brain samples were disrupted and homogenized in an appropriate volume of QIAzol lysis 
reagent (Qiagen, Crawley, United Kingdom) by using a TissueRuptor handheld rotor-stator 
homogenizer (Qiagen, Crawley, United Kingdom). Total RNA was extracted from the 
homogenates using the RNeasy Lipid Tissue Mini Kit (Qiagen, Crawley, United Kingdom), 
according to the manufacturer’s instructions. RNA quality was examined by capillary 
electrophoresis on an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA) and Agilent 2100 
Expert software was used to calculate the RNA Integrity number (RIN) of each sample. Purity 
of the RNA sample was assessed using a NanoDrop1000 Spectrophotometer. Capillary 
electrophoresis traces were also examined. Samples with RNA integrity number  scores 
(RIN) below 6, obvious RNA degradation, significant 18S or 28S ribosomal  RNA degradation, 
ratio of absorbance at 260nm and 280nm <1.95, or with  noticeable DNA or  background  
contaminants  did  not pass  QC,  and  were  withheld from microarray analysis.  It should be 
noted that RNA samples with RIN scores of 6 and lower have been successfully used for 3’ 
microarrays (Hawrylycz et al. 2012) and exon microarrays (Trabzuni et al. 2011). 
4.3.3 Microarray processing and quality control 
The microarrays were processed at the Centre for Genomics Research in the University of 
Liverpool. 50ng of total RNA was amplified and labelled using the Agilent Low Input Quick 
Amp One-Colour Labeling Kit and labelled RNA was hybridized to Agilent SurePrint G3 
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Custom Exon 8x60K Microarrays. Standard Agilent protocols were followed. The quality of 
the synthesized cRNA was assessed using an Agilent Bioanalyzer 2100—the resulting 
electropherograms were found to be satisfactory.  Each scanned image was viewed for 
visible artefacts, and if multiple artefacts were present, the array was rejected. Detailed QC 
reports were generated for each array using the Feature Extraction 11.0.1.1 Software 
(Agilent, Palo Alto, CA). Based on these reports, we excluded arrays in which more than 1% 
of features were non-uniform outliers, or the average of the net signals in negative controls 
was >40, or the average of the background-subtracted signals in negative controls was <-10 
or >5, or the standard deviation of the background-subtracted signals in negative controls 
was >10, or the residual noise after spatial detrending was >15, or the median coefficient of 
variation for spike-in probes or non-control probes was >12%, or the dose-response curve of 
the spike-ins had a slope of <0.9 or >1.20, or the spike-in detection limit was <0.01 or >2. 
One array failed on five of these metrices and, hence, was excluded. Intensity data was 
extracted from the remaining arrays using the Feature Extraction Software. Spatial and 
multiplicative detetrending and local background substraction was applied.  
We employed an unbiased approach for the detection of outlier samples: samples with 
average inter-array correlation (IAC) ≤ 2 standard deviations below the mean were 
removed. This approach has been used successfully in published studies (Yang et al. 2006a; 
Flight & Wentzell 2010; Yang et al. 2012). 
4.3.4 Data normalization, adjustment and filtering 
Data exported from Feature Extraction Software was imported into GeneSpring GX Software 
(Agilent, Palo Alto, CA). Features which were population outliers, saturated or non-uniform 
were flagged as ‘Compromised’ and filtered out. Non-expressed probes were filtered out: a 
probe was deemed expressed only if it was flagged ‘Detected’ in at least 25% of control or 
case samples. Quantile normalization was applied. As GeneSpring does not include functions 
that allow adjusting for confounders and covariates, probe-level intensities were exported 
for further processing. 
Batch effect was corrected using the ComBat (Johnson et al. 2007) algorithm implemented 
in the SVA Bioconductor package. Eight arrays (four cases and four controls) were processed 
per slide; hence, each batch comprised the eight samples processed together on a slide. To 
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adjust for known and unknown confounders, Independent Surrogate Variable Analysis 
(ISVA) (Teschendorff et al. 2011) was applied; RIN, age and sex were explicitly included in 
the ISVA adjustment. Where multiple probes mapped to the same gene and mRNA variant, 
the probe with the highest variance was retained, as the most variant probe is likely to be 
most informative. 
4.3.5 Assessing the influence of confounders 
To determine if there was residual confounding after data adjustment, we used the 
phenoTest Bioconductor package to test for association between probes and confounders 
(batch, RIN, age and sex).  
4.3.6 Assessing the influence of polymorphisms-in-probes (PIP) 
Polymorphisms present in the probe-target sequences have been shown to alter probe 
hybridization affinities, leading to reduced signal intensity measurements and resulting in 
false-positive results, at least for Affymetrix microarrays (Benovoy et al. 2008). Similar 
studies have not been performed for Agilent microarrays so far. To establish if PIP could be 
leading to false-positive results in our analysis, we used a recently devised tool (Ramasamy 
et al. 2013) to determine which probes in our microarray had polymorphisms located within 
the probe sequences; we then determined if these probes with polymorphisms were 
overrepresented within the list of differentially expressed probes. 
4.3.7 Differential expression analysis 
Differential expression analysis of the adjusted dataset was performed using the limma 
package (Smyth 2004). A probe was considered differentially expressed if FDR was < 0.05 
and FC was ≥ 1.5. 
4.3.8 External validation of differential expression 
As robust validation of our differential expression results, we determined if there was 
significant overlap and rank order similarity between our results and the results from three 
previous microarray studies on hippocampal tissue from epilepsy surgery (Lee et al. 2007; 
van Gassen et al. 2008; Venugopal et al. 2012). For comparison, we determined if our 
results show a significant overlap or a significant rank order similarity with a previously 
published microarray study on hippocampal tissue from Alzheimer’s disease sufferers (Liang 
et al. 2008).  
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Statistical significance of overlap was calculated using the hypergeometric equation, and 
statistical significance of rank order similarity was calculated using the OrderedList 
Bioconductor package (Yang et al. 2006b). 
4.3.9 Assessing the potential therapeutic relevance of differentially expressed genes 
We created a comprehensive list of the targets of all current AEDs by searching three 
publically-available databases of drug targets: Stitch, SuperTarget and DrugBank. We then 
determined if our microarray results were enriched with AED targets by calculating the 
statistical significance of the overlap between AED targets and our DEG-list. For comparison, 
we did the same analysis for all previously published microarray studies on brain tissue from 
epilepsy surgery. 
4.3.10 Assessing the potential causative relevance of differentially expressed genes 
We performed a genome-wide association study (GWAS) of pharmacoresistant epilepsy 
(described in detail in Chapter 5 of the current thesis). We determined if our DEG-set was 
significantly enriched in the GWAS. For comparison, we did the same analysis for all 
previously published microarray studies on brain tissue from epilepsy surgery.  
4.3.11 Differential connectivity 
For performing differential connectivity analysis, three algorithms were compared: 
Differential Correlation in Expression for meta-module Recovery (DICER) (Amar et al. 2013), 
coXpress (Watson 2006) and DiffCoEx (Tesson et al. 2010).  
Including all microarray probes in the analysis was not computationally feasible: the time 
and memory requirements were both prohibitive. Hence, the probes were sequentially 
filtered as follows: (1) only probes mapping to genes with valid current Entrez numbers and 
HUGO Gene Nomenclature Committee gene symbols were retained, (2) where multiple 
probes mapped to the same gene, the most variant probe only was retained, (3) the 10,000 
probes with the highest variance were retained. Hence, after filtering, 10,000 probes with 
high variance remained, each mapping to a unique gene. 
DICER was the best differential connectivity algorithm (see below). The genes in 
differentially connected clusters from DICER were used to perform pathway enrichment 
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analysis. For the enriched pathways, differential connectivity was further confirmed using 
the Gene Set Co-Expression Analysis (Choi & Kendziorski 2009) protocol.  
4.3.12 Pathway-enrichment analysis 
Pathway-enrichment analysis was performed using the Reactome database on the Gene Set 
Enrichment Analysis website.  
4.3.13 Network of pathways and network analysis 
Enrichment Map (Merico et al. 2010) tool was used to determine the connections between 
enriched pathways. Enrichment Map was used with default settings. Specifically, we 
employed an overlap coefficient cut-off of 0.5—two pathways were deemed connected only 
if the ratio of the size of the intersection over the size of the smallest pathway was 0.5 or 
more. The Network Analysis tool was used to calculate network parameters, including 
‘betweenness centrality’ of nodes. 
4.4 Results 
4.4.1 Detecting Outlier Arrays Using Inter-Array Correlation (IAC) 
Mean IAC for control samples was 0.98 (range 0.96 – 0.98), while mean IAC for disease 
samples was 0.95 (range 0.95 – 0.98). As there were no arrays with IAC ≤ 2 standard 
deviations below the mean, no arrays were deemed to be outliers and no arrays were 
excluded. 
Important patient and donor individual and sample characteristics are summarized in Table 4.1. 
4.4.2 Effective Adjustment for Confounders 
We confirmed that, after ComBat and ISVA treatment, confounders had been adjusted for 
appropriately: we found that no probes were associated with RIN, age, batch or sex at an 
FDR<0.10 in the adjusted data. 
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Table 4.1 Sample characteristics. RIN=RNA Integrity Number 
Sample Phenotype Age Sex RIN  Sample Phenotype Age Sex RIN 
D1 Case 41 F 7.4 N1 control 81 M 6.5 
D2 Case 23 F 6.8 N2 control 78 F 6.2 
D3 Case 51 M 6 N3 control 84 F 6.6 
D4 Case 49 F 6.9 N4 control 91 F 6.7 
D5 Case 50 F 7.8 N5 control 88 M 6.3 
D6 Case 45 F 6.6 N6 control 38 M 6.1 
D7 Case 12 M 7 N7 control 50 M 6.2 
D8 Case 29 F 7.8 N8 control 45 M 6.3 
D9 Case 33 M 6.8 N9 control 39 M 6.1 
D10 case 25 F 7.1 N10 control 40 M 6 
D11 case 34 M 7 N11 control 61 M 6.2 
D12 case 33 M 8.8 N12 control 63 F 6.2 
D13 case 33 M 8.6 N13 control 66 M 6.2 
D14 case 22 F 7.3 N14 control 22 F 6.3 
D15 case 48 M 7.6 N15 control 27 M 6.3 
D16 case 39 F 7.4 N16 control 45 M 6.9 
D17 case 29 F 7.1 N17 control 44 F 6.7 
D18 case 44 M 7.9 N18 control 50 M 6.5 
D19 case 40 F 6.6 N19 control 43 M 6.6 
D20 case 48 M 8.5 N20 control 46 M 6.8 
D21 case 23 M 8.4 N21 control 51 M 6.2 
D22 case 63 M 7.9 N22 control 48 M 6 
D23 case 31 M 8.2 N23 control 43 M 6.6 
D24 case 27 F 8.2      
 
4.4.3 Effect of PIP 
We found that, as opposed to Affymetrix microarrays (Merico et al. 2010), PIP are not a 
source of false-positive results in our Agilent microarray. Of all the probes included in our 
microarray, 18% had polymorphisms located within the probe sequences. We found that 
probes with polymorphisms were not overrepresented within the list of differentially 
expressed probes, for varying definitions of differential expression (Table 4.2). 
4.4.4 Differential Expression: External Replication 
There was a highly statistically significant overlap between the DEG-list from our study and 
from three previously published microarray studies on pharmacoresistant epileptic 
hippocampal tissue (Table 4.3). Furthermore, the rank order of the DEGs from our study and 
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the previously published studies was statistically significant (Table 4.3). For comparison, we 
demonstrated that our results show neither a significant overlap nor a significant rank order 
similarity with a previously published microarray study on hippocampal tissue from 
Alzheimer’s disease sufferers.  
Table 4.2 Proportion of probes with polymorphisms 
 Total probes Probes with 
polymorphisms 
Proportion 
All probes on microarray 61341 11027 18.0 
Differentially expressed probes: 
FDR<0.05 
22281 3872 17.4 
Differentially expressed probes: 
FDR<0.05 & FC≥1.5 
1729 304 17.6 
Differentially expressed probes: 
FDR<0.05 & FC≥2 
310 52 16.8 
Differentially expressed probes: 
FDR<0.03 
19144 3310 17.3 
Differentially expressed probes: 
FDR<0.03 & FC≥2 
308 53 17.2 
Differentially expressed probes: 
FDR<0.01 & FC≥1.5 
1541 258 16.7 
Differentially expressed probes: 
FDR<0.01 & FC≥2 
304 50 16.4 
 
Table 4.3 Statistical significance (FDR) of overlap and rank order similarity between the 
DEGs from the current microarray study and previously published microarrays on 
hippocampal tissue. AD= Alzheimer’s disease 
Phenotype Study Statistical 
significance of 
overlap 
Statistical significance of rank 
order similarity 
Epilepsy van Gassen et al., 2008 6.191x10-7 0 
Epilepsy Venugopal et al., 2012 2.245x10-8 0.027 
Epilepsy Lee et al., 2007 3.272x10-14 0.010 
AD Liang et al., 2008 1 0.707 
 
4.4.5 Differential Expression: Evidence of Potential Therapeutic Relevance 
We found that the DEG-lists from a number of microarray studies on brain tissue from 
epilepsy surgery have statistically significant overlaps with targets of current AEDs, but the 
most significant overlap by far was for our microarray study (Table 4.4 and Figure 4. 1). 
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Table 4.4 Enrichment within microarray DEGs for targets of current AEDs. FDR=false 
discovery rate 
 
 
 
 
 
 
 
Table 4.5 GWAS association of microarray DEG-sets. FDR=false discovery rate 
Study FDR 
Current study 1.92x10-18 
Lee et al., 2007 3.14x10-7 
van Gassen et al., 2008 1.43x10-2 
Arion et al., 2006 2.62x10-2 
Jamali et al., 2006 2.44x10-1 
Venugopal et al., 2012 2.84Ex10-1 
Xiao et al., 2008 4.20Ex10-1 
Becker et al., 2003 4.96Ex10-1 
Becker et al., 2002 2.75Ex10-1 
Ozbas-Gerceker et al., 2006 2.75Ex10-1 
 
4.4.6 Differential Expression: Evidence of Potential Causative Significance 
We found that the DEG-sets from a number of microarray studies on brain tissue from 
epilepsy surgery were significantly enriched in the focal epilepsy GWAS study, but the most 
significant enrichment by far was for our microarray study (Table 4.5 and Figure 4.2). 
 
Study FDR 
Current study 2.75x10-6 
Jamali et al., 2006 0.0008 
Lee et al., 2007 0.0013 
Arion et al., 2006 0.0024 
van Gassen et al., 2008 0.0306 
Ozbas-Gerceker et al., 2006 0.0956 
Becker et al., 2003 0.1445 
Xiao et al., 2008 0.6933 
Becker et al., 2002 1 
Venugopal et al., 2012 1 
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Figure 4.1 Statistical significance of overlaps between targets of current AEDs and DEG-lists from a number of microarray studies on brain tissue from 
epilepsy surgery. Red line demarcates the level of statistical significance at FDR=0.05. 
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Figure 4.2 GWAS enrichment of microarray DEG-sets. Red line demarcates the level of statistical significance at FDR=0.05. 
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4.4.7 Differential Expression: Pathway-Enrichment Analysis 
Pathway-enrichment analysis of the 1010 DEGs with valid gene symbols revealed 91 
significantly enriched pathways (FDR<0.05). The top 10 significantly-enriched pathways are 
listed in Table 4.6, while the remaining can be found in Appendix 9.  
Table 4.6 The 10 most significantly enriched Reactome pathways amongst DEGs. 
Gene set name FDR q-value 
Signalling by GPCR 0 
GPCR downstream signalling 0 
Transmembrane transport of small molecules 0 
GPCR ligand binding 0 
Class A1 rhodopsin-like receptors 0 
Neuronal system 0 
Transmission across chemical synapses 1.07 x10-14 
Peptide ligand binding receptors 8.89 x10-13 
G alpha I signalling events 1.85 x10-12 
SLC-mediated transmembrane transport 4.40 x10-12 
 
4.4.8 Differential Connectivity: Clusters and Genes 
We compared differentially connected clusters produced by DICER, coXpress and DiffCoEx. 
Pathway and GWAS enrichment analysis revealed that the results produced by DICER were 
the most functionally coherent and potentially causative (coXpress and DiffCoEx results not 
shown). 
DICER produced 36 differentially connected clusters, ranging in size from 15 genes to 102 
genes. 17 clusters exhibited increased connectivity in disease tissue, while 19 clusters 
exhibited decreased connectivity. The contents of each cluster are tabulated in Appendix 10. 
The plot in Figure 4.3 illustrates, as an example, the clearly contrasting connectivity between 
normal and disease tissue for one of the clusters. Similar plots for all identified clusters are 
shown in Appendix 11.  
In total, 890 of the 10,000 genes (9%) included in the DICER analysis were differentially 
connected. While 211 of these genes were also found in our list of differentially expressed 
genes, the majority (76%) were differentially connected without being significantly 
differentially expressed. 
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Figure 4.3 Plot illustrating differential connectivity in one of the identified clusters. Nodes represent genes and edges represent connectivity between genes. 
Edges are coloured from blue to red indicating correlation value of -1 to 1. 
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4.4.9 Differential Connectivity: Pathway-Enrichment Analysis 
Pathway-enrichment analysis of the 890 differentially connected genes revealed 75 
significantly enriched pathways (FDR<0.05). The top 10 significantly-enriched pathways are 
listed in Table 4.7, while the remaining can be found in the Appendix 9. We further 
confirmed that these pathways are differentially connected (FDR<0.05) using the GSCA 
package (see Appendix 9). 
Table 4.7 Differential connectivity: The top 10 significantly enriched Reactome pathways. 
Pathway FDR 
Neuronal system 2.73x10-08 
Transmembrane transport of small molecules 8.85x10-08 
Developmental biology 2.23x10-06 
Axon guidance 5.79x10-06 
Transmission across chemical synapses 9.58x10-06 
Generic transcription pathway 1.01x10-05 
SLC-mediated transmembrane transport 4.68x10-05 
Semaphorin interactions 1.25x10-04 
Sema3a PAK dependent axon repulsion 2.12x10-04 
Amino acid and oligopeptide SLC transporters 7.78x10-04 
 
4.4.10 Differential Connectivity: Evidence of Genetic Basis and Potential Causality 
The differentially connected gene-set was significantly enriched in the focal epilepsy GWAS 
(p= 4.50x10-10). We created a further gene-set consisting of genes which were differentially 
connected but not differentially expressed—this latter gene set was also significantly 
enriched in the GWAS (p=6.52x10-06). 
4.4.11 Identifying a Network of Pathways 
Enrichment Map analysis revealed a highly interconnected central network of pathways 
(Figure 4.4). In this central network, each pathway is directly connected to, on average, 10.5 
other pathways. In order to identify the most central ‘hub’ pathways, ‘betweeness 
centrality’ network analysis was performed; the results are illustrated in Figure 4.5 and the 
top 15 pathways are listed in Table 4.8. The complete ranked list can be found in the 
Appendix 9.  
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Figure 4.4 Network of pathways. Nodes with a red centre represent differentially expressed pathways, nodes with a blue border represent differentially 
connected pathways, and nodes with both a red centre and blue border represent pathways which are both differentially expressed and connected. Major 
functional groups containing at least three pathways are labelled. 
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Figure 4.5 The central network of interconnected pathways. Node sizes are proportional to their betweenness centrality. Major functional 
groups of pathways are labelled. 
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Table 4.8 Betweenness centrality 
Pathway Betweenness Centrality 
Signalling by NOTCH  0.6 
CREB phosphorylation through the activation of CAMKII  0.31572334 
Signalling by PDGF  0.22722128 
Nephrin interactions  0.225894 
Transmembrane transport of small molecules  0.18478239 
Signalling by GPCR  0.16146105 
Immune system  0.15259226 
Neuronal system  0.15097778 
Signalling by NOTCH3  0.15 
Receptor ligand binding initiates the second proteolytic cleavage 
of notch receptor  
0.15 
Transmission across chemical synapses  0.10843453 
NCAM signalling for neurite out growth  0.09770921 
NCAM1 interactions  0.09770921 
Post NMDA receptor activation events  0.08083733 
Neurotransmitter receptor binding and downstream transmission 
in the postsynaptic cell  
0.07588839 
 
4.5 Discussion 
Although there have been a number of previous microarray studies on brain tissue from 
surgery for pharmacoresistant epilepsy, the current analysis advances this field of study in a 
number of significant and novel ways, of which the following aspects are especially 
noteworthy: 
1. This is the largest transcriptomic study of hippocampal tissue from 
pharmacoresistant mesial temporal lobe epilepsy to date, having thrice the number 
of disease samples of the previous largest study. 
2. We have externally validated our results by showing statistically significant 
similarities with previously published studies (see results). 
3. Cutting edge analytical techniques have been applied which improve the sensitivity 
and reliability of our results: 
a. Batch effects have now been recognized as an important but overlooked 
source of confounding in transcriptomic studies; we have accounted and 
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corrected for batch effects using careful study design and appropriate data 
processing. 
b. We effectively adjusted for known confounders. We confirmed that, after 
ComBat and ISVA treatment, no probes were associated with RIN, age, batch 
or sex at an FDR<0.10 in the adjusted data. It should also be noted that 
Agilent microarrays are robust to differences in RIN values between 
compared samples (Opitz et al. 2010). 
c. We have adjusted for unknown confounders using the cutting edge 
Independent Surrogate Variable Analysis technique. 
d. Polymorphisms-in-probes (PIP) have recently been established as a potential 
source of false-positive results in many microarray studies; we have carefully 
assessed the influence of PIP in our study. 
4. We have shown the therapeutic and causal relevance of our results: 
a. We have demonstrated the functional and therapeutic relevance of our 
results by showing that they are enriched with antiepileptic drug targets and 
more so than any previous microarray study. 
b. We have demonstrated the causal relevance of our results by showing their 
enrichment in a genome-wide genetic association study of pharmacoresistant 
partial epilepsy. 
5. In addition to a differential expression analysis, we have performed a ‘differentially 
connectivity’ analysis; the first such analysis in epilepsy. 
6. We have revealed the extensively interconnected network of pathways underlying 
pharmacoresistant epilepsy and identified the ‘hub’ pathways. 
Some of these aspects are discussed in greater detail below. 
4.5.1 Adjustment for batch effect 
Batch effect refers to the systematic error introduced when samples are processed in 
multiple batches (Chen et al. 2011). Although batch effects can be reduced by careful 
experimental design, they cannot be eliminated unless the whole study is done in a single 
batch. Hence, batch effects are almost inevitable as practical considerations limit the 
number of samples that can be amplified and hybridized at one time. Combining data from 
different batches without carefully removing batch effects can give rise to misleading 
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results, since the bias introduced by the non-biological nature of the batch effects can be 
strong enough to mask, or confound true biological differences. However, of the thousands 
of DNA microarray papers published every year, few address the problem (Chen et al. 2011). 
Certainly, none of the human epilepsy transcriptomic studies published hence far have 
addressed this issue. 
A number of approaches have been developed for identifying and removing batch effects 
from microarray data. In the current study, we have utilized an empirical Bayes method 
called ComBat (Johnson et al. 2007), which has been shown to outperform other programs 
(Chen et al. 2011), and is currently the most widely used method for batch effect correction.  
After completing the data adjustment, we have demonstrated that our data has been 
effectively corrected by showing that the probes are not associated with batch or with other 
known confounding factors (age, sex and RNA quality). 
4.5.2 Adjustment for hidden confounders 
It is relatively straightforward to account for those confounders that are known and 
measured. When measured, inclusion of these known factors in the analytical model allows 
for a more sensitive analysis. For example, it is standard procedure to include covariates 
such as age and gender in the analysis. In practise it is not possible to measure or even be 
aware of all potential sources of variation. Unobserved hidden genetic, environmental, 
demographic, and technical factors may have substantial effects on gene expression levels, 
and may create spurious false associations or mask real genetic association signals (Leek & 
Storey 2007). These factors cannot be directly included in modelling if they are not 
measured, and techniques that have been used to explicitly adjust for known factors (for 
example, ComBat for batch effect) cannot be used. A number of statistical approaches have 
been developed to account for such hidden determinants of expression variation (Leek & 
Storey 2007; Kang et al. 2008; Teschendorff et al. 2011; Fusi et al. 2012; Stegle et al. 2012). 
Of these approaches, the most popular and widely is surrogate variable analysis (SVA) (Leek 
& Storey 2007), which has been shown to lead to improved estimates of statistical 
significance, biological accuracy and reproducibility. SVA uses the expression data itself to 
identify groups of genes affected by each unobserved factor and estimates the factor based 
on the expression of those genes; the confounding factors can then be regressed out of the 
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dataset. A recent improvement upon the SVA protocol is Independent Surrogate Variable 
Analysis (ISVA), which has been shown to outperform SVA (Teschendorff et al. 2011). ISVA is 
the protocol employed in the current study. 
4.5.3 Checking for the presence of false-positive results caused by polymorphisms-in-
probes 
Polymorphisms present in the probe-target sequences have been shown to alter probe 
hybridization affinities, leading to reduced signal intensity measurements and resulting in 
false-positive results in Affymetrix (Benovoy et al. 2008) and, to a lesser extent, in Illumina 
(Ramasamy et al. 2013) microarrays. Similar studies have not been performed for Agilent 
microarrays so far. To establish if PIP could be leading to false-positive results in our 
analysis, we used a recently devised tool (Ramasamy et al. 2013) to determine which probes 
in our microarray had polymorphisms located within the probe sequences; we then 
determined if these probes with polymorphisms were overrepresented within the list of 
differentially expressed probes. 
We have shown for the first time that Agilent gene expression microarrays are not 
deleteriously affected by PIP. This is an important methodological contribution to the 
analysis of Agilent microarrays. The differing susceptibility of the various microarray 
platforms to the PIP problem can be explained by the different lengths of the probes used. 
The presence of a polymorphism in a longer sequence has a less pronounced effect on the 
binding affinity than in a shorter sequence (Rennie et al. 2008). It has previously been 
shown that results generated using the Affymetrix array (25-mer probe design) are much 
more affected by the PIP problem than those results generated using the Illumina array (50-
mer probe design). We have now demonstrated that results generated using the Agilent 
array (60-mer probe design) are not significantly affected by PIP. However, previous 
pharmacoresistant human epilepsy microarray studies which were performed using the 
Affymetrix platform (Becker et al. 2003; Arion et al. 2006; Lee et al. 2007), and perhaps 
studies performed on other non-Agilent platforms, are likely to have been affected by the 
PIP problem. 
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4.5.4 Demonstrating the potential therapeutic and causal significance of our results 
The discovery of new therapeutic targets is one of the main motivations behind conducting 
microarray studies in pharmacoresistant epilepsy. From this point of view, we wished to 
determine if the DEGs we have identified are potentially enriched with novel AED targets. 
We reasoned that if our DEGs are enriched with targets of current AEDs, then the DEGs are 
also likely to be harbouring future AED targets. We created a comprehensive list of the 
known targets of current AEDs using an objective unbiased unsupervised methodology. We 
found that the DEG-lists from a number of microarray studies on brain tissue from epilepsy 
surgery have statistically significant overlaps with targets of current AEDs, but the most 
significant overlap by far was for our microarray study (Table 4.3 and Figure 4.1). This shows 
that our list of DEGs is likely to be a highly valuable source for future drug discovery. 
A limitation inherent in transcriptomic studies is that the gene expression changes identified 
can be a consequence, rather than a cause, of the disease. In order to demonstrate that the 
DEGs identified are causally relevant, we have devised a novel strategy: we have 
determined if the DEG-set is enriched in a GWAS study of pharmacoresistant partial epilepsy 
(described in Chapter 5). We found that the DEG-sets from a number of microarray studies 
on brain tissue from epilepsy surgery were significantly enriched in the focal epilepsy GWAS, 
but the most significant enrichment by far was for our microarray study (Table 4.4 and 
Figure 4.2). 
The above observations illustrate that our results are clearly more therapeutically and 
causally relevant than any previous microarray study on brain tissue from epilepsy surgery. 
We feel that our superior results can be attributed to our stringent QC and cutting edge 
data processing strategies (for example, adjustment for batch effect and hidden 
confounders, described above), which ensure that more false positive are filtered out from 
our results and our results are more enriched with true positives. 
4.5.5 Differential Connectivity 
All published transcriptomic studies on human epileptic brain tissue, and the vast majority 
of transcriptomic studies in general, have focused on identifying genes or gene sets showing 
average expression levels that vary across biological conditions. Although such differential 
expression approaches have been very successful, much of the information contained in 
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gene expression datasets is ignored. Disease genes are often not differentially expressed in 
diseases because genetic variations in the coding region can affect the function of the gene 
without affecting its expression level. Furthermore, a variety of post-translational 
modifications can affect regulatory activities of a gene product independently of its 
expression level. Hence, manifestation of disease can result from a de- or reregulation of 
genes that does not significantly affect each gene’s average expression level. For these 
reasons, it is being increasingly appreciated that focusing solely on differential expression 
and overlooking other types of differential regulation, such as differential connectivity (also 
known as differential co-expression or differential correlation) can be critically limiting 
(Mentzen et al. 2009). 
Differential connectivity is defined as a change in the correlation relationships between 
genes. Transcriptomic correlation analysis identifies sets of genes that are expressed in a 
coordinated fashion. Such correlation is considered evidence for possible coregulation 
under the principle of guilt-by-association (Chu et al. 1998). Hence, major changes in 
correlation patterns between classes may indicate changes in regulation. 
Differential connectivity analysis algorithms can be divided into two distinct types: (1) 
targeted approaches study gene modules that are defined a priori, while (2) untargeted 
approaches aim at grouping genes into modules on the basis of their differential correlation 
status. In order to ensure that our results are reliable, we utilized both an untargeted and a 
targeted approach. Starting with an untargeted approach, we used the program ‘Differential 
Correlation in Expression for meta-module Recovery’ (DICER), to identify differentially 
connected clusters. The plot in Figure 4.3 illustrates, as an example, the clearly contrasting 
connectivity between normal and disease tissue for one of the clusters. We confirmed the 
causal relevance of the differentially connected genes identified using DICER by showing 
that they are enriched in a GWAS study of pharmacoresistant partial epilepsy. The 
differentially connected gene-set remains enriched in the GWAS study even when we 
exclude those genes which are also differentially expressed. Pathway-enrichment analysis of 
the differentially connected genes revealed 75 significantly enriched pathways. We further 
confirmed that these pathways are differentially connected using a targeted algorithm, 
implemented in the package Gene Set Co-Expression Analysis (GSCA) (Choi & Kendziorski 
2009). 
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We have revealed for the first time that there is widespread differential connectivity in the 
pharmacoresistant epileptic hippocampus. In fact, we have shown that differential 
connectivity is more widespread than differential expression. Of the 10,000 probes 
subjected to DICER analysis, 890 (9%) were differentially connected. Of the 29,003 probes 
included in the differential expression analysis, 1176 probes (4%) were differentially 
expressed.  
4.5.6 Identifying a network of pathways and ‘hub’ pathways 
Figure 4.6 Differential expression (red) and connectivity (green) pathway-analysis confirm 
and complement each other. 
 
 
As illustrated in Figure 4.6, differential expression and differential connectivity pathway-
analyses confirm and complement each other. We identified 118 unique differentially 
regulated (differentially expressed or differentially connected) Reactome pathways. Out of 
these, 48 pathways (41%) were both differentially expressed and differentially connected, 
41 pathways (36%) were only differentially expressed, and 27 pathways (23%) were solely 
differentially connected (Figure 4.6). This point is further highlighted by looking at the ten 
most differentially expressed and the ten most differentially connected pathways (Tables 
4.6 and 4.7). Common to both Tables are pathways related to the neuronal system, 
transmission across chemical synapses and SLC-mediated transmembrane transport of small 
43 27 48 
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molecules. However, prominent amongst the most differentially expressed pathways, but 
not amongst the most differentially connected pathways, are pathways related to ligand 
binding to G protein-coupled receptors (GPCR), especially class A1 rhodopsin-like receptors 
such as chemokine receptor 1 (CCR1), and the resultant downstream signalling events. By 
contrast, prominent amongst the most differentially connected pathways, but not amongst 
the most differentially expressed pathways, are pathways related to axon guidance, 
especially via semaphorins. These observations demonstrate that considering only one form 
of differential regulation (that is, only differential expression or only differential 
connectivity) may lead to important biological processes being overlooked. 
The differentially expressed and differentially connected Reactome pathways identified in 
our microarray analysis (Tables 4.6 and 4.7,  and Appendix 9) could be deemed to represent 
disparate and disconnected processes, for example ‘axon guidance’, ‘transmembrane 
transport of small molecules’ and ‘class A1 rhodopsin-like receptors’. Using the Enrichment 
Map utility, we have shown that these differentially expressed and differentially connected 
pathways in fact form a highly interconnected central network (Figure 4.4). In this central 
network, each pathway is directly connected, on average, to 10.5 other pathways. The 
seemingly unrelated pathways, therefore, form a coherent whole and it can be expected 
that changes in one pathway in this network will have a cascading effect on the rest of the 
network. 
We acknowledge that alternative methods of network construction are available (see 
Chapter 1). We have adopted a strategy that begins with the identification of enriched 
biological pathways within the transcriptomic data and then constructs a network of the 
enriched pathways. This methodology is well suited to addressing a key unanswered 
question in epilepsy research: which pathways and processes are most central in the 
dysregulated transcriptomic network underlying pharmacoresistant epilepsy? The current 
analysis and previously published studies have shown that numerous functionally diverse 
genes are dysregulated in the epileptic human hippocampus. Starting with a pathway-
enrichment analysis approach allows immediate functional characterisation of these 
complex transcriptomic results, as each biological pathway serves a clearly defined purpose. 
Subsequent construction of a network of dysregulated pathways and analysis of network 
properties allows the identification of the most important hub pathways within the 
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network. In order to construct a network of dysregulated pathways, we have opted for a 
simple and intuitive approach not reliant on strong assumptions. The underlying assumption 
is that the dysfunction of a pathway will spread to overlapping pathways with which it 
shares constituent genes. 
Of particular importance in this network are likely to be the ‘hub pathways’ identified using 
betweenness centrality network analysis. Betweenness is a measure of the centrality of a 
node in a network, and is calculated as the fraction of shortest paths between node pairs 
that pass through the node of interest. Hence, betweenness is a measure of the influence a 
node has over the spread of information through the network. The most central pathway by 
far was ‘signalling by Notch’. We have conducted a literature review in order to highlight 
any published evidence of the potential role of Notch signalling in epilepsy.  
4.5.7 Notch signalling pathway in epilepsy: a literature review 
It is important to note that the differential expression of the Notch signalling pathway 
reported here can be independently and robustly confirmed: in a study published recently, 
it has been shown using Western Blots that Notch signalling is significantly upregulated in 
the pharmacoresistant epileptic human hippocampus (Sha et al. 2013).  
Notch is a cell surface receptor that engages at least two signal transduction pathways: one 
that controls nuclear gene expression and another that directly targets the cytoskeleton 
(Giniger 2012). Notch signalling plays critical roles in both the developing and the adult 
brain. In the developing brain, Notch regulates specification of neuronal identity and 
neuronal division, survival and migration, as well as axon guidance, morphogenesis of 
dendritic arbors and weighting of synapse strength (Giniger 2012). Notch pathway 
components are expressed throughout the adult brain (Ables et al. 2011). In the adult 
hippocampus and other brain regions, Notch is localized at synapses and is an essential 
contributor to synaptic plasticity (Wang et al. 2004; Dahlhaus et al. 2008; Alberi et al. 2011), 
and is involved in neuronal excitability and discharges (Alberi et al. 2011; Lieber et al. 2011). 
Using the kainate murine model of temporal lobe epilepsy, Sha and colleagues (Sha et al. 
2013) have recently shown that Notch is activated in response to seizure activity, and that 
the pharmacological induction of Notch expression has proconvulsant effects, while the 
inhibition of Notch suppresses seizures. The authors show that Notch enhances 
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transmission at glutamatergic synapses of CA1 pyramidal neurons. In summary, this data 
demonstrates that Notch is activated in response to seizure activity and that its activation in 
turn promotes seizures. 
Notch is known to modulate a number of transcription factors and this list is constantly 
growing (Borggrefe & Oswald 2009). Mutations in the NOTCH3 gene have been associated 
with human brain disorders: cerebral arteriopathy with subcortical infarcts and 
leukoencephalopathy (Rutten et al. 2014), and migraine (Menon et al. 2011). Based on the 
preceding observations, it can be postulated that the Notch signalling pathway occupies a 
central position in the transcriptional network that underlies the development of 
pharmacoresistant epilepsy. 
4.6 Conclusions 
We have performed the largest and most robust transcriptomic analysis of hippocampal 
tissue from pharmacoresistant mesial temporal lobe epilepsy to date. We have externally 
validated our results using previously published studies. We have shown the causal 
relevance of our results using novel objective methodology, and we have demonstrated that 
our list of DEGs is likely to be a highly valuable source for future drug discovery. For the first 
time, we have identified the differentially connected pathways in the pharmacoresistant 
epileptic hippocampus, and revealed the network of differentially expressed and 
differentially connected pathways underlying this disease, and identified the hub pathways. 
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Chapter 5: A Genome-Wide Association Study of 
Pharmacoresistant Partial Epilepsy: Pathway and 
Network Analysis 
5.1 Introduction 
It has been shown that genetic factors have a major influence on epilepsy prognosis 
(Johnson et al. 2003). However, for many complex traits, including pharmacoresistant 
epilepsy, the underlying pathobiology is not well understood, making it difficult to select 
candidate genes for analysis. For such traits, performing genome-wide association studies 
(GWAS) is an important initial strategy for identifying susceptibility genes. This approach can 
be quite successful—several highly significant SNP-disease associations have been found 
through GWAS that have been replicated across studies (Manolio et al. 2008), for example 
the association between interleukin-23 receptor polymorphisms and inflammatory bowel 
disease (Duerr et al. 2006; Raelson et al. 2007). Despite the success of single-marker 
association tests, this strategy has limited power to identify disease genes, given the 
hundreds of thousands of SNP markers used in most GWA studies. Some genes may be 
genuinely associated with disease status but may not reach a stringent genome-wide 
significance threshold in any GWAS. Most genetic associations have a small effect size and 
require very large sample sizes across several cohorts to be robustly identified. 
Furthermore, the small effect sizes for these associations do not explain the observed 
heritability of most traits (Maher 2008). In addition, it is can be challenging to translate a 
genetic association into a functional connection with the trait based only on the annotation 
of a single gene.  
In pathway-based association tests for GWAS, researchers examine a collection of 
predefined gene sets; each set represents a pathway (based on prior biological knowledge); 
and the significance of each pathway can be summarized based on the disease association 
of markers in or near genes that are components of that pathway (Wang et al. 2010). 
Intuitively, it seems likely that susceptibility markers for any given disorder are not randomly 
distributed among genes but instead, are distributed among one (or more) set(s) of genes 
whose functions are to some extent related (Holmans 2010). Hence, GWAS pathway 
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analysis can assess whether a group of genes with related functions are jointly associated 
with a trait of interest. 
The pathway-based GWAS approach offers several advantages over single-marker analysis. 
Firstly, pathway-based methods boost the power to identify genetic associations (Wang et 
al. 2007). Genetic heterogeneity may cause any one causal variant to exhibit only modest 
disease risk in the sample as a whole, since different individuals may possess different 
disease risk polymorphisms at different loci in the same gene, or in different genes. This will 
reduce power to detect any one variant by traditional association methods. However, if the 
genes in question are members of the same biological pathway, then considering the 
pathway as the unit of analysis may increase power to detect association between the 
genes and disease.  For similar reasons, association of disease with biological pathways may 
be easier to replicate across different studies than association with individual SNPs. This was 
clearly shown in an analysis of Crohn's disease (Wang et al. 2009), where the IL12/IL23 
pathway showed evidence of enrichment in four independent GWAS, despite the genes and 
SNPs involved differing between the studies. In addition, by identifying additional 
susceptibility genes, pathway-based analysis can be used to fill-in part of the ‘missing 
heritability’ described above (Fridley & Biernacka 2011). Furthermore, compared with SNP-
based analysis, pathway-based analysis may yield more secure insights into disease biology 
since an associated pathway is likely to implicate function better than a hit in a single gene 
that may have many functional possibilities. Finally, as the most associated gene in a 
pathway might not be the best candidate for therapeutic intervention, targeting 
susceptibility pathways might also have clinical implications for finding additional drug 
targets. 
To date, there has been only one GWAS of response to antiepileptic drugs. No single variant 
achieved genome-wide significance in this study, although a number of significant pathways 
were identified (Speed et al. 2013). The current study is distinct from the previously 
published work in three important ways:  (1) we have included only patients with partial 
epilepsy, (2) we have applied stringent definitions of pharmacoresistance (see below), and 
(3) we have used normal subjects as controls. These characteristics mean that the design of 
our GWAS closely mirrors the design of our transcriptomic study (Chapter 4), and the two 
types of studies can be effectively integrated (in Chapter 7). 
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5.2 Aims 
1. To perform a GWAS of pharmacoresistant partial epilepsy. 
2. To perform objective validation of a gene-set based analysis approach of our GWAS. 
3. To perform pathway-level enrichment analysis of GWAS results. 
4. To demonstrate pathway-level replication of GWAS results. 
5. To create a network of enriched pathways and identify ‘hub’ pathways. 
5.3 Methods 
5.3.1 Patients 
The control dataset consisted of 3000 subjects from the Wellcome Trust Case Control 
Consortium (WTCCC) 1958 British Birth Cohort (dataset EGAD00000000022). This dataset 
was downloaded from the European Genome-Phenome Archive after obtaining the 
requisite approval from the Wellcome Trust Case Control Consortium Data Access 
Committee. 
The epilepsy cases used in the discovery cohort were from amongst the patients recruited 
into the Standard and New Antiepileptic Drugs (SANAD) trial (Marson et al. 2007a, b). 
SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in 
the UK which examined the longer-term outcomes of standard versus new antiepileptic 
drugs. Patients were included in SANAD if they had a history of two or more clinically 
definite unprovoked epileptic seizures in the previous year. This allocation allowed inclusion 
of patients with newly diagnosed epilepsy, patients who had failed treatment with previous 
monotherapy, and patients who had entered a period of remission from seizures but had 
relapsed after withdrawal of treatment. Patients were excluded if the clinician or patient felt 
that treatment was contraindicated, if all their seizures had been acute symptomatic 
seizures (including febrile seizures), they were aged 4 years or younger, or if there was a 
history of progressive neurological disease. Clinicians were asked to classify seizures and 
epilepsy syndromes by International League Against Epilepsy (ILAE) classifications(1981; 
1989) as far as was possible, and at least to differentiate between partial onset (focal) or 
generalised onset seizures. Patients were seen for follow-up at 3 months, 6 months, 1 year, 
and at successive yearly intervals from the date of randomisation. At every visit, details of 
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the occurrence of seizures, adverse events, hospital admissions, and antiepileptic drug 
treatment were documented.  
For the purposes of our GWAS, we extracted subjects from the SANAD trial with a history of 
pharmacoresistant partial epilepsy. Pharmacoresistant epilepsy was defined as failure to 
achieve seizure freedom with two appropriately chosen antiepileptic drugs (used as 
monotherapies or in combination) at their minimum therapeutic doses or above for at least 
three months, in keeping with ILAE guidelines (Kwan et al. 2010). Seizure freedom was 
defined as freedom from all seizures for a minimum period of 12 months. Total daily 
minimum therapeutic doses of antiepileptic drugs used in our classification protocol were 
taken from the British National Formulary 60 (September 2010), and are listed in Table 5.1. 
Table 5.1 Total daily minimum therapeutic doses of antiepileptic drugs used in our 
classification of pharmacoresistance.  
Antiepileptic drug Minimum therapeutic dose (mg) 
Carbamazepine 600 
Clobazam 20 
Clonazepam 4 
Eslicarbazepine  800 
Ethosuximide 1000 
Gabapentin 1200 
Lacosamide 200* 
Lamotrigine 150 
Levetiracetam 1000* 
Oxcarbazepine 900 
Phenobarbital 60 
Phenytoin 200 
Pregabalin 300 
Primidone 750 
Tiagabine 15§ 
Topiramate 150 
Valproate 1000 
Vigabatrin 1000 
Zonisamide 150 
*Minimum therapeutic dose not stated in the British National Formulary and taken from 
product literature. §30mg in patients receiving enzyme inducing drugs. 
 
The epilepsy cases used in the replication cohort were from amongst the patients recruited 
into the ‘Pharmacogenetics of GABAergic Mechanisms of Benefit and Harm in Epilepsy’ 
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study. The aims of the study were: (i) to determine a genomic profile that predicts 
therapeutic response to clobazam (CLB), and (ii) to develop a gene-test for predicting 
vigabatrin (VGB) related visual field defects. Patients were recruited from hospital-based 
outpatient clinics in the UK. Patients were invited to join the CLB arm of the study if they 
had continued seizures despite current treatment with between one and three conventional 
antiepileptic drugs and the addition of CLB to the existing antiepileptic regime was clinically 
indicated. Patients were asked to join the VGB arm of the study if they were over the age of 
12 years and had taken VGB for at least 6 months. For the CLB and VGB studies, the dose 
and duration of use details for previously prescribed antiepileptic drugs was not recorded. 
Hence, it was not possible to make use of the ILAE definition stated above for the 
identification of pharmacoresistant patients. However, both CLB and VGB are used in the UK 
as adjunctive treatments in cases where first- and second-line antiepileptic drugs have 
proven ineffective. The chief investigator for the study, who is familiar with clinical practice 
at the participating hospitals, confirmed that both CLB and VGB are prescribed in 
pharmacoresistant patients in the concerned centres. To further ensure that we included 
only a pharmacoresistant phenotype in our GWAS, we selected only those patients who had 
active epilepsy for at least 10 years and were still uncontrolled at the time of initiating CLB 
or VGB. The epilepsy syndrome of the recruited patients was recorded as part of the CLB 
and VGB studies, and we included in our GWAS only those with documented partial 
epilepsy. 
5.3.2 Genotyping, imputation and quality control 
DNA was extracted from blood samples using standard procedures. All samples from 
patients with epilepsy were genotyped at the Wellcome Trust Sanger Institute on an 
Illumina 670K chip. Our standard data quality control (QC) procedures were as follows. 
Individuals were excluded on the basis of discordance between reported and observed sex, 
SNP call rate <95%, outlying autosomal heterozygosity rates (>3 standard deviations from 
the mean), inadvertent subject duplication or cryptic relatedness based on pairwise identity-
by-descent estimations (the individual with greater missing data was removed from each 
pair with -hat >0.1875), being outliers from the European cluster in a plot of the first two 
principal components of genotypes for samples from the study and HapMap Phase III. SNPs 
were excluded on the basis of genotype missing rate ≥5% if minor allele frequency (MAF) 
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was ≥0.05 and missing rate ≥1% if MAF was <0.05, observed minor allele frequency <0.01, 
significant deviation (P <10−4) from Hardy-Weinberg equilibrium, significant difference (P 
<10−4) in the genotype missing rate in cases compared to controls, and all non-autosomal 
SNPs. As an additional filter against false-positive associations resulting from genotyping 
errors, genotype imputation was used as a strategy for detecting genotyping errors 
(Marchini & Howie 2010). Samples were pre-phased using ShapeIt version 2 (Delaneau et al. 
2013) and then imputed using Impute2 (Howie et al. 2009), with 1000 Genomes Project 
haplotypes (released in March 2012) as the reference panel. Impute2 produces a 
concordance metric: each genotyped SNP in the study dataset is masked one at a time, and 
then imputed using information from the reference data and nearby study variants; 
concordance between imputed and original genotypes is then calculated. SNPs imputed 
with high certainty (Impute2 ‘info’ score >0.9) but with low concordance (<0.9) were 
excluded. 
For controls, we obtained the WTCCC 1958 British Birth Cohort dataset genotyped on the 
Illumina 1.2M chip. This dataset was chosen as the SNPs on our Illumina 670K chip are a 
complete subset of those on the Illumina 1.2M chip. This ensures maximal overlap between 
the genotyped SNPs for the control and epilepsy samples. Hence, we reduced the SNPs in 
the control dataset to those also found on the Illumina 670K chip. For QC, we started by 
excluding all 231 individuals listed as 'individual exclusions' in the data release 
documentation. We then applied our standard per-individual QC filters stated above—this 
led to the exclusion of only two additional individuals, based on outlying ancestry. We 
excluded all SNPs listed as 'SNP exclusions' in the WTCCC data release documentation. We 
then applied our standard per-SNP QC filters stated above. In total 68114 SNPs were 
excluded, 53326 of which were in the suggested SNP exclusions from the Wellcome Trust 
data release documentation, and 1209 were identified using the imputation-based filter. 
In the SANAD cohort, there were 84 genotyped samples with pharmacoresistant partial 
epilepsy. The final dataset, after applying the QC filters described above, included 76 
samples. 
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In the combined clobazam and vigabatrin cohort, there were 385 genotyped samples with 
pharmacoresistant partial epilepsy. The final dataset, after applying the QC filters described 
above, included 345 samples. 
For case-control analysis, our ‘discovery’ dataset comprised the SANAD cohort and half of 
the WTCCC 1958 British Birth Cohort chosen at random. Our ‘replication’ dataset comprised 
the combined clobazam and vigabatrin cohort and the other half of the WTCCC 1958 British 
Birth Cohort. Our standard QC filters were applied again to the discovery and replication 
cohorts. In the end, our discovery cohort consisted of 76 cases and 1312 controls genotyped 
over 509319 SNPs, and our replication cohort consisted of 345 cases and 1312 controls 
genotyped over 509269 SNPs. 
We also created a ‘mega-analysis’ dataset by merging the SANAD, clobazam, vigabatrin and 
WTCCC 1958 British Birth cohorts. After QC, this dataset comprised 421 cases and 2624 
controls genotyped over 509534 SNPs. 
Genotype imputation was performed in order to boost power and to aid fine mapping of 
any association signals (Marchini & Howie 2010). The ‘mega-analysis’ dataset were pre-
phased using ShapeIt version 2 (Delaneau et al. 2013) and then imputed using Impute2 
(Howie et al. 2009), with 1000 Genomes Project haplotypes (released in March 2012) as the 
reference panel. The QCTOOL software was used to exclude SNPs with an ‘info’ score of 
<0.9. GTOOL software was then used to transform the imputed data to PED format, with a 
posterior probability of 0.9 used as a threshold to call genotypes. In the end, our standard 
per-SNP QC filters, described above, were applied. The final dataset included 5,519,310 
genotyped and imputed SNPs. 
5.3.3 Association, pathway and network analysis 
SNP-level association analysis was performed using the chi-squared (2) test in Plink version 
1.07 (Purcell et al. 2007). Based on the results of the 2 test, genomic inflation factor () was 
calculated and quantile-quantile (QQ) plots were generated. Where results were inflated 
due to population stratification, the association analysis was performed using logistic 
regression with significant principal components (PCs) as covariates. Specifically, PC analysis 
was performed using the package SNPRelate (Zheng et al. 2012). Tracy-Widom (TW) statistic 
(Patterson et al. 2006) and significance for the eigenvalue of each PC was calculated using 
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the package EigenCorr (Lee et al. 2011); PCs with statistically significant eigenvalues 
(FDR<0.05) were included as covariates in the logistic regression analysis. Sex was not 
included as a covariate as this can substantially reduce power for the identification of 
associated variants when the disease prevalence is lower than a few percent (Pirinen et al. 
2012; Bezzina et al. 2013). 
We wished to demonstrate that GWAS gene-set analysis was able to discriminate 
functionally relevant from irrelevant gene-sets. For this purpose, we used a robust objective 
methodology for compiling a highly functionally relevant gene-set: we created a 
comprehensive list of the targets of all current AEDs by searching three publically-available 
databases of drug targets: Stitch, SuperTarget and DrugBank. For comparison, we divided 
the rest of the genome randomly into 122 gene-sets of the same size as our functional gene-
set. We determined the degree of enrichment of these gene-sets with our discovery and 
cohort association results. 
Gene-set and pathway-level enrichment analysis was performed using the widely used 
program GSA-SNP (Nam et al. 2010). For SNP-to-gene mapping, we used a mapping distance 
of 20kb, and compared results obtained with using the first and second most significant 
SNP. In order to maintain consistency with our transcriptomic pathway analysis, the 
Reactome pathways database downloaded from the Gene Set Enrichment Analysis website 
was used in the enrichment analysis.  
The statistical significance of the overlap between the list of enriched pathways in the 
discovery and replication cohorts was calculated using the hypergeometric equation.  
As described for our transcriptomic analysis, Enrichment Map (Merico et al. 2010) tool was 
used to determine the connections between enriched pathways. Enrichment Map was used 
with default settings. Specifically, we employed an overlap coefficient cut-off of 0.5—two 
pathways were deemed connected only if the ratio of the size of the intersection over the 
size of the smallest pathway was 0.5 or more. The Network Analysis tool was used to 
calculate network parameters, including ‘betweenness centrality’ of nodes. 
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5.4 Results 
5.4.1 SNP-level analysis 
For the discovery cohort 2 association analysis, the  was 1.01 and the QQ plot of the 
observed p-values revealed a good fit with the null distribution (Figure 5.1). For the 
replication cohort 2 association analysis, the  was 1.04. The eigenvalues for the first two 
PCs were statistically significant; these PCs were included as covariates in a logistic 
regression analysis. After PCA-adjustment, both the  (1.03) and the QQ plot showed 
appropriate improvement (Figure 5.2), suggesting that there was little evidence of residual 
inflation due to population stratification. For the combined cohort 2 association analysis, 
the  was 1.05. The eigenvalues for the first eight PCs were significant; these PCs were 
included as covariates in a logistic regression analysis. After PCA-adjustment, both the  
(1.03) and the QQ plot (Figure 5.3) showed appropriate improvement, suggesting that there 
was little evidence of residual inflation due to population stratification. The association 
results of the combined imputed dataset were adjusted by including the same eight PCs as 
covariates in the logistic regression analysis. Again, the the  (1.03) and the QQ plot (Figure 
5.4) showed little evidence of residual inflation due to population stratification. 
None of the p-values in our discovery or replication studies reached the now widely-
accepted 5×10−8 threshold for genome-wide significance in association studies (McCarthy et 
al. 2008), nor the 9.8×10−8 threshold required to achieve significance after applying 
Bonferroni correction for the 509316 tests in our discovery analysis or the 509266 tests in 
our replication analysis. 54 SNPs reached a suggestive (<5x10-5) level of significance in the 
discovery cohort and 39 in the replication cohort. There was no overlap between the 
suggestive SNPs in the two cohorts. 
In the combined analysis, one SNP (rs35452866) reached genome-wide significance 
(p=1.6x10-9), while 29 SNPs reached a suggestive level of significance (Table 5.2 and Figure 
5.5). In the combined imputed analysis, one SNP (rs35452866) reached genome-wide 
significance (p=3.4x10-9), while 402 reached a suggestive level of significance (Figure 5.6). 
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5.4.2 Gene-set enrichment validation 
We demonstrated that a gene-set comprised of all known targets of current AEDs is 
significantly enriched in both the discovery (FDR<0.005) and the replication (FDR<0.0004) 
GWAS (Figure 5.7). By contrast, out of 122 random gene-sets of the same size as our AED-
targets gene-set, none was significantly enriched in either GWAS (smallest FDR=0.15). 
Table 5.2 SNPs reaching genome-wide or suggestive level of significance in the combined 
analysis. BP: base-pair position. OR: odds ratio.  
Chromosome SNP BP OR P 
4 rs35452866 97950633 2.717 1.59x10-9 
2 rs2176529 194613887 1.701 1.33x10-7 
5 rs10069413 84055052 1.649 1.32x10-6 
8 rs6470428 87256166 1.451 5.77x10-6 
8 rs7815102 87270243 1.447 6.83x10-6 
15 rs12323994 44770917 1.423 9.89x10-6 
1 rs10493734 83221230 1.389 1.43x10-5 
1 rs1144256 83160157 1.385 1.73x10-5 
17 rs4789963 74741972 1.39 1.78x10-5 
5 rs1979006 156666964 1.845 1.88x10-5 
22 rs763280 23923452 1.381 2.39x10-5 
11 rs11606985 2800252 1.428 2.44x10-5 
1 rs11163625 83210060 1.374 2.65x10-5 
1 rs1144269 83169134 1.373 2.79x10-5 
20 rs6110905 16035405 0.6973 2.80x10-5 
4 rs2242226 189709167 1.525 2.88x10-5 
7 rs722037 7282916 1.367 3.39x10-5 
16 rs2531995 3953468 1.371 3.42x10-5 
1 rs11163602 83137141 1.366 3.56x10-5 
8 rs6996246 87281129 1.375 3.60x10-5 
16 rs2230742 3956677 1.507 3.60x10-5 
7 rs11974777 80050992 1.673 3.82x10-5 
7 rs1638210 7284485 1.364 3.95x10-5 
22 rs6000762 36248418 1.41 3.95x10-5 
13 rs7990091 25645138 1.455 4.27x10-5 
3 rs11710045 57212261 0.7202 4.45x10-5 
14 rs12586261 44062009 2.628 4.51x10-5 
3 rs269392 19824546 1.419 4.53x10-5 
3 rs4060726 57310916 0.7227 4.61x10-5 
20 rs1418925 52259138 1.357 4.70x10-5 
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Figure 5.1 QQ plot for GWAS discovery cohort 
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Figure 5.2 QQ plot of GWAS replication cohort 
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Figure 5.3 QQ plot for combined GWAS cohort 
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Figure 5.4 QQ plot for combined imputed GWAS dataset 
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Figure 5.5 Manhattan plot of association results for the combined cohort 
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Figure 5.6 Manhattan plot of association results for the combined imputed cohort 
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Figure 5.7 GWAS gene-set enrichment analysis
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5.4.3 Gene-set and pathway level replication of results 
The gene-set analysis p-values for the AED-targets gene-set and 122 random gene-sets were 
highly significantly correlated between the discovery and replication cohorts (Pearson’s 
correlation coefficient=0.8, one-sided p-value<2.2x10-16).  
For the Reactome pathway enrichment analysis, 49 pathways were enriched in the 
discovery cohort and 73 pathways were enriched in the replication cohort. Out of the top 10 
discovery cohort enriched pathways, all were replicated in the replication cohort; out of the 
top 20 discovery cohort enriched pathways, 17 were replicated in the replication cohort. In 
total 28 of the discovery cohort enriched pathways were replicated in the replication cohort 
(overlap hypergeometric p-value <3.7x10-17). 
The combined GWAS was also used to perform pathway enrichment analysis. The top 10 
pathways are listed in Table 5.3, while the rest can be found in Appendix 12. 
Table 5.3 Top 10 enriched Reactome pathways for the combined GWAS analysis. FDR=False 
Discovery Rate 
Pathway FDR 
Axon guidance 8.62x10-10 
Developmental biology 3.33x10-8 
Neuronal system 2.79x10-8 
Signalling by Rho GTPases 2.29x10-8 
Transmembrane transport of small molecules 3.67x10-7 
NRAGE signals death through JNK 4.10x10-7 
Netrin1 signalling 1.86x10-6 
Transmission across chemical synapses 1.24x10-5 
Cell death signalling via NRAGE, NRIF and NADE 3.27x10-5 
G12/G13  subunits signalling events 3.26x10
-5 
 
5.4.4 Identifying a Network of Pathways 
Enrichment Map analysis revealed a highly interconnected central network of pathways 
(Figure 5.8). In this central network, each pathway is directly connected to, on average, 8.4 
other pathways. In order to identify the most central ‘hub’ pathways, ‘betweeness 
centrality’ network analysis was performed; the results are illustrated in Figure 5.9 and the 
top 10 pathways are listed in Table 5.4. The complete ranked list can be found in Appendix 
12. 
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Table 5.4 The top 10 pathways according to betweenness centrality 
Pathway Betweenness Centrality 
Signalling by NGF  0.343469 
DSCAM interactions  0.273255 
Transmembrane transport of small molecules  0.238506 
Developmental biology  0.185783 
Signalling by GPCR  0.183818 
Haemostasis  0.085772 
Glucagon signalling in metabolic regulation  0.070287 
PKA mediated phosphorylation of CREB  0.0569 
G--z signalling events  0.056336 
Neuronal system  0.05371 
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Figure 5.8 Central network of pathways enriched in combined GWA analysis results 
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Figure 5.9 The central network of interconnected pathways. Node sizes are proportional to 
their betweenness centrality. 
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5.5 Discussion 
We have performed the first GWAS of pharmacoresistant partial epilepsy. 
One SNP (rs35452866) reached genome-wide significance in the combined ‘mega-analysis’. 
rs35452866 is an intergenic SNP. Its flanking genes (PDHA2 and COX7AP2) have no known 
role in epilepsy, and its neighbouring SNPs did not reach a genome-wide or suggestive level 
of significance (Figures 5.5 and 5.6). It would be advisable, therefore, to exercise caution in 
interpreting the importance to this SNPs, until it is replicated in future independent studies. 
We went on to perform a gene-set or pathway-level analysis. 
5.5.1 Validation of GWAS Gene-Set Analysis 
Although GWAS gene-set enrichment analysis is an increasingly utilized tool, we are not 
aware of any published study demonstrating objectively that this technique can successfully 
discriminate functionally relevant from irrelevant gene-sets. In previously published studies, 
the assertion that significantly enriched gene-sets are truly linked to the disease phenotype 
has been based on conjecture, sometimes supported by evidence picked from a literature-
review. However, the use of an inappropriate clinical cohort, genotyping errors, or 
employing a flawed GWAS gene-set analysis protocol could all render the GWAS gene-set 
enrichment analysis results unreliable. 
We, therefore, devised a novel strategy to show that both our discovery and replication 
GWAS analyses results are enriched with a gene-set of obvious objective relevance to drug-
resistant epilepsy: the targets of antiepileptic drugs. This gene-set was created in an 
unsupervised and unbiased manner using three different publically-available drug-target 
databases. This gene-set was significantly enriched in both our discovery and replication 
cohorts. We divided the rest of the genome into 122 random gene-sets of the same size as 
the antiepileptic-targets gene-set: none of these random gene-sets was enriched in either 
the discovery or the replication dataset. We consider this to be an objective validation of 
our clinical cohorts and of the GWAS gene-set analysis technique. 
5.5.2 Gene-set and pathway level replication of results 
Although there was no overlap between the suggestive SNPs in the discovery and 
replication cohorts, there was significant replication of results at the gene-set and pathway 
level. There was a striking correlation (Figure 5.7) between the discovery and replication 
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cohorts in the gene-set analysis results for the AED-targets gene-set and 122 random gene-
sets (Pearson’s correlation coefficient=0.8, one-sided p-value<2.2x10-16). Furthermore, out 
of the top 10 discovery cohort enriched pathways, all were replicated in the replication 
cohort; and out of the top 20 discovery cohort enriched pathways, 17 were replicated in the 
replication cohort. Overall, there was a highly significant overlap between the enriched 
pathways for the discovery and replication cohorts (hypergeometric distribution p-value 
<3.7x10-17).  
5.5.3 Identifying a Network of Pathways and Hub Pathways 
The Reactome pathways enriched in the GWAS (Table 5.3 and Appendix 12) could be 
deemed to represent disparate and disconnected processes, for example ‘axon guidance’, 
‘transmembrane transport of small molecules’ and ‘cell death signalling via NRAGE, NRIF 
and NADE’. Using the Enrichment Map utility, we have shown that these enriched pathways 
in fact form a highly interconnected central network (Figure 5.8). In this central network, 
each pathway is directly connected, on average, to 8.4 other pathways. The seemingly 
unrelated pathways, therefore, form a coherent whole and it can be expected that changes 
in one pathway in this network will have a cascading effect on the rest of the network. 
Of particular importance in this network are likely to be the ‘hub pathways’ identified using 
betweenness centrality network analysis. Betweenness is a measure of the centrality of a 
node in a network, and is calculated as the fraction of shortest paths between node pairs 
that pass through the node of interest. Hence, betweenness is a measure of the influence a 
node has over the spread of information through the network. 
5.5.4 The most important pathways: a literature review 
The ten most enriched pathways are shown in Table 5.3 and the ten most important 
pathways according to ‘betweenness centrality’ are listed in Table 5.4. It is remarkable that 
the enriched and central pathways identified are directly related to the formation and 
function of neuronal and supporting tissues. The relevance of pathways such as ‘axon 
guidance’, ‘neuronal system’ and ‘transmission across chemical synapses’ is self-evident. We 
will examine below the evidence from literature in support of a role in epilepsy 
pharmacoresistance for a number of the other pathways.  
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One of the most enriched pathways is ‘signalling by Rho GTPases’. The Rho family of 
GTPases and related molecules play an important role in various aspects of neuronal 
development, including neurite outgrowth and differentiation, axon path finding, and 
dendritic spine formation and maintenance (Govek et al. 2005). A recent GWAS found a SNP 
within the Rho GTPase ARHGAP11B to be associated with epilepsy prognosis at a suggestive 
level of significance (Speed et al. 2013). Genetic variants in ARHGEF9 and ARHGEF6, both 
members of the Rho GTPase signalling pathway, have been associated with early infantile 
epileptic encephalopathy (Harvey et al. 2004) and mental retardation with refractory 
seizures (Shimojima et al. 2011), respectively. 
 
One of the enriched pathways is ‘PPAR- activates gene expression’. Peroxisome 
proliferator-activated receptor- (PPAR-) is one of three subtypes of the nuclear receptor 
PPAR family. PPAR- is expressed at functionally significant levels in neuronal tissue 
(Cullingford 2008). PPAR- may have antiepileptic properties via modulation of gene 
expression. PPAR- can regulate genes encoding enzymes of neurotransmitter metabolism 
in the brain (Cullingford 2004). It can also regulate inflammatory pathways (Delerive et al. 
2001; Moraes et al. 2006). In addition, PPAR- directly interacts with proteins involved in 
acute voltage-dependent neuronal responses (LoVerme et al. 2006). Hence, PPAR- may 
favourably perturb neurotransmitter concentrations (Cullingford 2004); PPAR--induced 
anti-inflammatory actions may protect against convulsion-induced cell damage (Chen et al. 
2007); and PPAR--induced action on membrane channels may favourably perturb the 
nerve-cell membrane potential. In keeping with these observations, a single dose of PPAR- 
agonist WY14643 or chronic administration of PPAR--agonist fenofibrate significantly 
reduces behavioural and EEG expression of nicotine-induced seizures (Puligheddu et al. 
2013). PPAR- exhibits a broad ligand tolerance, including valproate, phenytoin, and 
polyunsaturated fatty acids (as present in the ketogenic diet) (Cullingford 2008). Thus PPAR-
 has potential relevance to the mechanism of several antiepileptic classes. Finally, it is 
worth mentioning that common human PPAR- polymorphisms, such as L162V, lead to 
different basal and ligand-induced PPAR- responses (Sapone et al. 2000) and, hence, are of 
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potential relevance in patients exhibiting diverse responses to the ketogenic diet and 
antiepileptics.  
Two other significantly enriched pathways are ‘cell death signalling via NRAGE, NRIF and 
NADE’ and ‘NRAGE signals death through JNK’. One of the most central pathways was 
‘Signalling by NGF’. The p75 neurotrophin receptor (p75NTR) is a key regulator of neuronal 
apoptosis, both during development and after injury. Apoptosis is triggered by binding of 
either mature neurotrophin, for example nerve growth factor (NGF), or proneurotrophin, 
for example proNGF, and requires activation of c-JUN N-terminal Kinase (JNK). The p75NTR 
signals by recruiting intracellular binding proteins. Many proteins have been identified that 
can interact with the p75NTR intracellular domain, and several of these proteins have been 
implicated in apoptotic signalling, such as neurotrophin receptor-interacting factor (NRIF), 
p75NTR-associated Cell Death Executor (NADE) and neurotrophin receptor–interacting MAGE 
homolog (NRAGE). NRIF is required for p75NTR-mediated apoptosis following seizures, as 
pilocarpine treatment of NRIF–/– mice yields significantly fewer dying neurons compared 
with wild-type mice (Volosin et al. 2008). NADE can be co-induced with p75NTR following 
kainate-induced seizures (Yi et al. 2003), and may also play a role in cell death signalling. In 
addition, NRAGE has been detected in a complex with NRIF following proNGF stimulation 
(Volosin et al. 2008). Therefore, these p75NTR adapter proteins may act together in a 
complex to stimulate downstream apoptotic signalling (Friedman 2010). Genetic variants in 
NGF genes have been associated with a neurological disorder hereditary sensory and 
autonomic neuropathy type V (Einarsdottir et al. 2004; Carvalho et al. 2011). 
 
One of the most significantly enriched pathways was ‘Netrin1 signalling’ and two central 
pathways were ‘DCC mediated attractive signalling’ and ‘DSCAM interactions’. All of these 
pathways play essential roles in appropriate axon guidance within the hippocampus. Proper 
axonal targeting is fundamental to the establishment of functional neural circuits. In 
temporal lobe epilepsy, there is aberrant axonal targeting, known as mossy fibre sprouting, 
which results in the formation of hyperexcitable recurrent networks (Muramatsu et al. 
2010). Netrins are secreted proteins that play an important role in neuronal migration and 
in axon guidance. Netrin1 is the most studied member of the family and has been shown to 
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play a crucial role in neuronal navigation through its interaction with its receptors. In the 
human hippocampus, netrin1 attracts mossy fibres to CA3, which is their normal target 
under physiological conditions (Muramatsu et al. 2010). The deleted in colorectal cancer 
receptor (DCC) is required for netrin-induced axon attraction (Muramatsu et al. 2010). 
Another netrin1 receptor is the Down syndrome cell adhesion molecule (DSCAM), which 
induces dendritic arborization. DSCAM expression in the epileptic foci of intractable epilepsy 
patients is significantly higher compared to controls (Shen et al. 2011). In addition, DSCAM is 
also highly expressed in the rat brain during the different phases of the epileptogenic and 
epileptic process; this suggests that DSCAM may be involved in the generation and the 
development of pharmacoresistant epilepsy (Shen et al. 2011). Furthermore, DSCAM was 
associated with susceptibility to epilepsy at a suggestive level of significance in a recent 
GWAS (Guo et al. 2012). 
 
5.6 Conclusions 
We have performed the first ever GWAS of pharmacoresistant partial epilepsy, and the first 
ever objective validation of the GWAS gene-set analysis approach. We have identified the 
most significant polymorphisms and pathways underlying pharmacoresistant partial 
epilepsy, and we have demonstrated that there is significant replication of the most 
significant pathways. Furthermore, we have shown that the enriched pathways form a 
highly interconnected central network and, finally, we have identified the hub pathways in 
this network. 
Potential future avenues of research, for further prioritizing from amongst the pathways identified in 
this work, would involve identifying ‘causal’ pathways (which we aim to do in Chapter 7) and 
performing functional studies in animal models of epilepsy to determine if genetic manipulation of 
key pathways leads to changes in drug responsiveness. 
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Chapter 6: Genetic Regulation of Gene Expression in 
the Pharmacoresistant Epileptic Human Hippocampus 
6.1 Introduction 
Genetic contribution to phenotypic diversity can result from changes in amounts of proteins 
as from functional modifications in them (Li & Burmeister 2005). Studies in animal and 
human tissues have revealed that the expression of a high percentage of genes is 
substantially influenced by DNA variants (Romanoski et al. 2010; van Nas et al. 2010; Orozco 
et al. 2012). Most significant SNPs in genome-wide association studies (GWAS) map outside 
protein-coding regions, and >75% of significant GWAS SNPs map to functional regulatory 
elements that have been identified in the Encyclopedia of DNA Elements (ENCODE) project 
(Schaub et al. 2012). Also, in contrast to polymorphisms that change the amino acid 
sequence of genes, genetic variants that are responsible for changes in gene expression 
might have more subtle phenotypic effects that better explain complex genetic diseases. 
These observations suggest that genetic variants that alter gene expression, rather than 
variants that alter protein sequences, form the primary basis of natural variation in complex 
traits. Hence, genetic variation driving gene expression is likely to be integral to the 
pathogenic processes active within the pharmacoresistant epileptic human hippocampus.  
We have performed whole-genome genotyping and transcriptome-expression analysis on a 
series of control and pharmacoresistant epileptic human hippocampal samples to reveal 
expression quantitative trait loci (eQTLs) that influence gene expression within the 
pharmacoresistant epileptic human hippocampus. eQTLs are genomic sequence variants (as 
determined by genome-wide polymorphism analysis) that correlate with gene-expression 
levels (as determined by genome-wide microarray analysis). eQTL studies are similar to 
traditional genetic-association studies, but instead of associating genetic variants with 
discrete traits such as disease status, eQTL studies correlate genetic variants with 
quantitative gene-expression levels. The outputs from this type of analysis are SNP-
transcript pairs in which gene expression is correlated with genotype in a dose-dependent 
fashion. ‘Cis’ associations are between a gene’s expression level and a nearby SNP (one 
located within an arbitrarily defined distance, such as 500kb). ‘Trans’ associations include all 
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non-cis pairs, and can be between the expression of a gene on one chromosome and a SNP 
located on another chromosome. 
In complex diseases, truly trait-associated SNPs are more likely to be eQTLs (Nicolae et al. 
2010), and it has been suggested that eQTL analysis is a powerful approach for the detection 
of novel disease risk loci (Schadt 2005). Furthermore, determining the relationship between 
disease-associated SNPs and gene expression levels offers potential insights into the 
pathological mechanisms associated with these SNPs. 
It has been shown that 69% to 80% of eQTLs operate in a cell-type specific manner (Dimas 
et al. 2009). We are aware of only one previously published eQTL study on human 
hippocampal tissue (Kim et al. 2012). This study was limited to cis-eQTL analysis. There are 
currently no published trans-eQTL analyses of hippocampal tissue, and no eQTL analyses of 
the epileptic human hippocampus. Our study not only examines eQTLs in hippocampal 
tissue, but specifically in samples with the disease, a strategy which may be necessary for 
the identification of the disease-related eQTLs (Ertekin-Taner 2011). 
6.2 Aims 
 To identify eQTLs within the pharmacoresistant epileptic human hippocampus. 
 To validate the identified eQTLs using previously published data. 
 To determine if the eQTLs are relevant to disease by establishing if 
o eQTLs are enriched within disease-associated SNPs. 
o more eQTLs converge on differentially-expressed than non-differentially-
expressed genes 
 To identify the most important eQTLs and determine the biological processes 
enriched within these eQTLs. 
 To illustrate the practical utility of our eQTL dataset by using it to prioritize GWAS 
SNPs and reveal their functional implications. 
6.3 Methods 
The normalized microarray gene expression data generated previously (Chapter 3) was 
utilized for the eQTL analysis. The methods used for generating this data are repeated 
below for the reader’s convenience. 
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6.3.1 Sample collection 
Samples used in the study originated from three UK sites: the Walton Centre for Neurology 
and Neurosurgery in Liverpool, the Salford Royal Hospital in Salford and the Southern 
General Hospital in Glasgow. We aimed to recruit patients of age 5 years and older with 
pharmacoresistant mesial temporal lobe epilepsy of at least 3 months durations for which a 
therapeutic temporal lobectomy was being undertaken. As recently proposed by the ILAE, 
pharmacoresistance was defined as the failure of adequate trials of two tolerated, 
appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or 
in combination) to achieve sustained seizure freedom. The diagnosis of MTLE was made by 
the treating clinician based on seizure semiology, MRI brain and EEG characteristics being 
consistent with a seizure focus in the mesial temporal lobe. Patients suspected of having a 
neoplastic or malignant temporal lobe lesion were excluded. After surgery, the 
hippocampus was divided into two portions: (1) one portion was preserved for RNA 
isolation, (2) the other portion underwent histological analysis by an experienced 
neuropathologist. Any subjects found to have a neoplastic or malignant lesion on 
histological analysis were excluded. The portion preserved for RNA isolation was either 
stored in RNAlater (Liverpool and Glasgow) or frozen directly at -80oC (Salford). It should be 
noted that the quality of the RNA generated from the directly frozen brain samples was not 
significantly different from RNAlater-preserved samples: mean RIN values were 7.82 and 
7.25 respectively, and two-sample t-test p-value for difference between group RINs was 
0.06554. 
Frozen post-mortem histologically-normal hippocampal samples from donors with no 
known brain diseases were obtained from the MRC Edinburgh Brain Bank (Edinburgh, UK) 
and the Queen Square Brain Bank (London, UK).  
6.3.2 RNA isolation 
Brain samples were disrupted and homogenized in an appropriate volume of QIAzol lysis 
reagent (Qiagen, Crawley, United Kingdom) by using a TissueRuptor handheld rotor-stator 
homogenizer (Qiagen, Crawley, United Kingdom). Total RNA was extracted from the 
homogenates using the RNeasy Lipid Tissue Mini Kit (Qiagen, Crawley, United Kingdom), 
according to the manufacturer’s instructions. RNA quality was examined by capillary 
electrophoresis on an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA) and Agilent 2100 
 
 
207 
 
Expert software was used to calculate the RNA Integrity number (RIN) of each sample. Purity 
of the RNA sample was assessed using a NanoDrop1000 Spectrophotometer. Capillary 
electrophoresis traces were also examined. Samples with RNA integrity number  scores 
(RIN) below 6, obvious RNA degradation, significant 18S or 28S ribosomal  RNA degradation, 
ratio of absorbance at 260nm and 280nm <1.95, or with  noticeable DNA or  background  
contaminants  did  not pass  QC,  and  were  withheld from microarray analysis.  It should be 
noted that RNA samples with RIN scores of 6 and lower have been successfully used for 3’ 
microarrays (Hawrylycz et al. 2012) and exon microarrays (Trabzuni et al. 2011). 
6.3.3 Microarray processing and quality control 
The microarrays were processed at the Centre for Genomics Research in the University of 
Liverpool. 50ng of total RNA was amplified and labelled using the Agilent Low Input Quick 
Amp One-Colour Labeling Kit and labelled RNA was hybridized to Agilent SurePrint G3 
Custom Exon 8x60K Microarrays designed to contain probes for each exon of 936 selected 
genes, including all known SLC genes. Standard Agilent protocols were followed. The quality 
of the synthesized cRNA was assessed using an Agilent Bioanalyzer 2100—the resulting 
electropherograms were satisfactory.  Each scanned image was viewed for visible artefacts, 
and if multiple artefacts were present, the array was rejected. Detailed QC reports were 
generated for each array using the Feature Extraction 11.0.1.1 Software (Agilent, Palo Alto, 
CA). Based on these reports, we excluded arrays in which more than 1% of features were 
non-uniform outliers, or the average of the net signals in negative controls was >40, or the 
average of the background-subtracted signals in negative controls was <-10 or >5, or the 
standard deviation of the background-subtracted signals in negative controls was >10, or 
the residual noise after spatial detrending was >15, or the median coefficient of variation for 
spike-in probes or non-control probes was >12%, or the dose-response curve of the spike-
ins had a slope of <0.9 or >1.20, or the spike-in detection limit was <0.01 or >2. One array 
failed on five of these metrices and, hence, was excluded. Intensity data was extracted from 
the remaining arrays using the Feature Extraction Software. Spatial and multiplicative 
detetrending and local background substraction was applied.  
We employed an unbiased approach for the detection of outlier samples: samples with 
average inter-array correlation (IAC) ≤ 2 standard deviations below the mean were 
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removed. This approach has been used successfully in published studies (Yang et al. 2006; 
Flight & Wentzell 2010; Yang et al. 2012). 
6.3.4 Data normalization, adjustment and filtering 
Data exported from Feature Extraction Software was imported into GeneSpring GX Software 
(Agilent, Palo Alto, CA). Features which were population outliers, saturated or non-uniform 
were flagged as ‘Compromised’ and filtered out. Non-expressed probes were filtered out: a 
probe was deemed expressed only if it was flagged ‘Detected’ in at least 25% of control or 
case samples. Quantile normalization was applied. As GeneSpring does not include functions 
that allow adjusting for confounders and covariates, probe-level intensities were exported 
for further processing. 
Batch effect was corrected using the ComBat (Johnson et al. 2007) algorithm implemented 
in the SVA Bioconductor package. Eight arrays (four cases and four controls) were processed 
per slide; hence, each batch comprised the eight samples processed together on a slide. To 
adjust for known and unknown confounders, Independent Surrogate Variable Analysis 
(ISVA) (Teschendorff et al. 2011) was applied; RIN, age and sex were explicitly included in 
the ISVA adjustment. Where multiple probes mapped to the same gene, the probe with the 
highest variance was retained, as the most variant probe is likely to be most informative. 
6.3.5 Excluding probes-with-polymorphisms (PwP) 
Polymorphisms present in the probe-target sequences have been shown to alter probe 
hybridization affinities, leading to reduced signal intensity measurements and resulting in 
false-positive results (Ramasamy et al. 2013). We used the ‘PIP Finder’ tool (Ramasamy et al. 
2013) to determine which probes in our microarray had polymorphisms with a minor allele 
frequency >1% in Europeans located within the probe sequences; all such probes were 
excluded from the eQTL analysis in keeping with current practice. 
6.3.6 Assessing the influence of confounders 
To determine if there was residual confounding after data adjustment, we used the 
phenoTest Bioconductor package to test for association between probes and confounders 
(batch, RIN, age and sex). 
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6.3.7 DNA extraction 
Cortical brain samples were available for some subjects; DNA was extracted from these 
cortical samples using the DNeasy Blood & Tissue Kit (Qiagen, Crawley, United Kingdom) 
according to the manufacturer’s recommended protocol. For other subjects, for whom 
cortical brain samples were not available, DNA was extracted from hippocampal 
homogenate in QIAzol that was prepared during RNA isolation, according to the protocol 
provide by Qiagen: In 1ml of homogenate, 200µl of chloroform was added, shaken 
vigorously and incubated at room temperature for 3 minutes, followed by centrifugation at 
12,000xg for 15 min at 4°C. The upper, aqueous phase was transferred to a new tube and 
stored at -80oC for future use. To precipitate the DNA pellet, 0.3ml of 100% ethanol was 
added to the interphase and phenol phase, the sample was incubated at room temperature 
3 min, and then centrifuged at 2,000xg for 2 min at 4°C. The DNA pellet was washed twice in 
sodium citrate: for each wash 1 ml sodium citrate solution was added to the pellet, followed 
by incubation at room temperature for 30 min, with mixing by inversion every 5 min, and 
then centrifugation at 2000xg for 5 min at 4°C. The DNA pellet was then washed in 75% 
ethanol: 2 ml of 75% ethanol was added to the DNA pellet, followed by incubation at room 
temperature for 20 min, with mixing by inversion every 5 min, and then centrifugation at 
2,000xg for 5 min at 4°C. The DNA pellet was air-dried and then re-dissolved in 500µl of 
8mM NaOH. The solution was centrifuged at 14,000xg for 10 min at room temperature. The 
supernatant, containing the DNA, was removed. 60µl of 0.1M HEPES and 5.5µl of 100mM 
EDTA was added to the DNA solution. Extracted DNA was quantitated using the PicoGreen® 
dsDNA Quantitation Kit (Invitrogen, UK). 
6.3.8 Genotyping and Quality Control 
All samples were genotyped on the Illumina Infinium HumanOmniExpressExome BeadChip 
in the ARK Genomics facility at the Roslin Institute, UK 
Our quality control (QC) procedures were as follows. Individuals were excluded on the basis 
of discordance between reported and observed sex, SNP call rate <95%, outlying autosomal 
heterozygosity rates (>3 standard deviations from the mean), inadvertent subject 
duplication or cryptic relatedness based on pairwise identity-by-descent estimations (the 
individual with greater missing data was removed from each pair with -hat >0.1875), being 
outliers from the European cluster in a plot of the first two principal components of 
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genotypes for samples from the study and HapMap Phase III. Three individuals were 
excluded from the eQTL analysis on the basis of these QC filters, and one further individual 
was excluded from the eQTL analysis having failed the microarray QC criteria. SNPs were 
excluded on the basis of genotype missing rate ≥5% if minor allele frequency (MAF) was 
≥0.05 and missing rate ≥1% if MAF was <0.05, observed minor allele frequency <0.01, 
significant deviation (P <10−4) from Hardy-Weinberg equilibrium, significant difference (P 
<10−4) in the genotype missing rate in cases compared to controls, and all non-autosomal 
SNPs. 250,985 SNPs were excluded on the basis of these QC criteria. The final data-set, after 
QC filtering, included 22 controls and 22 cases genotyped over 550,043 SNPs. 
6.3.9 Imputation 
Genotype imputation was performed using Impute2(Howie et al. 2009), with 1000 Genomes 
Project haplotypes (March 2012) as the reference panel. The QCTOOL software was used to 
exclude SNPs with an ‘info’ score of <0.9. GTOOL software was then used to transform the 
imputed data to PED format, with a posterior probability of 0.9 used as a threshold to call 
genotypes. Our standard per-SNP QC filters, described above, were then applied. The final 
dataset included 4,663,226 genotyped and imputed SNPs. 
6.3.10 eQTL analysis 
eQTL analysis was performed using the linear model in the program Matrix eQTL (Shabalin 
2012). To investigate potential confounding effects from population stratification, the 
principal components (PC) of variance of the genotyping dataset were calculated using the 
package SNPRelate (Zheng et al. 2012), and then the Tracy-Widom (TW) statistic (Patterson 
et al. 2006) and significance for the eigenvalue of each PC was calculated using the package 
EigenCorr (Lee et al. 2011). Furthermore, the top ten PCs were separately correlated with 
the probe expression profiles in R. 
6.3.11 External validation of eQTL results 
We are aware of only one previously published eQTL study on human hippocampal tissue 
(Kim et al. 2012). In this study, 61 hippocampal samples were analysed in total, obtained 
from post-mortem donors with schizophrenia and normal controls. This study was limited to 
cis-eQTL analysis. In order to perform a comparison with this study, we also performed a cis-
eQTL analysis using the linear model in the program Matrix eQTL (Shabalin 2012). cis-eQTLs 
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were defined as eQTLs that map within 20kb upstream or downstream of the physical 
location of the probe on the genomic sequence. To find ‘conditional’ eQTLs—eQTLs which 
are active in either the normal or the pharmacoresistant partial epilepsy phenotype only—a 
further analysis was carried out which included phenotype as an interaction term in the 
model (Ackermann et al. 2013); this analysis was limited to significant cis-eQTLs only as the 
computational requirements for analysing all SNPs and probes were prohibitive. 
We calculated the statistical significance of the overlap between the cis-eQTL genes 
discovered in our study and the study by Kim and colleagues.   
6.3.12 Enrichment of eQTLs within significant GWAS results 
We wished to determine if significant GWAS SNPs are enriched with significant eQTLs. We 
calculated the number of significant eQTLs within ‘suggestive’ GWAS SNPs (those with a p-
value <5x10-5). We calculated the statistical significance of the size of this enrichment by 
using permutation-based methods. There were 403 suggestive SNPs within our GWAS. We 
employed two permutation-based methods: (1) we generated 10,000 random sets of 403 
GWAS SNPs and then determined how many sets were as (or more) enriched with eQTLs as 
the suggestive SNPs, and (2) the GWAS SNPs were sorted in descending order of statistical 
significance and divided into 10,000 sets of 403 SNPs each, and we then determined how 
many sets were as (or more) enriched with eQTLs as the suggestive SNPs.  
6.3.13 eQTL genes and disease-associated genes under eQTL influence 
We created a list of eQTL genes: eQTL SNPs within 20kb of the flanking sequence of a gene 
were mapped to the gene. We calculated the number of probes whose expression is 
effected by each eQTL gene.  We also determined how many disease-associated genes 
(genes differentially expressed at FDR<0.05 and FC≥1.5) are under significant eQTL 
influence, and how many eQTL genes influence each disease-associated gene. Gene 
ontology analysis of the most prominent eQTL genes and targets was done using Broad 
Institute’s Gene-Set Enrichment Analysis web-tool.  
6.3.14 Utilizing eQTL data to prioritize GWAS SNPs and reveal their functional 
implications: practical examples 
There were no SNPs associated at a genome-wide level of significance (p<5x10-8) in our 
GWAS of pharmacoresistant partial epilepsy. We demonstrated how the eQTL data we have 
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generated can be utilised in order to select genetic variants for further study from amongst 
the large number of SNPs with a ‘suggestive’ level of significance (p<5x10-5). We determined 
which of these suggestive SNPs are significant eQTLs and which of these eQTLs influence the 
expression of genes which are differentially-expressed in the pharmacoresistant epileptic 
hippocampus. Finally, based on a literature-review, we examined the potential functional 
importance of this latter set of genes. 
Similarly, we extracted from the online ‘Catalog of Published Genome-Wide Association 
Studies’ a list of SNPs associated with schizophrenia at a suggestive level of significance. 
Again, we determined if any of these suggestive SNPs are significant eQTLs according to our 
data. Finally, we extracted from the same online database a list of variants associated with 
schizophrenia at a genome-wide level of significance, determined which of these SNPs are 
significant eQTLs, and examined the potential functional importance of the genes under 
eQTL influence based on a literature-review. 
6.4 Results 
6.4.1 Final datasets 
The final genetic and genomic datasets included 22 cases and 22 controls. The participant 
characteristics are shown in Table 6.1. The final genetic dataset included 4,663,226 
genotyped and imputed SNPs. The final genomic dataset, after applying the variance-based 
filter described above and removing probes-with-polymorphhisms, included 18,916 unique 
probes. 
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Table 6.1 Sample characteristics. RIN=RNA Integrity Number. The sample labels used in 
Chapter 3 have been maintained. 
Sample Phenotype Age Sex RIN  Sample Phenotype Age Sex RIN 
D1 case 41 F 7.4 N1 control 81 M 6.5 
D2 case 23 F 6.8 N2 control 78 F 6.2 
D3 case 51 M 6 N3 control 84 F 6.6 
D4 case 49 F 6.9 N4 control 91 F 6.7 
D5 case 50 F 7.8 N5 control 88 M 6.3 
D6 Case 45 F 6.6 N6 control 38 M 6.1 
D7 Case 12 M 7 N7 control 50 M 6.2 
D8 Case 29 F 7.8 N8 control 45 M 6.3 
D9 Case 33 M 6.8 N9 control 39 M 6.1 
D11 Case 34 M 7 N10 control 40 M 6 
D12 Case 33 M 8.8 N11 control 61 M 6.2 
D14 Case 22 F 7.3 N12 control 63 F 6.2 
D15 Case 48 M 7.6 N13 control 66 M 6.2 
D16 Case 39 F 7.4 N14 control 22 F 6.3 
D17 Case 29 F 7.1 N15 control 27 M 6.3 
D18 Case 44 M 7.9 N16 control 45 M 6.9 
D19 Case 40 F 6.6 N18 control 50 M 6.5 
D20 Case 48 M 8.5 N19 control 43 M 6.6 
D21 Case 23 M 8.4 N20 control 46 M 6.8 
D22 Case 63 M 7.9 N21 control 51 M 6.2 
D23 Case 31 M 8.2 N22 control 48 M 6 
D24 Case 27 F 8.2 N23 control 43 M 6.6 
 
6.4.2 Adjustment for confounders and population stratification 
After ComBat and ISVA treatment of the genomic dataset, confounders had been adjusted 
for appropriately: we found that no probes were associated with RIN, age, batch or sex at an 
FDR<0.10 in the adjusted dataset. 
Similarly, we found no evidence of confounding effects from population stratification. The 
eigenvalues of none of the PCs reached statistical significance. Furthermore, none of the 
probe expression profiles were significantly correlated with any of the top ten PCs, 
demonstrating that the gene expression profile was not significantly influenced by 
population stratification in this cohort (Fairfax et al. 2012). Hence, the PCs were not 
included as covariates in the analysis. 
 
 
214 
 
6.4.3 External validation of eQTL results 
We are aware of only one previously published eQTL study on human hippocampal tissue 
(Kim et al. 2012). In this study, 61 hippocampal samples were analysed in total, obtained 
from post-mortem donors with schizophrenia and normal controls. This study was limited to 
cis-eQTL analysis. In order to perform a comparison with this study, we also performed a cis-
eQTL analysis. Kim and colleagues found 281 significant cis-eQTL genes. 55 of these genes 
were also significant cis-eQTLs in our study; this overlap is highly statistically significant 
(hypergeometric distribution p-value 1.9x10-34).  
We also determined which of our significant cis-eQTLs are ‘conditional’—eQTLs which are 
active in either the normal or the pharmacoresistant partial epilepsy phenotype only—by 
performing a further analysis which included phenotype as an interaction term in the 
model. We found that only 4% of significant cis-eQTLs in our study are conditional. 
6.4.4 cis- and trans-eQTLs 
We found 298,703 SNPs (6.4% of all genotyped or imputed SNPs included in the eQTL 
analysis) to be significant (FDR<0.05) cis- or trans-eQTLs. 7516 probes were under significant 
eQTL influence; 5680 of these probes correspond to protein-coding genes, and the 
remaining probes correspond to long non-coding RNAs. The full list of eQTL SNPs and 
associated probes is provided in the Appendix 13. 
6.4.5 Enrichment of eQTLs within significant GWAS results 
There were 403 ‘suggestive’ SNPs (p-value <5x10-5) in our GWAS; 53 (13%) of these were 
significant eQTLs. In comparison, from the 5,519,309 SNPs in our GWAS as a whole, 200,835 
(3.6%) were eQTLs. This difference is statistically significant (p-value <0.001 for one-tailed 
test for significance of the difference between two proportions). 
Similarly, the ‘suggestive’ GWAS SNPs were significantly enriched with eQTLs based on our 
permutation-based tests: p-value <0.0001 based on 10,000 sets of 403 random SNPs, and p-
value <0.009 based on 10,000 sets of 403 SNPs ordered according to GWAS statistical 
significance. 
 
 
215 
 
6.4.6 eQTL ‘hub’ genes 
We created a list of eQTL genes: eQTL SNPs within 20kb of the flanking sequence of a gene 
were mapped to the gene. The median number of probes influenced by each eQTL gene was 
7, with a range of 1 to 284. We consider eQTL genes influencing 100 or more probes to be 
‘hub’ genes. Out of all the eQTL genes, 0.7% (158 genes, see list in Appendix 14) were hub 
genes. Out of eQTL genes which were also associated with the phenotype at an empirical p-
value<0.05 in our GWAS, 0.9% were hub genes; this proportion is significantly different 
compared to the hub genes amongst all eQTL genes (p=0.02, test for equality of 
proportions). Out of eQTL genes which were also associated with the phenotype at an 
empirical p-value<0.005 in our GWAS, 1.6% were hub genes; this proportion is significantly 
different compared to the hub genes amongst all eQTL genes (p=4.2x10-7, test for equality 
of proportions). In order to gain an understanding of the biological processes eQTL hub 
genes are involved in, we performed gene ontology enrichment analysis using all 158 eQTL 
hub genes; the results are shown in Table 6.2. 
6.4.7 Disease-associated genes under eQTL influence 
Of the 1010 significantly (FDR<0.05 and FC≥1.5) differentially-expressed genes from our 
microarray (see Chapter 4), 369 genes are under significant eQTL influence (FDR<0.05); we 
term these 369 genes ‘differentially-expressed plus genetically-regulated (DE+GR)’. We 
found that 3569 eQTL genes significantly (FDR<0.05) effect the expression of the 369 DE+GR 
genes (9.7 eQTL genes per target DE+GR gene). 16429 genes significantly (FDR<0.05) affect 
the expression of the 7147 genes which are not differentially-expressed (2.3 eQTL genes per 
target gene). Hence, there are 4.2 fold greater eQTL genes converging on each differentially-
expressed gene; this difference is statistically significant (one-tail two-sample test for 
equality of proportions p-value < 2.2x10-16). The difference becomes even more prominent 
if we restrict the eQTL genes to those that are also associated with pharmacoresistant focal 
epilepsy in our GWAS: eQTL genes which are also associated with the pharmacoresistant 
focal epilepsy phenotype at an empirical p-value of <0.05 converge 4.5 fold more on genes 
which are differentially-expressed than on those not differentially-expressed, and eQTL 
genes which are associated with the pharmacoresistant focal epilepsy phenotype at an 
empirical p-value of <0.005 converge 5 fold more on genes which are differentially-
expressed than on those not differentially-expressed 
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Table 6.2 Biological processes enriched with eQTL hub genes. GO=gene ontology 
GO Biological Process GO 
Accession 
FDR 
Extracellular structure organization and biogenesis GO:0043062 1.19x10-9 
Synaptogenesis GO:0007416 1.44x10-9 
Synapse organization and biogenesis GO:0050808 5.18x10-9 
Nervous system development GO:0007399 0.000106 
Anatomical structure development GO:0048856 0.000209 
System development GO:0048731 0.000209 
Synaptic transmission GO:0007268 0.000575 
Cell-cell signalling GO:0007267 0.000718 
Transmission of nerve impulse GO:0019226 0.000718 
Multicellular organismal development GO:0007275 0.000865 
Anti-apoptosis GO:0006916 0.000865 
Regulation of developmental process GO:0050793 0.00097 
Negative regulation of cellular process GO:0048523 0.00208 
Negative regulation of apoptosis GO:0043066 0.00208 
Negative regulation of programmed cell death GO:0043069 0.00208 
Negative regulation of biological process GO:0048519 0.00245 
Cell development GO:0048468 0.00461 
Negative regulation of developmental process GO:0051093 0.00608 
Signal transduction GO:0007165 0.00827 
Regulation of apoptosis GO:0042981 0.00827 
Regulation of programmed cell death GO:0043067 0.00827 
Generation of precursor metabolites and energy GO:0006091 0.00942 
Neurological system process GO:0050877 0.0131 
Defence response GO:0006952 0.0194 
Negative regulation of cell proliferation GO:0008285 0.0204 
Apoptosis go GO:0006915 0.0221 
Programmed cell death GO:0012501 0.0221 
Biopolymer metabolic process GO:0043283 0.0271 
Lipid metabolic process GO:0006629 0.0367 
Regulation of gene expression GO:0010468 0.039 
Positive regulation of transcription factor activity GO:0051091 0.0425 
Positive regulation of DNA binding GO:0043388 0.0483 
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6.4.8 Utilizing eQTL data to prioritize GWAS SNPs and reveal their functional 
implications: practical examples 
There were 403 SNPs within our GWAS with a ‘suggestive’ level of significance (p<5x10-5). 53 
of these SNPs were also significant (FDR<0.05) eQTLs in our genetical genomics study (see 
Appendix 14 for full list). From these 53 SNPs, one (rs11163824) was chosen as an example 
to demonstrate how eQTL data can be used to prioritize GWAS SNPs and reveal their 
functional implications. 
We extracted from the online ‘Catalog of Published Genome-Wide Association Studies’ a list 
of 125 SNPs associated with schizophrenia at a suggestive or genome-wide level of 
significance (see Appendix 14). Six of these SNPs are significant eQTLs according to our data 
(see Appendix 14). One SNP (rs11038167) associated with schizophrenia (Yue et al. 2011) at 
a genome-wide level of significance (p-value 1x10-11), is an eQTL according to our data. This 
SNP has a significant influence on the expression levels of genes SYNDIG1L and RFX4 
according to our study. We examined the potential functional importance of these genes 
through a literature-review. 
6.5 Discussion 
We present the first ever study to analyse trans-eQTLs in human hippocampal tissue and the 
first ever eQTL study to include epileptic human brain tissue. 
6.5.1 External validation and comparison 
Before proceeding to draw conclusions from our study, we have carried out external 
validation of our results. We are aware of only one previously published eQTL study on 
human hippocampal tissue (Kim et al. 2012). In this study, 61 hippocampal samples were 
analysed in total, obtained from post-mortem donors with schizophrenia and normal 
controls. This study was limited to cis-eQTL analysis. In order to perform a comparison with 
this study, we also performed a cis-eQTL analysis. Kim and colleagues found 281 significant 
cis-eQTL genes. Our study uncovered 577 cis-eQTL genes (not including lincRNAs, which 
were not assayed in the study by Kim and colleagues).  
Firstly, it is worth considering why we have discovered a much higher number of cis-eQTLs 
than Kim et al. One potential reason is than Kim and colleagues’ study included only 309,531 
SNPs, while our analysis included 4,663,227 SNPs. There are 15-fold fewer SNPs in Kim and 
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colleagues’ study and, hence, in their analysis there are likely to be more genes without 
SNPs within or near them. The 15-fold greater SNP coverage in our study also means that 
we are likely to capture associated genetic variants which are not covered in Kim and 
colleagues’ SNP panel. It should be noted that although we include 15-fold higher SNPs in 
our analysis, we only discover 2.3-fold more cis-eQTL genes. This suggests that our multiple-
testing correction methodology adequately controls the false-discovery rate from the 
significantly higher number of tests in our analysis. 
It may be argued that the overlap between the significant cis-eQTL genes from our study 
and Kim and colleagues’ study is small. However, this overlap is highly statistically significant 
(hypergeometric distribution p-value 1.9x10-34) and, hence, unlikely to be a chance 
occurrence.  
On the other hand, it may be argued that such a significant overlap between two eQTL 
studies on tissue from two different pathologies is unexpected. By including phenotype as 
an interaction term in our eQTL analysis model, we were able to show that only 4% of 
significant cis-eQTLs are ‘conditional’. Conditional eQTLs influence gene expression in only 
one of the two conditions in our study. The remaining 96% of significant cis-eQTLs are 
‘static’—they influence gene expression under any condition. In addition to this, it is being 
increasingly recognised that schizophrenia and epilepsy have common underlying causal 
mechanisms, including genetic mechanisms (Chang et al. 2011). Hence, it is possible that 
some of the conditional eQTLs relevant to epilepsy are also relevant to schizophrenia.  
6.5.2 eQTLs and their targets: characteristics and patterns 
We found that eQTLs are enriched within the most significantly trait-associated SNPs from 
our GWAS of pharmacoresistant partial epilepsy. This is consistent with the previously 
published observation that, in complex diseases, truly trait-associated SNPs are more likely 
to be eQTLs (Nicolae et al. 2010). This feature can be exploited in order to select genetic 
variants for further study from amongst a large number of SNPs with a ‘suggestive’ level of 
significance, as demonstrated in an example below. 
It is worth noting that not all eQTL genes and the genes under their influence (‘target 
genes’) have an exclusive one-to-one relationship; one-to-many and many-to-one 
relationships are a prominent feature of the genetic regulation of gene expression.  
 
 
219 
 
We found 158 eQTL-hub genes which effect the expression of 100 or more target genes 
each. These eQTL-hubs are likely to be of particular importance in the genetic regulation of 
gene expression and clinical traits. As shown in Table 6.2, the eQTL-hubs are enriched in 
many regulatory processes, such as ‘regulation of gene expression’ and ‘regulation of 
apoptosis’. The proportion of eQTL-hubs increased significantly amongst genes which were 
more strongly associated with the phenotype in our GWAS analysis. 
On the other hand, multiple eQTL genes often converge on the same target gene. We found 
that the number of convergent eQTL genes is significantly greater if the target gene is 
disease-linked (differentially-expressed in diseased tissue). We found that there were, on 
average, 9.7 eQTL genes targeting each DE+GR gene, which was over four fold greater than 
the number of eQTL genes targeting non-differentially expressed genes. This fold difference 
became even more prominent if we limited our analysis to those eQTL genes which are 
more strongly associated with the disease in our GWAS analysis. Similar patterns have 
previously been noted within eQTLs in the peripheral blood (Fehrmann et al. 2011). It has 
previously been suggested (Fehrmann et al. 2011) that for a particular phenotype the 
different associated genetic variants eventually converge on the same downstream target 
genes; our results are consistent with this observation. 
Taken together, the above observations suggest that in the pharmacoresistant epileptic 
human hippocampus: (1) genetic variants most significantly associated with the clinical 
phenotype are more likely to be eQTLs, (2) genes more significantly associated with the 
clinical phenotype are more likely to be eQTL-hubs, and (3) genes which are differentially 
expressed in this phenotype are under the influence of significantly higher numbers of 
disease-associated eQTLs. This demonstrates that the eQTLs identified in our study are 
relevant to the clinical phenotype. 
6.5.3 Applying the eQTL data 
In complex diseases, truly trait-associated SNPs are more likely to be eQTLs (Nicolae et al. 
2010). This feature can be exploited in order to select genetic variants for further study from 
amongst a large number of SNPs with a ‘suggestive’ level of significance. From the SNPs with 
a suggestive level of significance (p<5x10-5) in our pharmacoresistant epilepsy GWAS ‘mega-
analysis’, 53 SNPs were also significant (FDR<0.05) eQTLs in our genetical genomics study. 
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One of these 53 SNPs, rs11163824, was associated with the expression of gene ALDH5A1, 
which was significantly down regulated (FDR<0.05) in our microarray study. It is interesting 
to note that rs11163824 lies within a long non-coding RNA (lincRNA:chr1:84106887-
84316837). It can be postulated that altered activity of this lincRNA leads to differential 
expression of ALDH5A1. ALDH5A1 (also known as succinic semialdehyde dehydrogenase) is 
involved in the degradation of the inhibitory neurotransmitter GABA and patients with 
ALDH5A1 deficiency (an autosomal recessive disorder) suffer from seizures (Lorenz et al. 
2006). Furthermore, genetic variations within ALDH5A1 were among a set of SNPs found to 
contribute to disease predisposition in sporadic epilepsy (Cavalleri et al. 2007). 
As shown above, epilepsy and schizophrenia share many eQTLs. Hence, our dataset will 
prove useful for the study of schizophrenia and other diseases in which the hippocampus is 
affected. As an example, one SNP (rs11038167) associated with schizophrenia at a genome-
wide level of significance (p-value 1x10-11) in a previous study (Yue et al. 2011) is an eQTL 
according to our data. This SNP lies within the TSPAN18 gene and has a significant influence 
on the expression levels of genes SYNDIG1L and RFX4 according to our dataset. We 
examined the potential functional importance of these genes through a literature-review. 
TSPAN18 encodes one member of a large family of transmembrane proteins (tetraspanins) 
found in all multicellular eukaryotes. Expressed widely and in diverse cell types, the 
tetraspanins appear to affect cellular penetration, adhesion, motility, and signal conduction, 
and are thought to be influential in diverse physiologic processes and diseases (Charrin et al. 
2009; Rubinstein 2011). TSPAN18 genetic variants have been associated with both bipolar 
disorder and schizophrenia (Scholz et al. 2010; Yue et al. 2011). RFX4 is a transcription factor 
and is differentially expressed in patients with schizophrenia (Glatt et al. 2011). 
Interestingly, RFX4 is located in the linkage region of bipolar affective disorder (Ewald et al. 
1998) and schizophrenia (Holmans et al. 2009), and a RFX4 haplotype confers bipolar 
disorder disease risk (Glaser et al. 2005). SYNDIG1L is the Synaptic Differentiation Induced 
Gene I-Like gene. SYNDIG1 encodes a novel postsynaptic transmembrane protein that plays 
a critical role in excitatory synapse development (Diaz 2010). 
6.6 Conclusions 
We have presented the first ever study to analyse trans-eQTLs in human hippocampal tissue 
and the first ever eQTL study to include epileptic human brain tissue. We have shown that 
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these eQTLs are relevant to disease: genetic variants most significantly associated with the 
clinical phenotype are more likely to be eQTLs, genes more significantly associated with the 
clinical phenotype are more likely to be eQTL-hubs, and genes which are differentially 
expressed in this phenotype are under the influence of significantly higher numbers of 
disease-associated eQTLs. We have also identified the most enriched biological processes 
for eQTL-hubs. Finally, we have demonstrated how this eQTL dataset can be utilized in order 
to interpret and prioritize GWAS results from epilepsy and other disease. 
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Chapter 7: Testing the Intrinsic Severity Hypothesis 
and Identifying the Causal Pathways Underlying 
Intrinsic Severity 
7.1 Introduction 
In the current chapter, I will integrate the data and results from the previous chapters in 
order to present a combined view of the genetic and genomic changes which underlie 
pharmacoresistance in epilepsy. 
The analyses presented in the preceding chapters demonstrate that underlying epilepsy 
pharmacoresistance, at both genetic and transcriptomic levels, are diverse pathways and 
processes pertaining to disparate domains, such as axon guidance, neuroinflammation, 
transmembrane transport of small molecules and synaptic neurotransmitter release 
machinery. This observation lends credence to the intrinsic severity hypothesis of 
pharmacoresistance in epilepsy, which states that pharmacoresistance is the results of 
increased dysfunction of the neurobiological processes underlying epilepsy (please see 
Chapter 1 for a detailed discussion of this hypothesis). It has previously been suggested that 
genetic variations are likely to be key components of the biological factors that mediate 
increased severity and intractability (Rogawski 2013). The results presented in Chapters 5 
and 6 tend to support this suggestion, but this idea has never been objectively examined. In 
this chapter, I will objectively test the hypothesis that pharmacoresistance is the result of 
accumulation of deleterious genetic variations of increasing severity and/or numbers within 
the genes that constitute the core pathways and processes underlying epilepsy. In order to 
achieve this aim, I will first create a gene-set that represents the main pathways and 
processes underlying epilepsy, and then determine if this gene-set is more enriched in a 
GWAS of pharmacoresistant epilepsy than in a GWAS of pharmacoresponsive epilepsy. 
Following on from the above analysis, I will identify the ‘causal’ pathways underlying 
pharmacoresistant epilepsy, using the data presented in the previous chapters.  
 
 
 
228 
 
7.2 Aims 
I. To test the hypothesis that pharmacoresistance is the result of accumulation of 
deleterious genetic variations of increasing severity and/or numbers within the 
genes that constitute the core pathways and processes underlying epilepsy.   
II. To identify the causal pathways underlying pharmacoresistance in epilepsy.  
7.3 Methods 
7.3.1 Methods overview 
We wished to demonstrate that pharmacoresistance is the result of accumulation of 
deleterious genetic variations of increasing severity and/or numbers within the genes that 
constitute the core pathways and processes underlying epilepsy. In order to show this, we 
first identified the single most functionally-relevant gene-set in the epileptic human 
hippocampus and then determined if this was affected by genetic variation more in drug 
resistant than in drug responsive epilepsy. Putative functionally-relevant gene-sets were 
identified by performing Weighted Gene Co-expression Network Analysis (WGCNA) 
(Langfelder & Horvath 2008) on our microarray data from Chapter 4, and the most 
important gene-set was chosen (see below for details). In order to identify the genetic 
variations associated with drug responsive epilepsy, a genome-wide association study 
(GWAS) was performed of drug responsive epilepsy. Similarly, in order to identify the 
genetic variations associated with drug resistant epilepsy, a GWAS was performed of drug 
resistant epilepsy. We then compared the degree of enrichment of the functionally-relevant 
gene-set in the two GWAS. Finally, in order to perform a head-to-head comparison of drug 
responsive and resistant partial epilepsy, a GWAS of drug responsive versus resistant partial 
epilepsy was performed. 
In order to identify ‘causal’ pathways, we determined the Reactome pathways enriched in 
genes which are significant in the pharmacoresistant focal epilepsy GWAS and are also 
significant eQTLs for differentially-expressed genes. We also identified ‘intermediate’ 
pathways: the Reactome pathways enriched in genes which are genetically regulated by 
eQTLs and are also differentially expressed in the pharmacoresistant epileptic hippocampus.  
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7.3.2 Weighted Gene Co-expression Network Analysis (WGCNA) 
The microarray data was adjusted for batch effects and for known and unknown 
confounders using ComBat and ISVA, as described in Chapter 4. Including all microarray 
probes in the WGCNA was not computationally feasible: the time and memory 
requirements were both prohibitive. Hence, the probes were sequentially filtered as 
follows: (1) only probes mapping to genes with valid current Entrez numbers and HUGO 
Gene Nomenclature Committee gene symbols were retained, (2) where multiple probes 
mapped to the same gene, the most variant probe only was retained, (3) 75% of the probes 
with the highest variance were retained. Hence, after filtering, 13,367 probes with high 
variance remained, each mapping to a unique gene. 
WGCNA was performed using the WGCNA R package according to the authors’ instructions. 
WCGNA network construction and module detection was carried out using the one-step 
automatic network construction and module detection approach, with a soft threshold of 
β=9 and a minimum module size of 30. The most important module, from amongst those 
detected, was identified using techniques devised and validated by the authors of WGCNA 
(Langfelder & Horvath 2008) and used successfully by others. Briefly, the most important 
module was identified based on (a) the significance of its association with the phenotype of 
interest and lack of association with confounders, and (b) the strength of the correlation 
between module membership and gene significance. Gene significance of a gene is defined 
as {GeneSignificance(i)=|cor(xi, T)|} where xi is the gene expression profile of Gene i and T is 
the trait of interest. The module membership of a gene is the correlation between its gene 
expression profile and module eigengene of a given module; the module eigengene 
corresponds to the first principal component of a given module. 
Pathway-enrichment analysis for the most important module was performed using the 
Reactome database on the Gene Set Enrichment Analysis website. 
7.3.3 External validation of the chosen WGCNA module 
Before using the chosen WGCNA module in our own GWAS gene-set enrichment analysis, 
we validated the module using an independent previously published partial epilepsy GWAS 
dataset (Kasperaviciute et al. 2010). Complete genome-wide results for this study were 
downloaded from the authors’ website. The size of our chosen WGCNA module was 1594 
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genes. The rest of the genome was divided into 12 random gene-sets of 1594 genes. The 
chosen WGCNA module and the 12 random gene-sets were then tested for enrichment in 
the previously published independent GWAS using the GSA-SNP software. 
7.3.4 GWAS study cohorts 
Three GWAS analyses were carried out: 
i. Drug responsive partial epilepsy versus normal population controls (NPC) 
ii. Drug resistant partial epilepsy versus NPC 
iii. An extreme discordant phenotype (EDP) analysis: Drug resistant versus drug 
responsive partial epilepsy 
The epilepsy cases used in the drug responsive cohort were from amongst the patients 
recruited into the Standard and New Antiepileptic Drugs (SANAD) trial (Marson et al. 2007); 
this study has been described in detail in Chapter 5. For the purposes of this analysis, 
subjects were said to have drug responsive epilepsy if they entered 12-month remission 
immediately upon starting treatment. On this basis, 155 subjects from the SANAD study 
were classified as having drug responsive partial epilepsy. The epilepsy cases used in the 
drug resistant cohort were from amongst the patients recruited into the SANAD and 
‘Pharmacogenetics of GABAergic Mechanisms of Benefit and Harm in Epilepsy’ studies; 
these studies have been described in detail in Chapter 5. We utilized subjects included in 
our ‘mega-analysis’ (please see Chapter 5 for details). The definitions of drug resistance 
used in our analysis have been stated in Chapter 5. The control dataset consisted of subjects 
from the Wellcome Trust Case Control Consortium (WTCCC) 1958 British Birth Cohort 
(dataset EGAD00000000022). We used the 2624 subjects passing our quality control (QC) 
filters, as described in Chapter 5. 
7.3.5 GWAS genotyping and QC 
The genotyping and QC procedures employed have been detailed in Chapter 5.  
After per-individual QC, 146 cases remained in the drug responsive cohort. In order to allow 
a fair comparison, for the drug resistant partial epilepsy versus NPC analysis, 146 cases were 
chosen at random from the 421 total subjects in the drug resistant cohort. Hence, the final 
drug responsive partial epilepsy versus NPC dataset included 146 cases and 2624 normal 
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controls, and the final drug resistant partial epilepsy versus NPC dataset similarly included 
146 cases and 2624 normal controls. The EDP analysis included 146 drug responsive and 421 
drug resistant subjects. 
After per-SNP QC, there were 510501 SNPs in the drug responsive cohort and 509534 SNPs 
in the drug resistant cohort. In order to allow a fair comparison, both datasets were reduced 
to the 509534 SNPs which were common to both cohorts. 
7.3.6 Association and gene-set analysis 
Association analysis was performed using the chi-squared (2) test in Plink. In order to 
ensure consistency in correcting for inflation due to population stratification, the genomic 
control method, which has proven effectiveness (Bouaziz et al. 2011), was applied to both 
the drug responsive partial epilepsy versus NPC analysis and the drug resistant partial 
epilepsy versus NPC analysis. 
We tested the chosen WGCNA module for enrichment in three GWAS analyses using the 
program GSA-SNP. 
7.3.7 Causal genes and pathways 
The step-wise scheme for identifying causal genes is illustrated in Figure 7.1. In this 
approach, potentially causal genes are those that are (1) disease-associated, (2) eQTLs, and 
(3) influence the transcript levels of genes differentially-expressed in pharmacoresistant 
epilepsy. 
SNPs within 20kb of the flanking sequence of a gene were mapped to the gene. The results 
of the GWAS mega-analysis (Chapter 5) were used to identify disease-associated genes. In 
order to select a GWAS p-value cut-off for defining disease associated genes, we created 
sets of genes at various GWAS p-values cut-offs (0.05, 0.005, 0.0005), and then determined 
how enriched each set was with disease-specific eQTLs (eQTLs which regulate differentially-
expressed genes). After this process, we used an empirical p-value <0.005 cut-off to define 
disease-associated genes. Then, we retained the subset of disease-associated genes which 
are significant eQTLs (Chapter 6). Then, we retained the subset of eQTLs which regulate 
differentially-expressed genes (DEGs) identified through microarray analysis (Chapter 4); 
this final subset (721 genes) represents causal genes. 
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Figure 7.1 Step-wise scheme for the identification of causal genes. First, we used Genome-
Wide Association Study (GWAS) to identify diseased-associated genes (DAGs)—those 
bearing SNPs associated with the clinical phenotype. Then, we retained the subset of DAGs 
which are significant expression quantitative trait loci (eQTL) genes. Then, we retained the 
subset of eQTLs which regulate differentially-expressed genes (DEGs) identified through 
microarray analysis; this subset represents causal genes. 
 
As our initial GWAS empirical p-value<0.005 cut-off could be considered somewhat 
arbitrary, we determined if the chosen 721 genes were significantly associated with the 
pharmacoresistant focal epilepsy phenotype at the gene-set level, by analysing the 721 
genes as one set in the program GSA-SNP. For comparison, we divided the rest of the 
genome into 25 gene-sets of 721 genes and analysed them similarly in GSA-SNP.  
We performed Reactome pathway enrichment analysis on this set of 721 genes using the 
Gene Set Enrichment Analysis website. These pathways were designated ‘causal’ pathways, 
as they are likely to represent the genetic changes which influence the transcriptomic 
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intermediate phenotype which, in turn, contributes to the development of the clinical 
phenotype. Enrichment Map (Merico et al. 2010) tool was used to determine the 
connections between enriched pathways. Enrichment Map was used with default settings.  
Betweenness centrality network analysis was used to identify the most central pathways in 
this network. 
7.3.8 Intermediate genes and pathways  
We collated the list of genes which are under significant (FDR<0.05) eQTL control of causal 
genes and significantly differentially expressed (FDR<0.05 and FC≥1.5) in pharmacoresistant 
epileptic tissue. We performed Reactome pathway enrichment analysis on this set of genes 
using the Gene Set Enrichment Analysis website. These pathways were designated 
‘intermediate’ pathways, as they are likely to represent the true transcriptomic 
intermediate phenotype which contributes to the development of the clinical phenotype of 
interest. Enrichment Map (Merico et al. 2010) tool was used to determine the connections 
between enriched pathways. Enrichment Map was used with default settings. 
7.4  Results 
7.4.1 WGCNA  
WGCNA revealed 18 distinct modules. Out of the 18 modules detected, the blue module 
was deemed most relevant and important because (1) it was the module most significantly 
(p-value=7.1x10-7) associated with the phenotype, and it was not associated with any 
confounders (Appendix 15), and (2) module membership in the blue module was highly 
correlated with gene-significance (correlation=0.94, p<1x10-200, Figure 7.2). The genes 
included in the blue module, and all other detected modules, are tabulated in the Appendix 
15. The Reactome pathways enriched in the blue module are also listed in the Appendix 15. 
7.4.2 External validation of the chosen WGCNA module  
We tested the blue module and 11 other random gene-sets of equal size for enrichment 
within the results of a previously published GWAS study of partial epilepsy. We found that 
while the blue module was highly significantly enriched in this GWAS analysis (FDR<3x10-17), 
none of the other gene-sets showed significant enrichment (minimum FDR 0.15); the gene-
set enrichment analysis results can be found in the Appendix 15. 
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7.4.3 GWAS analyses of drug responsive and drug resistant epilepsy  
The quantile-quantile (QQ) plots of the GWAS analysis of drug responsive partial epilepsy 
versus NPC and drug resistant partial epilepsy versus NPC are shown in the Appendix 15. 
Gene-set analysis of the blue module showed that there was greater enrichment for these 
genes in the drug resistant (p=2.6x10-14) than in the drug responsive (p=1.1x10-9) GWAS 
study.  
The genomic inflation factor (1.01) and the QQ plot (Figure 7.3) for the EDP GWAS study 
showed that there no significant inflation in the results and, hence, the no further 
adjustments were applied to the analysis. Gene-set analysis showed significant enrichment 
(p<8.5x10-10) of the blue module in the EDP GWAS analysis.  
7.4.4 Causal genes and pathways 
We found 721 genes that associated with the pharmacoresistant focal epilepsy phenotype 
in our genome-wide genetic-association (GWAS) analysis at an empirical p-value <0.005 and 
were also significant (FDR<0.05) eQTLs for differentially-expressed genes. This particular 
GWAS p-value cut-off was chosen for the following reason: as increasingly stringent GWAS 
p-values are used, the proportion of selected genes which are also eQTLs for DEGs 
increases; GWAS p-value <0.005 is the final cut-off at which this proportion is significantly 
increased compared to more lenient cut-offs (Bonferroni corrected p-value 6.7x10-16 for 2-
sample test for equality of proportions). We also determined if these 721 genes were 
significantly associated in the pharmacoresistant epilepsy GWAS at the gene-set level. These 
721 genes were significantly associated with the pharmacoresistant focal epilepsy 
phenotype at the gene-set level (FDR<5x10-20), while 25 random sets of 721 genes were not 
(minimum FDR=0.7). We performed Reactome pathway enrichment analysis on this set of 
721 genes. We term these enriched pathways ‘causal’ pathways—the 10 most enriched 
pathways are shown in Table 7.1 and the complete list in the Appendix 15. Enrichment Map 
analysis revealed a highly interconnected network of pathways (Figure 7.4). In this network, 
each pathway is directly connected to, on average, 9 other pathways. In order to identify 
the most central ‘hub’ pathways, ‘betweeness centrality’ network analysis was performed; 
the top 10 most central pathways are listed in Table 7.2, and the complete ranked list can be 
found in the Appendix 15. 
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Figure 7.2 Module membership versus gene significance for the blue module 
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 Table 7.1 The 10 most enriched ‘causal’ pathways: enriched Reactome pathways for 721 
genes that are significant (FDR<0.05) eQTLs for differentially-expressed genes and also 
significantly associated with the pharmacoresistant focal epilepsy phenotype at the gene-
level (empirical p-value <0.005) and gene-set level (FDR<5x10-20). 
Pathway P-Value FDR 
Signalling by NGF 5.66x10-9 3.81x10-6 
Axon guidance 4.40x10-8 1.48x10-5 
Developmental biology 2.21x10-7 4.95x10-5 
GPVI-mediated activation cascade 1.28x10-6 1.99x10-4 
Regulation of signalling by CBL 1.47x10-6 1.99x10-4 
Nephrin interactions 2.62x10-6 2.94x10-4 
Metabolism of lipids and lipoproteins 3.59x10-6 3.46x10-4 
p75-neurotrophin receptor mediated signalling 4.38x10-6 3.69x10-4 
Netrin1 signalling 7.07x10-6 4.97x10-4 
Transmembrane transport of small molecules 7.37x10-6 4.97x10-4 
 
Table 7.2 Top 10 central causal pathways 
Pathway 
Transmembrane transport of small molecules  
DCC mediated attractive signalling  
Axon guidance  
Cell-cell communication  
Developmental biology  
Signalling by NGF  
Immune system  
TIE2 signalling  
Signalling by constitutively active EGFR  
CREB phosphorylation through the activation of RAS  
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Figure 7.3 Quantile-quantile plot for extreme discordant phenotype genome-wide genetic association analysis 
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 Figure 7.4 Network of causal pathways. Major functional groups of pathways are labelled. 
  
Transmembrane transport 
of small molecules 
Axon guidance 
Activation of 
NMDA receptor 
upon glutamate 
binding and 
postsynaptic 
events 
Signal transduction 
Immune 
system 
Metabolism 
Haemostasis 
Cell-cell communication 
 
 
239 
 
7.4.5 Intermediate genes and pathways 
We collated the list of genes which are both differentially expressed (FDR<0.05 and FC≥1.5) 
and significantly (FDR<0.05) regulated by causal genes. Of the 1010 genes which are 
differentially expressed (FDR<0.05 and FC≥1.5), the expression of 369 (37%) is significantly 
(FDR<0.05) influenced by causal genes (see list in Appendix 15). This set of 369 genes is 
highly functionally coherent, being enriched (FDR<0.05) with 58 Reactome pathways. We 
term these enriched pathways ‘intermediate’ pathways—the 10 most enriched pathways 
are shown in Table 7.3, and the full list of 58 enriched pathways is tabulated in the Appendix 
15. Enrichment Map analysis revealed a highly interconnected network of pathways (Figure 
7.5). In this network, each pathway is directly connected to, on average, 10 other pathways.  
Table 7.3 Top 10 ‘intermediate’ pathways: enriched Reactome pathways for 369 
differentially-expressed genetically-regulated genes 
Pathway p-value FDR 
Transmembrane transport of small molecules 2.22x10-16 1.50x10-13 
Neuronal system 6.66x10-16 2.24x10-13 
Class A1 rhodopsin-like receptors 4.00x10-15 8.98x10-13 
Signalling by GPCR 1.13x10-14 1.91x10-12 
GPCR downstream signalling 7.33x10-14 9.88x10-12 
SLC-mediated transmembrane transport 9.53x10-14 1.07x10-11 
GPCR ligand binding 1.16x10-12 1.12x10-10 
Transport of inorganic cations, anions and amino acids oligopeptides 2.34x10-12 1.97x10-10 
Transmission across chemical synapses 3.74x10-12 2.80x10-10 
Axon guidance 2.63x10-10 1.77x10-8 
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Figure 7.5 Network of intermediate pathways. Major functional groups of pathways are 
labelled. 
 
7.5  Discussion 
Our first task was to objectively test the hypothesis that pharmacoresistance is the result of 
accumulation of deleterious genetic variations of increasing severity and/or numbers within 
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the genes that constitute the core pathways and processes underlying epilepsy. In order to 
achieve this aim, we first created a gene-set that represents the main pathways and 
processes underlying epilepsy, and then determined:  
1. If this gene-set is more enriched in a GWAS of pharmacoresistant epilepsy than in a 
GWAS of pharmacoresponsive epilepsy 
2. If this gene-set is enriched in a GWAS of pharmacoresponsive vs pharmacoresistant 
epilepsy. 
7.5.1 Creating a gene-set that represents the main pathways and processes underlying 
epilepsy 
It has previously been shown in a number of studies that WGCNA can identify functionally 
and causally relevant gene modules. For example, it has been demonstrated that a 
significant WGCNA module from a microarray study of mouse weight is enriched with eQTLs 
for mouse weight (Ghazalpour et al. 2006). Similar to our findings in epilepsy, Roussos and 
colleagues found that WGCNA modules from transcriptomic profiling of post-mortem brain 
samples in schizophrenia are enriched in an independent schizophrenia GWAS (Roussos et 
al. 2012).  
Before using the selected WGCNA module for testing our hypothesis, we took two steps to 
‘validate’ it—we confirmed that it was a functionally relevant and causally significant gene-
set: 
1. We analysed the Reactome pathways enriched in this module (please see Appendix 
15), and found that they were appropriate and consistent with our previous 
pathways analyses in Chapters 1, 4, 5 and 6.  
2. We demonstrated that this module was highly enriched in an independent 
previously published GWAS of partial epilepsy, while 12 random gene-sets of equal 
size were not. 
7.5.2 Testing our hypothesis using GWAS enrichment analysis 
We showed that the selected WGCNA module was significantly enriched in the 
pharmacoresponsive epilepsy GWAS (p=1.1x10-9), but considerably more enriched in the 
pharmacoresistant epilepsy GWAS (p=2.6x10-14). To ensure that the comparison was fair, 
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both GWAS datasets had genotype data for the same SNPs and the same normal population 
control samples and the same number of disease samples. Additionally, in order to ensure 
consistency in correcting for inflation due to population stratification, the stringent genomic 
control method, which has proven effectiveness (Bouaziz et al. 2011), was applied to both 
the GWAS analyses. In the genomic control method, one calculates the λGC (the ratio of the 
observed-to-expected median 2 test statistic) and divides all of the test statistics by the 
λGC (Devlin & Roeder 1999).  
The above findings suggest that the same gene-set potentially plays a causal role in both 
pharmacoresponsive and pharmacoresistant epilepsy, but is considerably more enriched 
with genetic variations in the latter condition. This lends support to our hypothesis that 
pharmacoresistance is the result of accumulation of deleterious genetic variations of 
increasing severity and/or numbers within the genes that constitute the core pathways and 
processes underlying epilepsy. 
To confirm that there is a significant difference in the burden of genetic variations within 
this gene-set between the two conditions, we performed a further ‘extreme discordant 
phenotype’ GWAS analysis with pharmacoresistant cases and pharmacoresponsive controls; 
the gene-set was highly enriched in this analysis. 
7.5.3 Causal pathways 
It has previously been suggested that an eQTL that maps to a disease locus can be 
considered a likely causal gene underlying the disease (Thessen Hedreul et al. 2013). We 
have advanced this concept in two novel respects: 
1. We have made this concept more stringent by only including eQTLs that target 
significantly differentially expressed genes (FDR<0.05, fold change ≥ 1.5) in the 
disease tissue. 
2. We have extended this concept to the gene-set and pathway level, by identifying the 
pathways enriched within the causal genes. 
 
721 genes fulfilled the criteria of being significantly associated with the pharmacoresistant 
focal epilepsy phenotype at the gene-level (empirical p-value <0.005) and gene-set level 
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(FDR<5x10-20), and also being significant (FDR<0.05) eQTLs for differentially-expressed 
genes. 61 Reactome pathways were enriched within these 721 genes.  
The 61 enriched Reactome pathways form a highly interconnected network, which is shown 
in Figure 7.4 with the major groups labelled. This figure illustrates the major causal 
processes in pharmacoresistant epilepsy, for example immune system and activation of 
NMDA receptors. The 10 most enriched individual pathways are shown in Table 7.1, and the 
10 most central pathways are shown in Table 7.2  
7.5.4 Intermediate genes and pathways  
Table 7.4 Pathways which are both causal and intermediate. 
Pathway 
Axon guidance 
CREB phosphorylation through the activation of RAS 
Cytokine signalling in immune system 
Developmental biology 
Downstream signal transduction 
GPCR downstream signalling 
Haemostasis 
Interaction between L1 and ankyrins 
L1CAM interactions 
Neuronal system 
RAS activation upon calcium influx through NMDA receptor 
Signalling by FGFR 
Signalling by FGFR in disease 
Signalling by GPCR 
Signalling by PDGF 
Transmembrane transport of small molecules 
 
Gene expression is an informative intermediate phenotype that links variation in genetic 
information to human disease (Williams et al. 2007; Fehrmann et al. 2011). Of the genes 
that were significantly differentially expressed (FDR<0.05 and FC≥1.5), 369 were under 
significant cis- or trans-eQTL (FDR<0.05) control of causal genes; we term these 
‘intermediate’ genes. This gene-set is highly functionally coherent, being enriched 
(FDR<0.05) with 58 Reactome pathways. We term these enriched pathways ‘intermediate’ 
pathways. These 58 enriched Reactome pathways form a highly interconnected network, 
which is shown in Figure 7.5 with the major groups labelled. This Figure illustrates the major 
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intermediate processes in pharmacoresistant epilepsy, for example cytokine signalling in the 
immune system. The most enriched individual pathways are shown in Table 7.3. 
16 Reactome pathways (Table 7.4) were both causal and intermediate pathways and, hence, 
can be considered of special interest, as therapeutic targets, because they bear not only 
causal genetic variations but also the transcriptomic changes that link causal genetic 
variations to the disease. 
As an example, we demonstrate below, using a literature review, the potential relevance of 
a pathway which is both a causal and an intermediate pathway. 
7.5.5 Fibroblast growth factors in epilepsy 
Fibroblast growth factors (FGFs) are a family of growth factors. Many members of the FGF 
family are dysregulated in brain tissue from epilepsy surgery (Paradiso et al. 2013), for 
example FGF2 (Sugiura et al. 2008; Ueda et al. 2011). FGFs have been implicated in a 
number of morphological and functional alterations associated with epileptogenesis in the 
hippocampus, including apoptosis, astrocytosis, blood-brain barrier disruption, changes in 
synaptogenesis, axonal sprouting, and aberrant neurogenesis (Paradiso et al. 2013). The 
therapeutic potential of FGFs has also been demonstrated in an animal model of epilepsy: 
injecting a viral vector expressing FGF2, as well as brain-derived neurotrophic factor, into 
the hippocampus of pilocarpine-treated rats significantly reduces neuronal loss and 
prevents the emergence of spontaneous recurrent seizures (Paradiso et al. 2011). Genetic 
variants in a fibroblast growth factor FGF14 are associated with a human neurological disorder: 
spinocerebellar ataxia 27 (van Swieten et al. 2003; Dalski et al. 2005). 
 
7.6 Conclusions 
Using novel bioinformatics strategies, we have presented evidence in support of the 
hypothesis that pharmacoresistance is the result of accumulation of deleterious genetic 
variations of increasing severity and/or numbers within the genes that constitute the core 
pathways and processes underlying epilepsy.  We have identified the causal and 
intermediate pathways that are likely to be of particular importance in the development of 
pharmacoresistant epilepsy. 
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Chapter 8: Discussion 
Epilepsy effects up to 1% of the population, and up to a third of people with epilepsy are 
pharmacoresistant—they continue to experience seizures despite treatment with maximal 
doses of multiple antiepileptic drugs with differing molecular targets and mechanisms of 
action. As detailed in Chapter 1, two different theories have gained the widest acceptance 
as possible explanations of pharmacoresistance: the multidrug transporter hypothesis and 
the intrinsic severity hypothesis. In the present work, we started by studying previously 
unexplored aspects of the multidrug transporter hypothesis, and then focused our attention 
on the intrinsic severity hypothesis. 
8.1 An in silico and ex vivo analysis of SLC transporters in the 
pharmacoresistant epileptic hippocampus 
According to the MDT hypothesis, pharmacoresistance results from decreased drug 
concentrations at the epileptic focus secondary to a localized dysregulation of drug 
transporters (Chayasirisobhon 2009), which could either increase drug efflux from, or 
reduce influx into, the epileptic focus. There are two main superfamilies of drug 
transporters: ABC proteins and SLC proteins. Research on multidrug transporters in epilepsy 
pharmacoresistance has been focused almost exclusively on ABC transporters. In spite of 
twenty years of research on the role of ABC proteins in intractable epilepsy, there remains a 
lack of convincing evidence that these transporters mediate pharmacoresistance. 
Meanwhile, SLC proteins, which constitute a much larger superfamily of transporters—there 
are over 400 known SLC proteins and less than 50 known ABC proteins—have hence far 
been neglected within epilepsy research. In order to identify the SLCs which are 
dysregulated in the pharmacoresistant epileptic hippocampus, we devised a robust in silico 
approach that exploits relevant published data and builds upon them using cutting-edge 
computational tools; we then verified the output using a robust ex vivo approach. 
It has been recognized in the study of cancers that SLCs typically mediate uptake of drugs 
(Huang & Sadee 2006; Nakanishi 2007), and lower activity of these transporters may result 
in resistance to chemotherapy (Rochat 2009; Rosenbaum 2011). As SLCs are primarily influx 
transporters, we focused on SLCs that are significantly downregulated in the 
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pharmacoresistant epileptic hippocampus. We extracted data relating to downregulated 
SLCs from (1) our integrative analysis of microarray studies on brain tissue from epilepsy 
surgery (Chapter 2), and (2) a comprehensive review of published literature on epilepsy 
pharmacoresistance, and integrated all the data using ‘convergent functional genomics 
(CFG)’—a validated technique (Bertsch et al. 2005) for prioritizing genes involved in complex 
diseases by collating evidence using a pre-defined scoring system. To identify SLCs which 
have not been studied in epilepsy pharmacoresistance but could potentially be involved, we 
employed a computational gene prioritization tool called Endeavour (Tranchevent et al. 
2008), using SLCs with the highest CFG-scores as the training genes. We validated this 
computationally prioritized gene list by (1) prioritizing the same candidate genes using a 
robust independent ‘positive control’ training set comprising the 10 most consistently 
downregulated genes from the aforementioned integrative analysis and, then, 
demonstrating significant rank order similarity with the original list, and (2) prioritizing the 
same candidate genes using a ‘negative control’ training set comprising 10 randomly chosen 
genes from the aforementioned integrative analysis and demonstrating no significant rank 
order similarity with the original list.  
As our in silico strategy was novel, we validated our in silico strategy by ex vivo analysis of 
human brain tissue. We used a custom one-colour Agilent oligonucletoide microarray 
containing exon probes for all known SLCs to analyse 24 hippocampal samples obtained 
from surgery for pharmacoresistant mesial temporal lobe epilepsy and 24 hippocampal 
samples from normal post-mortem controls. The whole-transcript amplification protocol of 
exon arrays allows more accurate measurement of gene expression than standard 
microarrays (Kapur et al. 2007; Xing et al. 2007; Lockstone 2011). Stringent QC filters were 
applied to arrays and individual features, and a ‘percent present’ filter was applied to the 
genes to reduce false positives. Finally, important technical (batch and RIN) and clinical (age 
and sex) covariates were included in the linear model; this reduced the false positive rate 
significantly. Our exon array identified 18 SLCs significantly (FDR <0.05) downregulated in 
the epileptic hippocampus by 1.5 fold or more. There was a highly significant overlap 
between the genes identified by our in silico and ex vivo strategies: p <9.0x10−7 
(hypergeometric distribution) for the overlap between the top bioinformatically-identified 
SLCs and the 18 experimentally-identified SLCs. Our successful in silico strategy can be 
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adapted in order to prioritize genes relevant to epilepsy from other gene families. qRT-PCR 
results for the three tested SLC genes were highly concordant with the microarray results. 
The vast majority of the identified SLC proteins are either small metal ion exchangers or 
transporters of neurotransmitters, particularly glutamate (see Table 3.6 in Chapter 3). Given 
the key roles played by ionic transport and gluatmatergic transmission in neuronal function, 
it stands to reason that these should be the most important SLC proteins in the epileptic 
hippocampus. However, for SLC transporters of metal ions, there is as yet no evidence of 
non-endogenous substrate transport—their small endogenous ionic substrates are markedly 
dissimilar to most xenobiotics, so it might be expected that they are not readily involved in 
xenobiotic transport (Dobson & Kell 2008). Similarly, there is no evidence as yet that the 
transporters of glutamate or of other neurotransmitters are able to transport therapeutic 
drugs. Therefore, while these SLCs potentially mediate pharmacoresistance in epilepsy, it is 
unlikely that they do this through altered transport of AEDs, but rather by enhancing the 
intrinsic severity of epilepsy (Schmidt & Loscher 2009).   
8.2 Objective evidence in support of the intrinsic severity hypothesis 
According to the intrinsic severity hypothesis, pharmacoresistance in epilepsy is the 
manifestation of increased dysfunction of the processes and pathways which underlie 
epilepsy. It has previously been suggested that genetic variations are likely to play a key role 
in producing increased dysfunction of these pathways and processes (Rogawski 2013). We 
are not aware of any previous attempts to test the hypothesis that pharmacoresistance is 
the result of accumulation of deleterious genetic variations of increasing severity and/or 
numbers within the genes that constitute the core pathways and processes underlying 
epilepsy. In order to test this hypothesis, we first identified the single most functionally-
relevant gene-set that represents the main pathways and processes underlying epilepsy, 
through the widely-used and validated WGCNA,  and then determined if this gene-set was 
affected by genetic variation more in drug resistant than in drug responsive epilepsy. In 
order to identify the genetic variations associated with drug responsive epilepsy, a GWAS 
was performed of drug responsive epilepsy. Similarly, in order to identify the genetic 
variations associated with drug resistant epilepsy, a GWAS was performed of drug resistant 
epilepsy. We then compared the degree of enrichment of the functionally-relevant gene-set 
in the two GWAS. We showed that the gene-set was significantly enriched in the 
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pharmacoresponsive epilepsy GWAS (p=1.1x10-9), but considerably more enriched in the 
pharmacoresistant epilepsy GWAS (p=2.6x10-14). To ensure that the comparison was fair, 
both GWAS datasets had genotype data for the same SNPs and the same normal population 
control samples and the same number of disease samples. To confirm that there is a 
significant difference in the burden of genetic variations within this gene-set between the 
two conditions, we performed a further ‘extreme discordant phenotype’ GWAS analysis 
with pharmacoresistant cases and pharmacoresponsive controls; the gene-set was highly 
enriched in this analysis. Using this strategy, we have demonstrated that 
pharmacoresistance is the result of accumulation of deleterious genetic variations of 
increasing severity and/or numbers within the genes that constitute the core pathways and 
processes underlying epilepsy. 
What are the different pathways underlying pharmacoresistant epilepsy and which of these 
are most important? In order to answer these questions, we have taken a step-wise 
analytical approach: 
1. Complexity: Identifying the different and diverse dysfunctional pathways underlying 
pharmacoresistant epilepsy. 
2. Coherence: Mapping a coherent interconnected network formed by the above 
dysfunctional pathways. 
3. Centrality: Identifying the most central ‘hub’ pathways in the above network. 
8.3 Complexity: The pathways underlying epilepsy pharmacoresistance are 
diverse 
The pathways underlying epilepsy belong to diverse functional domains—this was suggested 
by our integrative analysis of previously published large-scale gene expression profiling 
studies on brain tissue from epilepsy surgery (Chapter 2), and confirmed by our microarray 
analysis (Chapter 4), and further supported by our GWAS analysis (Chapter 5).  
In the integrative analysis of previously published large-scale gene expression profiling 
studies on brain tissue from epilepsy surgery (Chapter 2), we integrated the lists of 
differentially expressed genes from nine previously published microarray studies. The 
validity of our integrative approach was demonstrated by using an inter-study cross-
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validation technique and by demonstrating a statistically significant overlap with CarpeDB, a 
dynamic continuously updated epilepsy genetics database. The integrated gene list was 
then subjected to pathway and gene ontology analysis. The enriched pathways belonged to 
a number of different functional domains, but three domains were most prominently 
overrepresented in the integrated gene list: neuro-inflammation, modulation of synaptic 
transmission, and restructuring of neuronal networks. 
Although, as stated above, there have been a number of previous microarray studies on 
brain tissue from surgery for pharmacoresistant epilepsy, we went onto perform our own 
microarray analysis that is superior to the previous studies in a number of significant and 
novel ways. This is the largest transcriptomic study of hippocampal tissue from 
pharmacoresistant mesial temporal lobe epilepsy to date, having thrice the number of 
disease samples of the previous largest study. Furthermore, cutting edge analytical 
techniques have been applied which improve the sensitivity and reliability of our results: we 
have accounted and corrected for batch effects using careful study design and appropriate 
data processing; we have adjusted for unknown confounders using the cutting edge 
Independent Surrogate Variable Analysis technique; we have demonstrated the functional 
and therapeutic relevance of our results by showing that they are enriched with 
antiepileptic drug targets and more so than any previous microarray study; we have 
demonstrated the causal relevance of our results by showing their enrichment in a GWAS of 
pharmacoresistant partial epilepsy; and we have performed a ‘differentially connectivity’ 
analysis, which is the first such analysis in epilepsy. We identified 118 unique dysregulated 
(differentially expressed or differentially connected) pathways. As found in the integrative 
analysis of previously published microarray studies, the enriched pathways identified in our 
microarray analysis belong to diverse functional domains, for example ‘axon guidance’, 
‘transmembrane transport of small molecules’ and ‘class A1 rhodopsin-like receptors’. 
We performed the first ever genome-wide association study (GWAS) of pharmacoresistant 
partial epilepsy, with discovery and replication cohorts including, in total, 421 cases and 
2624 normal population controls, and 5,519,310 genotyped and imputed SNPs. At the single 
SNP level, there was no overlap in the top results of the two cohorts. We went on to 
perform gene-set and pathway-level analyses. We carried out the first ever objective 
validation of the GWAS gene-set analysis approach by showing that a gene-set comprising 
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antiepileptic drug targets is very significantly enriched in the GWAS, while random gene-sets 
of equal size are not. We then demonstrated that, at the gene-set and pathway level, there 
is clear replication of results between the two cohorts: there was a striking correlation 
between the discovery and replication cohorts in the gene-set analysis results (Pearson’s 
correlation coefficient=0.8, one-sided p-value<2.2x10-16). Furthermore, out of the top 10 
enriched pathways in the discovery cohort, all were replicated in the replication cohort. 
Overall, there was a highly significant overlap between the enriched pathways for the 
discovery and replication cohorts (hypergeometric distribution p-value <3.7x10-17). The 
combined GWAS ‘mega-analysis’ was used to perform pathway enrichment analysis. Again, 
the pathways enriched in the GWAS represent disparate processes, for example ‘axon 
guidance’, ‘transmembrane transport of small molecules’ and ‘cell death signalling via 
NRAGE, NRIF and NADE’. 
8.4 Coherence: the dysfunctional pathways underlying epilepsy form a 
coherent interconnected network 
Enrichment Map (Merico et al. 2010) tool was used to determine the connections between 
enriched pathways. Enrichment Map was used with default settings. Specifically, we 
employed an overlap coefficient cut-off of 0.5. Given sets A and B, and the cardinality 
operator | | where |X| equals to the number of elements within set X, the overlap 
coefficient (OC) is defined as: 
 
In other words, two pathways were deemed connected only if the ratio of the size of the 
intersection over the size of the smallest pathway was 0.5 or more 
Enrichment Map analysis of our transcriptomic study revealed a highly interconnected 
central network of pathways in which each pathway is directly connected to, on average, 
10.5 other pathways. Similarly, Enrichment Map analysis of our GWAS study revealed a 
highly interconnected central network of pathways in which each pathway is directly 
connected to, on average, 8.4 other pathways.  
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The above analysis shows that the dysregulated pathways underlying epilepsy 
pharmacoresistance, though seemingly unrelated, in fact form a coherent whole, and it can 
be expected that changes in one pathway in this network will have a cascading effect on the 
rest of the network. 
8.5 Centrality: Identifying the most central ‘hub’ pathways  
The Network Analysis tool was used to calculate the ‘betweenness centrality’ of nodes 
(individual pathways) in the networks. Betweenness is a measure of the centrality of a node 
in a network, and is calculated as the fraction of shortest paths between node pairs that 
pass through the node of interest. Hence, betweenness is a measure of the influence a node 
has over the spread of information through the network.  
In our transcriptomic analysis, the most central pathway by far was ‘signalling by Notch’. In 
our genetic analysis, the most central pathway by far was ‘signalling by NGF’. We have 
conducted literature reviews in order to highlight previously published evidence of the 
potential role of Notch signalling (see Chapter 4) and signalling by NGF (see Chapter 5) in 
epilepsy.  
It must be noted, however, that the central pathways identified are not necessarily causal. 
For example, it is possible that some of the gene expression changes identified in our 
transcriptomic analysis are the consequence, rather than the cause, of refractory seizures. 
Similarly, some of the genetic changes identified in our GWAS might be ‘bystander’ 
variations that do not have a causal link with the phenotype. In order to identify, with 
greater certainty, the pathways which are likely to be causal, we performed an expression 
quantitative trait loci (eQTL) analysis, and integrated the results with our genetic and 
transcriptomic analyses. 
8.6 Causality 
Our eQTL analysis included hippocampal samples from 22 patients with mesial temporal 
lobe epilepsy and from 22 normal controls. It has been shown that 69% to 80% of eQTLs 
operate in a cell-type specific manner (Dimas et al. 2009). There is only one previously 
published eQTL study on human hippocampal tissue (Kim et al. 2012); this study was limited 
to cis-eQTL analysis. There are currently no published trans-eQTL analyses of hippocampal 
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tissue, and no eQTL analyses of the epileptic human hippocampus. Our study not only 
examines eQTLs in hippocampal tissue, but specifically in samples with the disease, a 
strategy which may be necessary for the identification of the disease-related eQTLs (Ertekin-
Taner 2011).  
In complex diseases, truly trait-associated SNPs are more likely to be eQTLs (Nicolae et al. 
2010), and eQTL analysis is a powerful approach for the detection of novel disease risk loci 
(Schadt 2005). It has been suggested that an eQTL that maps to a disease locus can be 
considered a likely causal gene underlying the disease (Thessen Hedreul et al. 2013). We 
found 721 genes that were associated with the pharmacoresistant focal epilepsy phenotype 
in our GWAS analysis at an empirical p-value <0.005 and were also significant (FDR<0.05) 
eQTLs for differentially-expressed genes from our microarray study. Because our chosen 
GWAS p-value cut-off of 0.005 could be criticised for being uncorrected, we determined if 
these genes were significantly associated with pharmacoresistant epilepsy at the gene-set 
level. These 721 genes were significantly associated with the pharmacoresistant focal 
epilepsy phenotype at the gene-set level (FDR<5x10-20), while 25 random sets of 721 genes 
were not (minimum FDR=0.7). 61 Reactome pathways were enriched within these 721 
genes. These 61 pathways were designated ‘causal’ pathways, as they are likely to represent 
the genetic changes which influence the transcriptomic intermediate phenotype which, in 
turn, contributes to the development of the clinical phenotype. As shown previously for our 
genetic and transcriptomic pathway analysis, we demonstrated again that these 61 causal 
pathways, although apparently diverse and disparate, form a highly interconnected 
coherent network. The top 10 most central pathways in this causal network are shown in 
Table 8.1 
We also collated the list of genes which are under significant (FDR<0.05) eQTL control of 
causal genes and significantly differentially expressed (FDR<0.05 and FC≥1.5) in 
pharmacoresistant epileptic tissue. We performed Reactome pathway enrichment analysis 
on this set of genes. These pathways were designated ‘intermediate’ pathways, as they are 
likely to represent the true transcriptomic intermediate phenotype which contributes to the 
development of the clinical phenotype of interest. 16 Reactome pathways (see Table 7.3 in 
Chapter 7) were both causal and intermediate pathways and, hence, can be considered of 
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special interest, as therapeutic targets, because they bear not only causal genetic variations 
but also the transcriptomic changes that link causal genetic variations to the disease.  
Table 8.1 Top 10 central causal pathways 
Pathway 
Transmembrane transport of small molecules  
DCC mediated attractive signalling  
Axon guidance  
Cell-cell communication  
Developmental biology  
Signalling by NGF  
Immune system  
TIE2 signalling  
Signalling by constitutively active EGFR  
CREB phosphorylation through the activation of RAS  
 
8.7 Limitations 
The potential limitations of this work should be considered.  
The first point to consider is the type of control tissue used in the transcriptomic analysis. 
Table 8.2 lists the desired features of the ‘ideal’ control tissue for a transcriptomic study on 
the causes of pharmacoresistant MTLE.  
Table 8.2 Desired features of the ‘ideal’ control tissue for a transcriptomic study on the 
causes of pharmacoresistant MTLE 
Desired features of the ‘ideal’ control tissue 
1. Tissue is from donors: 
a. with drug responsive epilepsy 
b. exposed to the same range of AEDs as the disease group 
2. Epileptic hippocampus; free from other diseases 
3. Surgically resected and stored under conditions similar to disease tissue 
4. Histologically similar to the disease/pharmacoresistant group 
5. Comparable subsections of the hippocampus are used for both disease and control 
groups 
6. Tissue is available for research studies! 
 
Considering the features listed in table 8.2, it is evident that the ideal control tissue for a 
transcriptomic study on the causes of pharmacoresistant MTLE is non-existent and 
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unobtainable. For example, patients with drug responsive epilepsy will not be exposed to 
the same range of AEDs as those with drug resistant epilepsy, and patients with drug 
responsive epilepsy will not undergo epilepsy surgery. Hence, various types of alternative 
brain tissue have been tried by epilepsy researchers (see Table 2.1 in Chapter 2). For 
example, Lee and colleagues (Lee et al. 2007) utilized hippocampi from surgery for drug 
resistant MTLE that were not affected by hippocampal sclerosis, even though the 
hippocampi were thought to be the epileptic foci. However, comparing drug resistant 
epileptic hippocampi in such a way runs the risk of failing to discover important 
transcriptional changes contributing to pharmacoresistant epilepsy. Becker and colleagues 
(Becker et al. 2002) used hippocampal tissue adjacent to and resected along with brain 
tumours. This hippocampal tissue was thought to be normal. This approach also poses 
certain difficulties. It is impossible to be certain that there is no cancerous contamination 
within the hippocampal tissue which lies just adjacent to the tumour. Even if there is no 
overt histological evidence of contamination with cancer cells within the portions of 
hippocampal tissue being used for transcriptomic analysis, some of these hippocampal cells 
may be in a ‘pre-cancerous’ state at the transcriptomic level. Becker and colleagues (Becker 
et al. 2003) also tried using different subsections of the same hippocampus for disease and 
control tissue: CA1 formation was treated as disease tissue, while the dentate gyrus was 
treated as control tissue. This methodology is also flawed. Firstly, the denate gyrus also 
plays a role in MTLE (Kralic et al. 2005; Sloviter et al. 2012). Secondly, the transcriptomic 
profiles of two histologically distinct tissues will be significantly dissimilar.  
Normal post-mortem hippocampal tissue has been used as the control in a number of 
studies (Ozbas-Gerceker et al. 2006; van Gassen et al. 2008; Venugopal et al. 2012). The use 
of such control tissue offers a number of benefits. Various parts of the donor brain have 
been histologically studied to ensure that they are free from pathology. Also, the whole 
hippocampus is available and, hence, equivalent anatomical subsections of the 
hippocampus can be used for control and disease groups. Furthermore, utilizing normal 
hippocampus, rather than drug resistant epileptic hippocampus, does not run the risk of 
obscuring important transcriptional changes contributing to epilepsy pharmacoresistance. 
On the other hand, some will argue that comparing pharmacoresistant epileptic 
hippocampus with normal hippocampus will reveal changes underlying epilepsy in general 
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and not epilepsy pharmacoresistance in particular. However, as we have shown in the 
present work, epilepsy pharmacoresistance results from the increased dysfunction of the 
same pathways and processes that underlie epilepsy. This being the case, using normal post-
mortem hippocampal control tissue is likely to be the most effective and efficient strategy 
for uncovering the causes of epilepsy and epilepsy pharmacoresistance.  
The final point presented in the above discussion is also applicable to GWAs analyses. We 
used normal controls in the GWAS analysis presented in Chapter 5. Again, a possible 
criticism is that comparing pharmacoresistant epilepsy with normal controls will reveal 
changes underlying epilepsy in general and not epilepsy pharmacoresistance in particular. 
However, as stated above, epilepsy pharmacoresistance results from the increased 
dysfunction of the same pathways and processes that underlie epilepsy and, hence, 
studying epilepsy and epilepsy pharmacoresistance in unison, rather than in artificial 
isolation, is likely to be most fruitful and efficient. This can be achieved by comparing 
pharmacoresistant epilepsy with normal controls 
Finally, in previous studies by other researchers (Thessen Hedreul et al. 2013), an eQTL that 
maps to a disease locus has been considered potentially causal. We have adopted an even 
more robust and selective approach to identifying potentially causal genes. In this approach, 
(Figure 8.1) potentially causal genes are those that are (1) disease-associated, (2) eQTLs, and 
(3) influence the transcript levels of genes differentially-expressed in pharmacoresistant 
epilepsy. However, even such a stringent approach is, on its own, insufficient for confirming 
the causal influence of the identified genes. Causality can only be confirmed using functional 
studies; one such functional strategy is proposed in the next section. 
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Figure 8.1 Overall scheme for the identification of causal genes. eQTL: expression 
quantitative trait locus; DEGs: differentially expressed genes. 
 
 
8.8 Coming full circle and future work 
We started this work by focusing on the multidrug transporter hypothesis. Specifically, we 
determined which SLC proteins are dysregulated in the pharmacoresistant epileptic 
hippocampus and, based on current knowledge about substrates of these proteins, we 
judged whether they are likely to transport antiepileptic drugs. We found a number of SLC 
proteins to be dysregulated in the pharmacoresistant epileptic hippocampus. However, 
these particular SLC proteins are highly unlikely to be transporters of xenobiotics (although 
we cannot completely exclude this as we did not undertake transport studies). Instead, as 
we suggested in Chapter 2, these SLC proteins are more likely to contribute to the 
development of pharmacoresistance through altered transport of small metal ions or 
neurotransmitters.  
We then turned our attention to the intrinsic severity hypothesis, and used genome-wide 
genetic, transcriptomic and integrative systems level approaches to find the most important 
pathways underlying epilepsy pharmacoresistance. At the genetic level, the 
Causal genes 
eQTLs for DEGs 
eQTL genes 
Disease-associated 
genes 
 
 
261 
 
‘transmembrane transport of small molecules’ pathway was one of the most significant in 
our GWAS of pharmacoresistant epilepsy and one of the most central. Similarly, at the 
transcriptomic level, this pathway was one of the most significantly differentially expressed, 
differentially connected and central pathways. Most importantly, in our integrative systems 
level analysis for discovering ‘causal’ pathways, we found the ‘transmembrane transport of 
small molecules’ pathway to be most central. As expected, this pathway was also one of the 
‘intermediate’ pathways, which represent the true transcriptomic intermediate phenotype 
which contributes to the development of the clinical phenotype of interest.  
This brings us back full circle to the conclusion drawn from our initial exon array analysis: 
altered transport of small molecules plays an important role in the development of 
pharmacoresistant epilepsy. The central position of transporters of small molecules within a 
network comprising diverse and distinct biological pathways suggests a potential role for 
these transporters in the regulation of many processes. How can we identify the key 
transporters which are likely to be most influential? A proposed integrative schema is 
illustrated in Figure 8.2. Steps 1 and 2 of this schema represent the strategy employed for 
finding causal genes in Chapter 7; this strategy is based on the observation that an eQTL 
that maps to a disease locus can be considered a likely causal gene underlying the disease 
(Thessen Hedreul et al. 2013). Steps 2 and 3 represent two complimentary and proven 
methods for identifying genes with the most prominent regulatory roles. Step 2 identifies 
important eQTLs: transporters whose genotype is significantly correlated with differentially 
expressed genes. Step 3 utilises a recently developed innovative method for identifying 
genes with an important regulatory role: the ‘Regulatory Impact Factor (RIF)’ (Reverter et al. 
2010). RIF identifies the regulator genes that are most consistently differentially co-
expressed with differentially expressed genes. RIF analysis has been shown to recover well-
recognised experimentally validated regulator genes for the processes studied, for example 
PPAR signalling in adipose development and the importance of transduction of oestrogen 
signals in breast cancer survival and sexual differentiation (Reverter et al. 2010). 
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Figure 8.2 Suggested schema for the identification of transporters of causal and regulatory 
importance in pharmacoresistant epilepsy. 
Steps  Rationale  Procedure 
      
Step 1  
C
au
sal gen
es 
  Transporters associated with phenotype at a 
nominal level of significance in GWAS 
Step 2  
R
egu
lato
ry gen
es 
  
Transporters which are significant 
eQTL genes for differentially 
expressed genes 
 
Step 3      
Transporters with 
high ‘Regulatory 
Impact Factor’ 
  
Step 4  In vitro studies    
Hippocampal slice 
cultures 
  
Step 5  Therapeutics    Drug repositioning   
 
After the identification of transporters of putative causal and regulatory importance, in vitro 
studies can be performed to confirm the functional significance of these proteins in 
epilepsy. As the transporters potentially exert an influence upon diverse functional domains, 
including electrophysiological and histological, they must be studied in an in vitro model 
that allows detailed investigation of cellular and molecular features of epilepsy, yet is 
amenable and rapidly responsive to genetic and pharmacological manipulation. The 
organotypic hippocampal slice culture (OHSC) is such a model. 
OHSCs are becoming an increasingly popular tool in the study of epileptogenesis, chronic 
epilepsy and antiepileptics. OHSCs are a robust and rapid model of epileptogenesis, and can 
be maintained for weeks or longer (Dyhrfjeld-Johnsen et al. 2010). The key features of 
human epileptogenesis are reproduced in this model (Berdichevsky et al. 2012): latency (the 
cultures become spontaneously epileptic after a latent period in vitro), electrographic 
spiking prior to the onset of spontaneous seizures, clustering of seizure activity, suppression 
of seizures but not interictal spikes by anticonvulsants and the gradual development of 
anticonvulsant resistance. Advantages of this preparation include dramatically improved 
 
 
263 
 
experimental accessibility (Wahab et al. 2010): organotypic cultures easily lend themselves 
to continuous recordings of electrical activity, imaging of cellular plasticity, gene transfer 
and transduction, and chronic application of drugs. Given the convenience of in vitro 
preparations and the relative compressed time frame of epileptogenesis in OHSCs, this 
model could serve for high-throughput screening of candidate antiepileptic drugs. The best 
candidates from the initial in vitro screen could then be tested further in traditional in vivo 
models of epilepsy. 
A number of different transporters are targeted by widely-used medicinal agents, for 
example cardiac glycosides and proton pump inhibitors (Alexander 2011). Hence, after the 
identification of transporters of putative clinical significance in epilepsy, the first strategy 
should be to employ computational drug repositioning (Hurle et al. 2013) in order to 
repurpose therapeutic agents that can be used to tackle the problem of pharmacoresistant 
epilepsy. 
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Appendix 
Appendices can be found in the enclosed compact disc. 
